date generated: 2022-05-18
Mitch performs unidimensional and multidimensional gene set enrichment analysis. The concept behind this dates to work by Cox and Mann (https://doi.org/10.1186/1471-2105-13-S16-S12). This implementation is suited to R based workflows of multi-omics datasets. This software was developed by Antony Kaspi and Mark Ziemann. Learn more about Mitch at the website: https://github.com/markziemann/Mitch
Here is the first few lines of the input profile.
## metric
## PSMB8 -15.09965
## TAPBP -14.48290
## CSNK2B -18.35266
## TAP1 -13.58930
## TRIM27 -17.73811
## BAT4 -18.19374
Here are some metrics about the input data profile:
Profile metrics | |
---|---|
num_genesets | 2546 |
num_genes_in_profile | 12012 |
duplicated_genes_present | 0 |
num_profile_genes_in_sets | 5835 |
num_profile_genes_not_in_sets | 6177 |
Here is a plot of the input profiles. Note the dynamic ranges.
Here is the contour plot of the profile including all detected genes.
Gene sets metrics | |
---|---|
num_genesets | 2546 |
num_genesets_excluded | 1344 |
num_genesets_included | 1202 |
Significance is calculated by -log10(p-value). All points shown are FDR<0.05.
Significance is calculated by -log10(p-value). Top N sets shown irrespective of FDR.
set | setSize | pANOVA | s.dist | p.adjustANOVA |
---|---|---|---|---|
Signaling by FGFR2 IIIa TM | 15 | 9.84e-05 | -0.581 | 0.00169 |
TNFs bind their physiological receptors | 10 | 9.35e-03 | 0.475 | 0.03660 |
Inhibition of DNA recombination at telomere | 18 | 6.78e-04 | -0.463 | 0.00559 |
FGFR2 mutant receptor activation | 17 | 1.17e-03 | -0.455 | 0.00775 |
TP53 Regulates Transcription of Genes Involved in G1 Cell Cycle Arrest | 12 | 8.90e-03 | -0.436 | 0.03530 |
TNFR1-induced proapoptotic signaling | 12 | 9.03e-03 | -0.435 | 0.03560 |
mRNA Capping | 26 | 2.06e-04 | -0.421 | 0.00239 |
Signaling by FGFR2 in disease | 24 | 3.66e-04 | -0.420 | 0.00352 |
Competing endogenous RNAs (ceRNAs) regulate PTEN translation | 10 | 2.14e-02 | 0.420 | 0.07260 |
Purine salvage | 11 | 1.76e-02 | -0.413 | 0.06270 |
Abortive elongation of HIV-1 transcript in the absence of Tat | 22 | 9.32e-04 | -0.408 | 0.00691 |
SLBP Dependent Processing of Replication-Dependent Histone Pre-mRNAs | 10 | 2.74e-02 | -0.403 | 0.08630 |
Aberrant regulation of mitotic G1/S transition in cancer due to RB1 defects | 16 | 5.49e-03 | -0.401 | 0.02360 |
Defective binding of RB1 mutants to E2F1,(E2F2, E2F3) | 16 | 5.49e-03 | -0.401 | 0.02360 |
Synthesis of Leukotrienes (LT) and Eoxins (EX) | 10 | 2.88e-02 | 0.399 | 0.08960 |
Assembly of the ORC complex at the origin of replication | 10 | 2.93e-02 | 0.398 | 0.09080 |
Endosomal/Vacuolar pathway | 10 | 2.97e-02 | -0.397 | 0.09140 |
RNA Pol II CTD phosphorylation and interaction with CE | 24 | 8.47e-04 | -0.394 | 0.00656 |
RNA Pol II CTD phosphorylation and interaction with CE during HIV infection | 24 | 8.47e-04 | -0.394 | 0.00656 |
FGFR2 alternative splicing | 22 | 1.57e-03 | -0.389 | 0.00921 |
alpha-linolenic (omega3) and linoleic (omega6) acid metabolism | 10 | 3.93e-02 | -0.376 | 0.11300 |
alpha-linolenic acid (ALA) metabolism | 10 | 3.93e-02 | -0.376 | 0.11300 |
Processing of Intronless Pre-mRNAs | 15 | 1.25e-02 | -0.373 | 0.04680 |
SUMOylation of immune response proteins | 10 | 4.43e-02 | -0.367 | 0.12600 |
Other semaphorin interactions | 10 | 4.54e-02 | 0.365 | 0.12800 |
Signaling by ERBB2 ECD mutants | 10 | 4.65e-02 | -0.364 | 0.13100 |
Antigen Presentation: Folding, assembly and peptide loading of class I MHC | 26 | 1.58e-03 | -0.358 | 0.00921 |
Disorders of Developmental Biology | 10 | 5.00e-02 | -0.358 | 0.13500 |
Disorders of Nervous System Development | 10 | 5.00e-02 | -0.358 | 0.13500 |
Loss of function of MECP2 in Rett syndrome | 10 | 5.00e-02 | -0.358 | 0.13500 |
Pervasive developmental disorders | 10 | 5.00e-02 | -0.358 | 0.13500 |
Degradation of cysteine and homocysteine | 10 | 5.03e-02 | -0.357 | 0.13600 |
HIV elongation arrest and recovery | 27 | 1.33e-03 | -0.357 | 0.00838 |
Pausing and recovery of HIV elongation | 27 | 1.33e-03 | -0.357 | 0.00838 |
HIV Transcription Initiation | 39 | 1.26e-04 | -0.355 | 0.00175 |
RNA Polymerase II HIV Promoter Escape | 39 | 1.26e-04 | -0.355 | 0.00175 |
RNA Polymerase II Promoter Escape | 39 | 1.26e-04 | -0.355 | 0.00175 |
RNA Polymerase II Transcription Initiation | 39 | 1.26e-04 | -0.355 | 0.00175 |
RNA Polymerase II Transcription Initiation And Promoter Clearance | 39 | 1.26e-04 | -0.355 | 0.00175 |
RNA Polymerase II Transcription Pre-Initiation And Promoter Opening | 39 | 1.26e-04 | -0.355 | 0.00175 |
Processing of Capped Intronless Pre-mRNA | 23 | 3.31e-03 | -0.354 | 0.01650 |
Purine ribonucleoside monophosphate biosynthesis | 10 | 5.39e-02 | -0.352 | 0.14200 |
PIWI-interacting RNA (piRNA) biogenesis | 16 | 1.50e-02 | -0.351 | 0.05440 |
Cross-presentation of soluble exogenous antigens (endosomes) | 38 | 1.80e-04 | -0.351 | 0.00223 |
Ubiquitin Mediated Degradation of Phosphorylated Cdc25A | 44 | 5.62e-05 | -0.351 | 0.00111 |
p53-Independent DNA Damage Response | 44 | 5.62e-05 | -0.351 | 0.00111 |
p53-Independent G1/S DNA damage checkpoint | 44 | 5.62e-05 | -0.351 | 0.00111 |
Viral Messenger RNA Synthesis | 41 | 1.08e-04 | -0.350 | 0.00175 |
Striated Muscle Contraction | 10 | 5.69e-02 | -0.348 | 0.14700 |
Formation of the Early Elongation Complex | 30 | 1.26e-03 | -0.340 | 0.00815 |
set | setSize | pANOVA | s.dist | p.adjustANOVA |
---|---|---|---|---|
Signaling by FGFR2 IIIa TM | 15 | 9.84e-05 | -0.581000 | 1.69e-03 |
TNFs bind their physiological receptors | 10 | 9.35e-03 | 0.475000 | 3.66e-02 |
Inhibition of DNA recombination at telomere | 18 | 6.78e-04 | -0.463000 | 5.59e-03 |
FGFR2 mutant receptor activation | 17 | 1.17e-03 | -0.455000 | 7.75e-03 |
TP53 Regulates Transcription of Genes Involved in G1 Cell Cycle Arrest | 12 | 8.90e-03 | -0.436000 | 3.53e-02 |
TNFR1-induced proapoptotic signaling | 12 | 9.03e-03 | -0.435000 | 3.56e-02 |
mRNA Capping | 26 | 2.06e-04 | -0.421000 | 2.39e-03 |
Signaling by FGFR2 in disease | 24 | 3.66e-04 | -0.420000 | 3.52e-03 |
Competing endogenous RNAs (ceRNAs) regulate PTEN translation | 10 | 2.14e-02 | 0.420000 | 7.26e-02 |
Purine salvage | 11 | 1.76e-02 | -0.413000 | 6.27e-02 |
Abortive elongation of HIV-1 transcript in the absence of Tat | 22 | 9.32e-04 | -0.408000 | 6.91e-03 |
SLBP Dependent Processing of Replication-Dependent Histone Pre-mRNAs | 10 | 2.74e-02 | -0.403000 | 8.63e-02 |
Aberrant regulation of mitotic G1/S transition in cancer due to RB1 defects | 16 | 5.49e-03 | -0.401000 | 2.36e-02 |
Defective binding of RB1 mutants to E2F1,(E2F2, E2F3) | 16 | 5.49e-03 | -0.401000 | 2.36e-02 |
Synthesis of Leukotrienes (LT) and Eoxins (EX) | 10 | 2.88e-02 | 0.399000 | 8.96e-02 |
Assembly of the ORC complex at the origin of replication | 10 | 2.93e-02 | 0.398000 | 9.08e-02 |
Endosomal/Vacuolar pathway | 10 | 2.97e-02 | -0.397000 | 9.14e-02 |
RNA Pol II CTD phosphorylation and interaction with CE | 24 | 8.47e-04 | -0.394000 | 6.56e-03 |
RNA Pol II CTD phosphorylation and interaction with CE during HIV infection | 24 | 8.47e-04 | -0.394000 | 6.56e-03 |
FGFR2 alternative splicing | 22 | 1.57e-03 | -0.389000 | 9.21e-03 |
alpha-linolenic (omega3) and linoleic (omega6) acid metabolism | 10 | 3.93e-02 | -0.376000 | 1.13e-01 |
alpha-linolenic acid (ALA) metabolism | 10 | 3.93e-02 | -0.376000 | 1.13e-01 |
Processing of Intronless Pre-mRNAs | 15 | 1.25e-02 | -0.373000 | 4.68e-02 |
SUMOylation of immune response proteins | 10 | 4.43e-02 | -0.367000 | 1.26e-01 |
Other semaphorin interactions | 10 | 4.54e-02 | 0.365000 | 1.28e-01 |
Signaling by ERBB2 ECD mutants | 10 | 4.65e-02 | -0.364000 | 1.31e-01 |
Antigen Presentation: Folding, assembly and peptide loading of class I MHC | 26 | 1.58e-03 | -0.358000 | 9.21e-03 |
Disorders of Developmental Biology | 10 | 5.00e-02 | -0.358000 | 1.35e-01 |
Disorders of Nervous System Development | 10 | 5.00e-02 | -0.358000 | 1.35e-01 |
Loss of function of MECP2 in Rett syndrome | 10 | 5.00e-02 | -0.358000 | 1.35e-01 |
Pervasive developmental disorders | 10 | 5.00e-02 | -0.358000 | 1.35e-01 |
Degradation of cysteine and homocysteine | 10 | 5.03e-02 | -0.357000 | 1.36e-01 |
HIV elongation arrest and recovery | 27 | 1.33e-03 | -0.357000 | 8.38e-03 |
Pausing and recovery of HIV elongation | 27 | 1.33e-03 | -0.357000 | 8.38e-03 |
HIV Transcription Initiation | 39 | 1.26e-04 | -0.355000 | 1.75e-03 |
RNA Polymerase II HIV Promoter Escape | 39 | 1.26e-04 | -0.355000 | 1.75e-03 |
RNA Polymerase II Promoter Escape | 39 | 1.26e-04 | -0.355000 | 1.75e-03 |
RNA Polymerase II Transcription Initiation | 39 | 1.26e-04 | -0.355000 | 1.75e-03 |
RNA Polymerase II Transcription Initiation And Promoter Clearance | 39 | 1.26e-04 | -0.355000 | 1.75e-03 |
RNA Polymerase II Transcription Pre-Initiation And Promoter Opening | 39 | 1.26e-04 | -0.355000 | 1.75e-03 |
Processing of Capped Intronless Pre-mRNA | 23 | 3.31e-03 | -0.354000 | 1.65e-02 |
Purine ribonucleoside monophosphate biosynthesis | 10 | 5.39e-02 | -0.352000 | 1.42e-01 |
PIWI-interacting RNA (piRNA) biogenesis | 16 | 1.50e-02 | -0.351000 | 5.44e-02 |
Cross-presentation of soluble exogenous antigens (endosomes) | 38 | 1.80e-04 | -0.351000 | 2.23e-03 |
Ubiquitin Mediated Degradation of Phosphorylated Cdc25A | 44 | 5.62e-05 | -0.351000 | 1.11e-03 |
p53-Independent DNA Damage Response | 44 | 5.62e-05 | -0.351000 | 1.11e-03 |
p53-Independent G1/S DNA damage checkpoint | 44 | 5.62e-05 | -0.351000 | 1.11e-03 |
Viral Messenger RNA Synthesis | 41 | 1.08e-04 | -0.350000 | 1.75e-03 |
Striated Muscle Contraction | 10 | 5.69e-02 | -0.348000 | 1.47e-01 |
Formation of the Early Elongation Complex | 30 | 1.26e-03 | -0.340000 | 8.15e-03 |
Formation of the HIV-1 Early Elongation Complex | 30 | 1.26e-03 | -0.340000 | 8.15e-03 |
Gluconeogenesis | 24 | 3.97e-03 | -0.340000 | 1.83e-02 |
Chk1/Chk2(Cds1) mediated inactivation of Cyclin B:Cdk1 complex | 13 | 3.53e-02 | -0.337000 | 1.04e-01 |
Defects in vitamin and cofactor metabolism | 16 | 1.97e-02 | -0.337000 | 6.78e-02 |
Binding and Uptake of Ligands by Scavenger Receptors | 10 | 6.54e-02 | -0.336000 | 1.62e-01 |
Constitutive Signaling by EGFRvIII | 10 | 6.58e-02 | -0.336000 | 1.62e-01 |
Signaling by EGFRvIII in Cancer | 10 | 6.58e-02 | -0.336000 | 1.62e-01 |
Degradation of GLI2 by the proteasome | 50 | 4.16e-05 | -0.335000 | 9.13e-04 |
GLI3 is processed to GLI3R by the proteasome | 50 | 4.16e-05 | -0.335000 | 9.13e-04 |
Pausing and recovery of Tat-mediated HIV elongation | 26 | 3.12e-03 | -0.335000 | 1.56e-02 |
Tat-mediated HIV elongation arrest and recovery | 26 | 3.12e-03 | -0.335000 | 1.56e-02 |
Formation of HIV elongation complex in the absence of HIV Tat | 37 | 4.38e-04 | -0.334000 | 4.01e-03 |
Association of TriC/CCT with target proteins during biosynthesis | 29 | 1.87e-03 | -0.334000 | 1.06e-02 |
Ubiquitin-dependent degradation of Cyclin D | 44 | 1.30e-04 | -0.334000 | 1.75e-03 |
TRAF6 mediated IRF7 activation | 16 | 2.10e-02 | -0.333000 | 7.13e-02 |
Nucleotide salvage | 18 | 1.45e-02 | -0.333000 | 5.31e-02 |
Sulfur amino acid metabolism | 17 | 1.76e-02 | -0.333000 | 6.27e-02 |
Transport of Mature mRNAs Derived from Intronless Transcripts | 41 | 2.37e-04 | -0.332000 | 2.64e-03 |
Metabolism of folate and pterines | 11 | 5.68e-02 | -0.332000 | 1.47e-01 |
Transport of Mature mRNA Derived from an Intronless Transcript | 40 | 2.85e-04 | -0.332000 | 3.03e-03 |
TRAF6 mediated NF-kB activation | 19 | 1.28e-02 | -0.330000 | 4.76e-02 |
Signaling by PDGFR in disease | 15 | 2.79e-02 | -0.328000 | 8.74e-02 |
Synthesis of glycosylphosphatidylinositol (GPI) | 14 | 3.42e-02 | -0.327000 | 1.01e-01 |
Regulation of PTEN stability and activity | 56 | 2.73e-05 | -0.324000 | 7.14e-04 |
GSK3B and BTRC:CUL1-mediated-degradation of NFE2L2 | 46 | 1.63e-04 | -0.321000 | 2.08e-03 |
AUF1 (hnRNP D0) binds and destabilizes mRNA | 46 | 1.71e-04 | -0.320000 | 2.17e-03 |
Rev-mediated nuclear export of HIV RNA | 33 | 1.51e-03 | -0.319000 | 8.96e-03 |
Interactions of Rev with host cellular proteins | 34 | 1.29e-03 | -0.319000 | 8.28e-03 |
Processive synthesis on the lagging strand | 13 | 4.65e-02 | -0.319000 | 1.31e-01 |
Keratan sulfate/keratin metabolism | 18 | 1.93e-02 | -0.318000 | 6.71e-02 |
Generation of second messenger molecules | 15 | 3.29e-02 | 0.318000 | 9.74e-02 |
SCF(Skp2)-mediated degradation of p27/p21 | 52 | 7.35e-05 | -0.318000 | 1.40e-03 |
Formation of HIV-1 elongation complex containing HIV-1 Tat | 36 | 9.77e-04 | -0.318000 | 7.03e-03 |
HIV Transcription Elongation | 36 | 9.77e-04 | -0.318000 | 7.03e-03 |
Tat-mediated elongation of the HIV-1 transcript | 36 | 9.77e-04 | -0.318000 | 7.03e-03 |
Cooperation of Prefoldin and TriC/CCT in actin and tubulin folding | 19 | 1.68e-02 | -0.317000 | 6.03e-02 |
Role of phospholipids in phagocytosis | 16 | 2.83e-02 | -0.317000 | 8.84e-02 |
Degradation of GLI1 by the proteasome | 51 | 9.34e-05 | -0.316000 | 1.63e-03 |
Lagging Strand Synthesis | 17 | 2.40e-02 | -0.316000 | 7.87e-02 |
Autodegradation of the E3 ubiquitin ligase COP1 | 44 | 2.91e-04 | -0.316000 | 3.04e-03 |
Negative regulation of NOTCH4 signaling | 48 | 1.56e-04 | -0.316000 | 2.02e-03 |
ERKs are inactivated | 11 | 7.02e-02 | -0.315000 | 1.67e-01 |
Transcription of the HIV genome | 57 | 4.18e-05 | -0.314000 | 9.13e-04 |
Activation of IRF3/IRF7 mediated by TBK1/IKK epsilon | 13 | 5.00e-02 | -0.314000 | 1.35e-01 |
B-WICH complex positively regulates rRNA expression | 27 | 4.84e-03 | -0.313000 | 2.16e-02 |
Mismatch repair (MMR) directed by MSH2:MSH3 (MutSbeta) | 12 | 6.11e-02 | -0.312000 | 1.53e-01 |
Elevation of cytosolic Ca2+ levels | 10 | 8.77e-02 | -0.312000 | 1.97e-01 |
RNA Polymerase III Transcription Initiation From Type 2 Promoter | 26 | 5.95e-03 | -0.312000 | 2.51e-02 |
RNA Polymerase III Transcription Initiation From Type 1 Promoter | 27 | 5.21e-03 | -0.311000 | 2.29e-02 |
Degradation of AXIN | 47 | 2.40e-04 | -0.310000 | 2.64e-03 |
Vif-mediated degradation of APOBEC3G | 43 | 4.52e-04 | -0.309000 | 4.05e-03 |
Diseases associated with N-glycosylation of proteins | 18 | 2.31e-02 | -0.309000 | 7.70e-02 |
Glycogen synthesis | 11 | 7.68e-02 | -0.308000 | 1.79e-01 |
Vpr-mediated nuclear import of PICs | 32 | 2.63e-03 | -0.307000 | 1.39e-02 |
MicroRNA (miRNA) biogenesis | 21 | 1.52e-02 | -0.306000 | 5.48e-02 |
Formation of tubulin folding intermediates by CCT/TriC | 14 | 4.74e-02 | -0.306000 | 1.31e-01 |
Interleukin-7 signaling | 14 | 4.76e-02 | -0.306000 | 1.31e-01 |
Interleukin-35 Signalling | 11 | 7.92e-02 | -0.306000 | 1.82e-01 |
Loss of Nlp from mitotic centrosomes | 56 | 8.80e-05 | -0.303000 | 1.56e-03 |
Loss of proteins required for interphase microtubule organization from the centrosome | 56 | 8.80e-05 | -0.303000 | 1.56e-03 |
Prefoldin mediated transfer of substrate to CCT/TriC | 17 | 3.11e-02 | -0.302000 | 9.36e-02 |
NRIF signals cell death from the nucleus | 14 | 5.06e-02 | -0.302000 | 1.36e-01 |
Regulation of activated PAK-2p34 by proteasome mediated degradation | 42 | 7.24e-04 | -0.302000 | 5.80e-03 |
Interactions of Vpr with host cellular proteins | 33 | 2.80e-03 | -0.301000 | 1.45e-02 |
CLEC7A (Dectin-1) induces NFAT activation | 11 | 8.42e-02 | -0.301000 | 1.91e-01 |
RNA Polymerase II Pre-transcription Events | 68 | 1.88e-05 | -0.300000 | 5.45e-04 |
Formation of RNA Pol II elongation complex | 50 | 2.41e-04 | -0.300000 | 2.64e-03 |
RNA Polymerase II Transcription Elongation | 50 | 2.41e-04 | -0.300000 | 2.64e-03 |
Voltage gated Potassium channels | 13 | 6.09e-02 | 0.300000 | 1.53e-01 |
Removal of the Flap Intermediate | 12 | 7.27e-02 | -0.299000 | 1.71e-01 |
Peptide ligand-binding receptors | 20 | 2.08e-02 | 0.299000 | 7.09e-02 |
Dual incision in TC-NER | 56 | 1.15e-04 | -0.298000 | 1.75e-03 |
Vpu mediated degradation of CD4 | 44 | 6.53e-04 | -0.297000 | 5.44e-03 |
Gap-filling DNA repair synthesis and ligation in TC-NER | 55 | 1.45e-04 | -0.296000 | 1.92e-03 |
SCF-beta-TrCP mediated degradation of Emi1 | 47 | 4.49e-04 | -0.296000 | 4.05e-03 |
Telomere C-strand (Lagging Strand) Synthesis | 29 | 5.93e-03 | -0.295000 | 2.51e-02 |
Export of Viral Ribonucleoproteins from Nucleus | 31 | 4.53e-03 | -0.295000 | 2.03e-02 |
Hedgehog ligand biogenesis | 52 | 2.40e-04 | -0.295000 | 2.64e-03 |
RNA Polymerase III Transcription Termination | 21 | 1.96e-02 | -0.294000 | 6.78e-02 |
Regulation of PTEN mRNA translation | 11 | 9.15e-02 | 0.294000 | 2.02e-01 |
Regulation of Apoptosis | 45 | 6.56e-04 | -0.294000 | 5.44e-03 |
Anchoring of the basal body to the plasma membrane | 80 | 6.34e-06 | -0.292000 | 2.18e-04 |
G1/S DNA Damage Checkpoints | 58 | 1.26e-04 | -0.291000 | 1.75e-03 |
TRAF3-dependent IRF activation pathway | 14 | 6.02e-02 | -0.290000 | 1.53e-01 |
ER-Phagosome pathway | 69 | 3.21e-05 | -0.290000 | 7.57e-04 |
RAF-independent MAPK1/3 activation | 20 | 2.55e-02 | -0.289000 | 8.21e-02 |
Regulation of ornithine decarboxylase (ODC) | 43 | 1.08e-03 | -0.288000 | 7.59e-03 |
Regulation of RUNX2 expression and activity | 57 | 1.77e-04 | -0.287000 | 2.22e-03 |
Transport of the SLBP Dependant Mature mRNA | 34 | 3.76e-03 | -0.287000 | 1.80e-02 |
Cyclin E associated events during G1/S transition | 72 | 2.72e-05 | -0.286000 | 7.14e-04 |
Nuclear import of Rev protein | 31 | 5.86e-03 | -0.286000 | 2.50e-02 |
Transport of the SLBP independent Mature mRNA | 33 | 4.53e-03 | -0.286000 | 2.03e-02 |
GAB1 signalosome | 10 | 1.18e-01 | -0.286000 | 2.41e-01 |
FBXL7 down-regulates AURKA during mitotic entry and in early mitosis | 46 | 8.12e-04 | -0.285000 | 6.42e-03 |
Signaling by NTRK2 (TRKB) | 15 | 5.60e-02 | -0.285000 | 1.47e-01 |
Regulation of RAS by GAPs | 56 | 2.28e-04 | -0.285000 | 2.61e-03 |
Notch-HLH transcription pathway | 21 | 2.41e-02 | -0.284000 | 7.89e-02 |
Glucose metabolism | 72 | 3.15e-05 | -0.284000 | 7.57e-04 |
Polymerase switching on the C-strand of the telomere | 22 | 2.16e-02 | -0.283000 | 7.30e-02 |
Ovarian tumor domain proteases | 29 | 8.54e-03 | -0.282000 | 3.42e-02 |
RORA activates gene expression | 11 | 1.07e-01 | -0.281000 | 2.25e-01 |
Telomere C-strand synthesis initiation | 10 | 1.25e-01 | -0.280000 | 2.50e-01 |
Cyclin A:Cdk2-associated events at S phase entry | 74 | 3.11e-05 | -0.280000 | 7.57e-04 |
VEGFR2 mediated cell proliferation | 16 | 5.28e-02 | -0.280000 | 1.40e-01 |
BMAL1:CLOCK,NPAS2 activates circadian gene expression | 16 | 5.36e-02 | -0.279000 | 1.41e-01 |
Leading Strand Synthesis | 12 | 9.61e-02 | -0.277000 | 2.09e-01 |
Polymerase switching | 12 | 9.61e-02 | -0.277000 | 2.09e-01 |
p53-Dependent G1 DNA Damage Response | 56 | 3.43e-04 | -0.277000 | 3.37e-03 |
p53-Dependent G1/S DNA damage checkpoint | 56 | 3.43e-04 | -0.277000 | 3.37e-03 |
HCMV Early Events | 50 | 7.31e-04 | -0.276000 | 5.82e-03 |
TP53 Regulates Transcription of DNA Repair Genes | 52 | 5.83e-04 | -0.276000 | 5.08e-03 |
Heme signaling | 26 | 1.51e-02 | -0.275000 | 5.48e-02 |
NEP/NS2 Interacts with the Cellular Export Machinery | 30 | 9.16e-03 | -0.275000 | 3.60e-02 |
Synaptic adhesion-like molecules | 10 | 1.32e-01 | 0.275000 | 2.63e-01 |
Transcriptional regulation by small RNAs | 45 | 1.47e-03 | -0.274000 | 8.83e-03 |
Platelet calcium homeostasis | 17 | 5.06e-02 | -0.274000 | 1.36e-01 |
Deregulated CDK5 triggers multiple neurodegenerative pathways in Alzheimer’s disease models | 20 | 3.56e-02 | -0.271000 | 1.04e-01 |
Neurodegenerative Diseases | 20 | 3.56e-02 | -0.271000 | 1.04e-01 |
mRNA decay by 5’ to 3’ exoribonuclease | 15 | 6.91e-02 | -0.271000 | 1.67e-01 |
Antigen processing-Cross presentation | 76 | 4.53e-05 | -0.271000 | 9.72e-04 |
Postmitotic nuclear pore complex (NPC) reformation | 26 | 1.71e-02 | -0.270000 | 6.12e-02 |
Diseases of programmed cell death | 37 | 4.49e-03 | -0.270000 | 2.03e-02 |
AURKA Activation by TPX2 | 59 | 3.52e-04 | -0.269000 | 3.41e-03 |
G1/S-Specific Transcription | 27 | 1.55e-02 | -0.269000 | 5.59e-02 |
HDR through Single Strand Annealing (SSA) | 35 | 5.92e-03 | -0.269000 | 2.51e-02 |
Hh mutants abrogate ligand secretion | 49 | 1.14e-03 | -0.269000 | 7.72e-03 |
Regulation of RUNX3 expression and activity | 49 | 1.15e-03 | -0.269000 | 7.73e-03 |
Early Phase of HIV Life Cycle | 13 | 9.42e-02 | -0.268000 | 2.06e-01 |
Transcription-Coupled Nucleotide Excision Repair (TC-NER) | 69 | 1.23e-04 | -0.267000 | 1.75e-03 |
SUMOylation of SUMOylation proteins | 32 | 8.93e-03 | -0.267000 | 3.53e-02 |
Dectin-1 mediated noncanonical NF-kB signaling | 52 | 8.69e-04 | -0.267000 | 6.57e-03 |
The role of GTSE1 in G2/M progression after G2 checkpoint | 52 | 8.74e-04 | -0.267000 | 6.57e-03 |
DNA strand elongation | 28 | 1.47e-02 | -0.266000 | 5.38e-02 |
Processive synthesis on the C-strand of the telomere | 17 | 5.75e-02 | -0.266000 | 1.48e-01 |
Degradation of beta-catenin by the destruction complex | 68 | 1.49e-04 | -0.266000 | 1.95e-03 |
Degradation of DVL | 48 | 1.46e-03 | -0.266000 | 8.83e-03 |
Triglyceride catabolism | 11 | 1.28e-01 | -0.265000 | 2.55e-01 |
Stabilization of p53 | 49 | 1.35e-03 | -0.265000 | 8.45e-03 |
Signaling by FGFR in disease | 39 | 4.23e-03 | -0.265000 | 1.92e-02 |
Asymmetric localization of PCP proteins | 51 | 1.10e-03 | -0.264000 | 7.59e-03 |
mRNA Splicing - Minor Pathway | 49 | 1.38e-03 | -0.264000 | 8.55e-03 |
NIK–>noncanonical NF-kB signaling | 51 | 1.11e-03 | -0.264000 | 7.59e-03 |
Base-Excision Repair, AP Site Formation | 15 | 7.70e-02 | -0.264000 | 1.79e-01 |
Hh mutants are degraded by ERAD | 47 | 1.77e-03 | -0.264000 | 1.02e-02 |
Mismatch Repair | 13 | 1.00e-01 | -0.263000 | 2.14e-01 |
Interleukin-6 signaling | 10 | 1.51e-01 | -0.263000 | 2.84e-01 |
DNA Damage/Telomere Stress Induced Senescence | 24 | 2.60e-02 | -0.263000 | 8.32e-02 |
Elastic fibre formation | 17 | 6.10e-02 | 0.262000 | 1.53e-01 |
Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants | 14 | 8.92e-02 | -0.262000 | 1.99e-01 |
Signaling by Ligand-Responsive EGFR Variants in Cancer | 14 | 8.92e-02 | -0.262000 | 1.99e-01 |
Signaling by NOTCH4 | 68 | 1.88e-04 | -0.262000 | 2.27e-03 |
Host Interactions of HIV factors | 106 | 3.46e-06 | -0.261000 | 1.30e-04 |
Diseases associated with glycosylation precursor biosynthesis | 15 | 8.03e-02 | -0.261000 | 1.84e-01 |
Synthesis of IP3 and IP4 in the cytosol | 16 | 7.10e-02 | -0.261000 | 1.68e-01 |
Rap1 signalling | 11 | 1.36e-01 | -0.260000 | 2.66e-01 |
Defective Intrinsic Pathway for Apoptosis | 23 | 3.13e-02 | -0.259000 | 9.39e-02 |
Transport of Ribonucleoproteins into the Host Nucleus | 30 | 1.40e-02 | -0.259000 | 5.17e-02 |
RIPK1-mediated regulated necrosis | 25 | 2.50e-02 | -0.259000 | 8.09e-02 |
Regulation of necroptotic cell death | 25 | 2.50e-02 | -0.259000 | 8.09e-02 |
SEMA3A-Plexin repulsion signaling by inhibiting Integrin adhesion | 10 | 1.56e-01 | 0.259000 | 2.89e-01 |
Ub-specific processing proteases | 134 | 2.56e-07 | -0.258000 | 1.40e-05 |
TP53 Regulates Transcription of Cell Cycle Genes | 43 | 3.41e-03 | -0.258000 | 1.68e-02 |
Glyoxylate metabolism and glycine degradation | 19 | 5.14e-02 | -0.258000 | 1.36e-01 |
Nuclear events mediated by NFE2L2 | 67 | 2.65e-04 | -0.258000 | 2.84e-03 |
Beta-catenin phosphorylation cascade | 15 | 8.46e-02 | -0.257000 | 1.91e-01 |
Resolution of Sister Chromatid Cohesion | 92 | 2.12e-05 | -0.257000 | 5.92e-04 |
Cobalamin (Cbl, vitamin B12) transport and metabolism | 11 | 1.40e-01 | -0.257000 | 2.70e-01 |
Inhibition of replication initiation of damaged DNA by RB1/E2F1 | 10 | 1.61e-01 | -0.256000 | 2.95e-01 |
APC:Cdc20 mediated degradation of cell cycle proteins prior to satisfation of the cell cycle checkpoint | 63 | 4.46e-04 | -0.256000 | 4.05e-03 |
Collagen degradation | 14 | 9.91e-02 | 0.255000 | 2.13e-01 |
Formation of TC-NER Pre-Incision Complex | 46 | 2.95e-03 | -0.254000 | 1.50e-02 |
RNA Polymerase III Chain Elongation | 17 | 7.07e-02 | -0.253000 | 1.68e-01 |
Defective TPR may confer susceptibility towards thyroid papillary carcinoma (TPC) | 28 | 2.05e-02 | -0.253000 | 7.00e-02 |
Regulation of Glucokinase by Glucokinase Regulatory Protein | 28 | 2.05e-02 | -0.253000 | 7.00e-02 |
Transcription of E2F targets under negative control by p107 (RBL1) and p130 (RBL2) in complex with HDAC1 | 15 | 8.98e-02 | -0.253000 | 1.99e-01 |
Cdc20:Phospho-APC/C mediated degradation of Cyclin A | 62 | 5.92e-04 | -0.252000 | 5.12e-03 |
TP53 regulates transcription of additional cell cycle genes whose exact role in the p53 pathway remain uncertain | 18 | 6.39e-02 | -0.252000 | 1.59e-01 |
Separation of Sister Chromatids | 147 | 1.47e-07 | -0.252000 | 9.28e-06 |
Regulation of expression of SLITs and ROBOs | 124 | 1.37e-06 | -0.251000 | 5.75e-05 |
Influenza Infection | 130 | 7.70e-07 | -0.251000 | 3.56e-05 |
tRNA Aminoacylation | 23 | 3.75e-02 | -0.251000 | 1.09e-01 |
Telomere Maintenance | 57 | 1.10e-03 | -0.250000 | 7.59e-03 |
RNA Polymerase I Transcription Termination | 25 | 3.09e-02 | -0.249000 | 9.33e-02 |
CLEC7A (Dectin-1) signaling | 84 | 8.06e-05 | -0.249000 | 1.51e-03 |
APC/C:Cdc20 mediated degradation of mitotic proteins | 65 | 5.34e-04 | -0.249000 | 4.72e-03 |
PCNA-Dependent Long Patch Base Excision Repair | 18 | 6.85e-02 | -0.248000 | 1.66e-01 |
Translocation of SLC2A4 (GLUT4) to the plasma membrane | 45 | 4.14e-03 | -0.247000 | 1.89e-02 |
Vitamin B5 (pantothenate) metabolism | 11 | 1.56e-01 | -0.247000 | 2.89e-01 |
Sema4D induced cell migration and growth-cone collapse | 12 | 1.39e-01 | 0.247000 | 2.70e-01 |
RNA Polymerase I Promoter Escape | 27 | 2.66e-02 | -0.247000 | 8.43e-02 |
HIV Life Cycle | 129 | 1.39e-06 | -0.247000 | 5.75e-05 |
Mitochondrial tRNA aminoacylation | 18 | 7.03e-02 | -0.246000 | 1.67e-01 |
SARS-CoV-2 modulates autophagy | 11 | 1.57e-01 | -0.246000 | 2.89e-01 |
APC truncation mutants have impaired AXIN binding | 12 | 1.40e-01 | -0.246000 | 2.70e-01 |
AXIN missense mutants destabilize the destruction complex | 12 | 1.40e-01 | -0.246000 | 2.70e-01 |
Signaling by AMER1 mutants | 12 | 1.40e-01 | -0.246000 | 2.70e-01 |
Signaling by APC mutants | 12 | 1.40e-01 | -0.246000 | 2.70e-01 |
Signaling by AXIN mutants | 12 | 1.40e-01 | -0.246000 | 2.70e-01 |
Truncations of AMER1 destabilize the destruction complex | 12 | 1.40e-01 | -0.246000 | 2.70e-01 |
MAPK6/MAPK4 signaling | 69 | 4.11e-04 | -0.246000 | 3.83e-03 |
Base Excision Repair | 38 | 8.73e-03 | -0.246000 | 3.48e-02 |
G-protein activation | 13 | 1.25e-01 | 0.246000 | 2.50e-01 |
Signaling by ALK | 18 | 7.15e-02 | -0.245000 | 1.69e-01 |
Late Phase of HIV Life Cycle | 117 | 5.20e-06 | -0.244000 | 1.84e-04 |
Influenza Viral RNA Transcription and Replication | 113 | 7.73e-06 | -0.244000 | 2.58e-04 |
Metabolism of polyamines | 48 | 3.53e-03 | -0.244000 | 1.72e-02 |
UCH proteinases | 74 | 2.97e-04 | -0.243000 | 3.08e-03 |
Amplification of signal from unattached kinetochores via a MAD2 inhibitory signal | 83 | 1.29e-04 | -0.243000 | 1.75e-03 |
Amplification of signal from the kinetochores | 83 | 1.29e-04 | -0.243000 | 1.75e-03 |
Activation of APC/C and APC/C:Cdc20 mediated degradation of mitotic proteins | 66 | 6.36e-04 | -0.243000 | 5.38e-03 |
Chromosome Maintenance | 78 | 2.07e-04 | -0.243000 | 2.39e-03 |
Resolution of Abasic Sites (AP sites) | 31 | 1.92e-02 | -0.243000 | 6.69e-02 |
Recruitment of NuMA to mitotic centrosomes | 65 | 7.08e-04 | -0.243000 | 5.75e-03 |
Glycolysis | 57 | 1.52e-03 | -0.243000 | 9.01e-03 |
Signaling by FLT3 ITD and TKD mutants | 12 | 1.45e-01 | -0.243000 | 2.77e-01 |
G2/M DNA damage checkpoint | 54 | 2.04e-03 | -0.243000 | 1.13e-02 |
Interleukin-1 signaling | 79 | 1.94e-04 | -0.243000 | 2.31e-03 |
APC/C:Cdc20 mediated degradation of Securin | 58 | 1.43e-03 | -0.242000 | 8.77e-03 |
FCERI mediated NF-kB activation | 64 | 8.58e-04 | -0.241000 | 6.56e-03 |
Defective pyroptosis | 10 | 1.89e-01 | -0.240000 | 3.35e-01 |
Diseases of DNA repair | 45 | 5.39e-03 | -0.240000 | 2.33e-02 |
Activation of NF-kappaB in B cells | 57 | 1.75e-03 | -0.240000 | 1.02e-02 |
Nucleotide Excision Repair | 99 | 4.05e-05 | -0.239000 | 9.13e-04 |
SUMOylation of intracellular receptors | 19 | 7.21e-02 | -0.238000 | 1.70e-01 |
NS1 Mediated Effects on Host Pathways | 38 | 1.12e-02 | -0.238000 | 4.30e-02 |
RUNX3 regulates NOTCH signaling | 11 | 1.73e-01 | -0.237000 | 3.11e-01 |
HIV Infection | 190 | 1.91e-08 | -0.237000 | 1.77e-06 |
TP53 Regulates Transcription of Genes Involved in G2 Cell Cycle Arrest | 16 | 1.01e-01 | -0.237000 | 2.16e-01 |
G1/S Transition | 115 | 1.20e-05 | -0.237000 | 3.81e-04 |
G0 and Early G1 | 24 | 4.50e-02 | -0.236000 | 1.27e-01 |
Oxygen-dependent proline hydroxylation of Hypoxia-inducible Factor Alpha | 53 | 3.02e-03 | -0.236000 | 1.53e-02 |
Signaling by NOTCH2 | 18 | 8.36e-02 | -0.236000 | 1.90e-01 |
Retrograde transport at the Trans-Golgi-Network | 45 | 6.45e-03 | -0.235000 | 2.67e-02 |
TBC/RABGAPs | 40 | 1.05e-02 | -0.234000 | 4.06e-02 |
Potassium Channels | 30 | 2.68e-02 | 0.234000 | 8.47e-02 |
Cellular response to hypoxia | 60 | 1.76e-03 | -0.234000 | 1.02e-02 |
Defective CFTR causes cystic fibrosis | 52 | 3.60e-03 | -0.233000 | 1.74e-02 |
Regulation of TP53 Activity through Phosphorylation | 79 | 3.45e-04 | -0.233000 | 3.37e-03 |
Autodegradation of Cdh1 by Cdh1:APC/C | 56 | 2.57e-03 | -0.233000 | 1.37e-02 |
Caspase activation via Death Receptors in the presence of ligand | 10 | 2.03e-01 | -0.232000 | 3.55e-01 |
SUMOylation of ubiquitinylation proteins | 37 | 1.48e-02 | -0.232000 | 5.39e-02 |
RUNX3 regulates p14-ARF | 10 | 2.05e-01 | -0.231000 | 3.57e-01 |
Mitotic Prometaphase | 158 | 5.78e-07 | -0.231000 | 2.78e-05 |
Estrogen-dependent gene expression | 70 | 8.51e-04 | -0.231000 | 6.56e-03 |
Transport of Mature Transcript to Cytoplasm | 64 | 1.44e-03 | -0.231000 | 8.77e-03 |
Nonsense Mediated Decay (NMD) enhanced by the Exon Junction Complex (EJC) | 88 | 1.89e-04 | -0.231000 | 2.27e-03 |
Nonsense-Mediated Decay (NMD) | 88 | 1.89e-04 | -0.231000 | 2.27e-03 |
Translesion synthesis by POLI | 15 | 1.22e-01 | -0.230000 | 2.47e-01 |
Class A/1 (Rhodopsin-like receptors) | 49 | 5.34e-03 | 0.230000 | 2.32e-02 |
Positive epigenetic regulation of rRNA expression | 40 | 1.19e-02 | -0.230000 | 4.51e-02 |
Deposition of new CENPA-containing nucleosomes at the centromere | 23 | 5.64e-02 | -0.230000 | 1.47e-01 |
Nucleosome assembly | 23 | 5.64e-02 | -0.230000 | 1.47e-01 |
Regulation of gene expression in late stage (branching morphogenesis) pancreatic bud precursor cells | 11 | 1.87e-01 | -0.230000 | 3.32e-01 |
CDK-mediated phosphorylation and removal of Cdc6 | 62 | 1.77e-03 | -0.230000 | 1.02e-02 |
RNA Polymerase I Transcription Initiation | 40 | 1.26e-02 | -0.228000 | 4.73e-02 |
Nonsense Mediated Decay (NMD) independent of the Exon Junction Complex (EJC) | 74 | 7.07e-04 | -0.228000 | 5.75e-03 |
CTNNB1 S33 mutants aren’t phosphorylated | 13 | 1.55e-01 | -0.228000 | 2.88e-01 |
CTNNB1 S37 mutants aren’t phosphorylated | 13 | 1.55e-01 | -0.228000 | 2.88e-01 |
CTNNB1 S45 mutants aren’t phosphorylated | 13 | 1.55e-01 | -0.228000 | 2.88e-01 |
CTNNB1 T41 mutants aren’t phosphorylated | 13 | 1.55e-01 | -0.228000 | 2.88e-01 |
Signaling by CTNNB1 phospho-site mutants | 13 | 1.55e-01 | -0.228000 | 2.88e-01 |
Signaling by GSK3beta mutants | 13 | 1.55e-01 | -0.228000 | 2.88e-01 |
Deubiquitination | 198 | 3.72e-08 | -0.228000 | 2.80e-06 |
Mismatch repair (MMR) directed by MSH2:MSH6 (MutSalpha) | 12 | 1.74e-01 | -0.227000 | 3.11e-01 |
Mitotic G1 phase and G1/S transition | 129 | 9.08e-06 | -0.227000 | 2.95e-04 |
Hedgehog ‘on’ state | 63 | 1.95e-03 | -0.226000 | 1.09e-02 |
RHO GTPases Activate Formins | 102 | 8.45e-05 | -0.226000 | 1.54e-03 |
TNFR1-induced NFkappaB signaling pathway | 20 | 8.08e-02 | -0.226000 | 1.85e-01 |
tRNA processing in the nucleus | 55 | 3.87e-03 | -0.225000 | 1.82e-02 |
Downstream signaling events of B Cell Receptor (BCR) | 70 | 1.13e-03 | -0.225000 | 7.72e-03 |
KEAP1-NFE2L2 pathway | 86 | 3.25e-04 | -0.224000 | 3.31e-03 |
Gene Silencing by RNA | 62 | 2.26e-03 | -0.224000 | 1.24e-02 |
Polo-like kinase mediated events | 15 | 1.34e-01 | -0.224000 | 2.65e-01 |
RUNX1 regulates transcription of genes involved in differentiation of HSCs | 57 | 3.52e-03 | -0.224000 | 1.72e-02 |
EML4 and NUDC in mitotic spindle formation | 87 | 3.29e-04 | -0.223000 | 3.32e-03 |
Signaling by ROBO receptors | 154 | 1.89e-06 | -0.223000 | 7.58e-05 |
Signaling by EGFR in Cancer | 16 | 1.25e-01 | -0.222000 | 2.50e-01 |
Gap-filling DNA repair synthesis and ligation in GG-NER | 23 | 6.60e-02 | -0.221000 | 1.62e-01 |
Centrosome maturation | 66 | 1.92e-03 | -0.221000 | 1.08e-02 |
Recruitment of mitotic centrosome proteins and complexes | 66 | 1.92e-03 | -0.221000 | 1.08e-02 |
Orc1 removal from chromatin | 62 | 2.66e-03 | -0.221000 | 1.40e-02 |
Regulation of APC/C activators between G1/S and early anaphase | 70 | 1.44e-03 | -0.220000 | 8.77e-03 |
Downstream signal transduction | 20 | 8.84e-02 | -0.220000 | 1.98e-01 |
Purine catabolism | 10 | 2.28e-01 | -0.220000 | 3.86e-01 |
Diseases associated with O-glycosylation of proteins | 21 | 8.09e-02 | 0.220000 | 1.85e-01 |
Dual Incision in GG-NER | 35 | 2.46e-02 | -0.220000 | 8.00e-02 |
Transcription of E2F targets under negative control by DREAM complex | 18 | 1.07e-01 | -0.219000 | 2.26e-01 |
Pyruvate metabolism | 20 | 8.99e-02 | -0.219000 | 1.99e-01 |
Hedgehog ‘off’ state | 75 | 1.07e-03 | -0.219000 | 7.59e-03 |
RNA Polymerase III Abortive And Retractive Initiation | 39 | 1.82e-02 | -0.219000 | 6.41e-02 |
RNA Polymerase III Transcription | 39 | 1.82e-02 | -0.219000 | 6.41e-02 |
Impaired BRCA2 binding to RAD51 | 32 | 3.28e-02 | -0.218000 | 9.74e-02 |
Negative regulators of DDX58/IFIH1 signaling | 34 | 2.78e-02 | -0.218000 | 8.73e-02 |
ABC transporter disorders | 59 | 3.82e-03 | -0.218000 | 1.81e-02 |
Meiotic recombination | 19 | 1.00e-01 | -0.218000 | 2.14e-01 |
Regulation of PLK1 Activity at G2/M Transition | 74 | 1.22e-03 | -0.218000 | 7.94e-03 |
CD28 dependent PI3K/Akt signaling | 18 | 1.10e-01 | -0.218000 | 2.29e-01 |
ERK/MAPK targets | 16 | 1.32e-01 | -0.217000 | 2.63e-01 |
Condensation of Prometaphase Chromosomes | 10 | 2.36e-01 | -0.217000 | 3.95e-01 |
G2/M Checkpoints | 119 | 4.63e-05 | -0.217000 | 9.77e-04 |
Glycogen metabolism | 17 | 1.22e-01 | -0.216000 | 2.47e-01 |
Regulation of cholesterol biosynthesis by SREBP (SREBF) | 48 | 9.69e-03 | -0.216000 | 3.78e-02 |
HDR through Homologous Recombination (HRR) or Single Strand Annealing (SSA) | 84 | 6.46e-04 | -0.216000 | 5.43e-03 |
SRP-dependent cotranslational protein targeting to membrane | 88 | 4.84e-04 | -0.215000 | 4.31e-03 |
Selenoamino acid metabolism | 78 | 1.05e-03 | -0.215000 | 7.46e-03 |
Mitotic Metaphase and Anaphase | 196 | 2.44e-07 | -0.214000 | 1.40e-05 |
p75NTR signals via NF-kB | 11 | 2.18e-01 | -0.214000 | 3.73e-01 |
APC/C-mediated degradation of cell cycle proteins | 77 | 1.17e-03 | -0.214000 | 7.75e-03 |
Regulation of mitotic cell cycle | 77 | 1.17e-03 | -0.214000 | 7.75e-03 |
Cleavage of the damaged pyrimidine | 14 | 1.65e-01 | -0.214000 | 3.00e-01 |
Depyrimidination | 14 | 1.65e-01 | -0.214000 | 3.00e-01 |
Recognition and association of DNA glycosylase with site containing an affected pyrimidine | 14 | 1.65e-01 | -0.214000 | 3.00e-01 |
Sema4D in semaphorin signaling | 15 | 1.51e-01 | 0.214000 | 2.85e-01 |
Pyruvate metabolism and Citric Acid (TCA) cycle | 41 | 1.78e-02 | -0.214000 | 6.33e-02 |
S Phase | 141 | 1.25e-05 | -0.214000 | 3.85e-04 |
Diseases associated with glycosaminoglycan metabolism | 16 | 1.40e-01 | -0.213000 | 2.70e-01 |
Mitotic Anaphase | 195 | 3.32e-07 | -0.213000 | 1.74e-05 |
Long-term potentiation | 11 | 2.22e-01 | 0.212000 | 3.78e-01 |
LDL clearance | 12 | 2.04e-01 | -0.212000 | 3.56e-01 |
Cap-dependent Translation Initiation | 95 | 3.80e-04 | -0.211000 | 3.59e-03 |
Eukaryotic Translation Initiation | 95 | 3.80e-04 | -0.211000 | 3.59e-03 |
Processing of DNA double-strand break ends | 55 | 6.80e-03 | -0.211000 | 2.79e-02 |
Homology Directed Repair | 90 | 5.63e-04 | -0.211000 | 4.94e-03 |
Ion homeostasis | 26 | 6.38e-02 | -0.210000 | 1.59e-01 |
APC/C:Cdh1 mediated degradation of Cdc20 and other APC/C:Cdh1 targeted proteins in late mitosis/early G1 | 64 | 3.79e-03 | -0.209000 | 1.80e-02 |
Eukaryotic Translation Termination | 72 | 2.15e-03 | -0.209000 | 1.18e-02 |
Citric acid cycle (TCA cycle) | 19 | 1.16e-01 | -0.208000 | 2.39e-01 |
Nuclear Pore Complex (NPC) Disassembly | 34 | 3.57e-02 | -0.208000 | 1.04e-01 |
Eukaryotic Translation Elongation | 72 | 2.29e-03 | -0.208000 | 1.25e-02 |
Signaling by NTRK3 (TRKC) | 11 | 2.32e-01 | -0.208000 | 3.91e-01 |
InlB-mediated entry of Listeria monocytogenes into host cell | 11 | 2.32e-01 | -0.208000 | 3.91e-01 |
Signaling by Retinoic Acid | 17 | 1.38e-01 | -0.208000 | 2.70e-01 |
HCMV Infection | 71 | 2.59e-03 | -0.207000 | 1.38e-02 |
Downstream TCR signaling | 71 | 2.63e-03 | -0.207000 | 1.39e-02 |
Selenocysteine synthesis | 70 | 2.85e-03 | -0.206000 | 1.47e-02 |
Regulation of pyruvate dehydrogenase (PDH) complex | 11 | 2.36e-01 | -0.206000 | 3.95e-01 |
Cell Cycle Checkpoints | 228 | 9.43e-08 | -0.206000 | 6.67e-06 |
Mitotic Spindle Checkpoint | 98 | 4.37e-04 | -0.206000 | 4.01e-03 |
Cyclin A/B1/B2 associated events during G2/M transition | 22 | 9.65e-02 | -0.205000 | 2.09e-01 |
Activation of HOX genes during differentiation | 41 | 2.35e-02 | -0.205000 | 7.78e-02 |
Activation of anterior HOX genes in hindbrain development during early embryogenesis | 41 | 2.35e-02 | -0.205000 | 7.78e-02 |
COPI-mediated anterograde transport | 71 | 2.95e-03 | -0.204000 | 1.50e-02 |
Regulation of mRNA stability by proteins that bind AU-rich elements | 77 | 2.01e-03 | -0.204000 | 1.12e-02 |
NOTCH3 Activation and Transmission of Signal to the Nucleus | 15 | 1.72e-01 | -0.204000 | 3.10e-01 |
Signaling by FGFR2 | 48 | 1.47e-02 | -0.204000 | 5.38e-02 |
RHO GTPases activate CIT | 14 | 1.87e-01 | -0.204000 | 3.33e-01 |
M Phase | 297 | 2.01e-09 | -0.203000 | 2.01e-07 |
Resolution of AP sites via the multiple-nucleotide patch replacement pathway | 20 | 1.17e-01 | -0.202000 | 2.40e-01 |
Glutathione conjugation | 21 | 1.09e-01 | -0.202000 | 2.27e-01 |
Mitochondrial Fatty Acid Beta-Oxidation | 26 | 7.47e-02 | -0.202000 | 1.75e-01 |
Triglyceride metabolism | 16 | 1.62e-01 | -0.202000 | 2.96e-01 |
Removal of the Flap Intermediate from the C-strand | 15 | 1.77e-01 | -0.201000 | 3.17e-01 |
Activation of gene expression by SREBF (SREBP) | 36 | 3.68e-02 | -0.201000 | 1.07e-01 |
Thrombin signalling through proteinase activated receptors (PARs) | 20 | 1.19e-01 | 0.201000 | 2.43e-01 |
RNA polymerase II transcribes snRNA genes | 71 | 3.47e-03 | -0.201000 | 1.70e-02 |
Transcriptional regulation by RUNX3 | 75 | 2.69e-03 | -0.201000 | 1.41e-02 |
Peptide chain elongation | 69 | 4.03e-03 | -0.200000 | 1.85e-02 |
Mitotic G2-G2/M phases | 158 | 1.51e-05 | -0.200000 | 4.55e-04 |
Homologous DNA Pairing and Strand Exchange | 39 | 3.10e-02 | -0.200000 | 9.33e-02 |
Metabolism of carbohydrates | 181 | 3.82e-06 | -0.200000 | 1.39e-04 |
Organelle biogenesis and maintenance | 204 | 9.52e-07 | -0.200000 | 4.24e-05 |
DNA Double-Strand Break Repair | 117 | 1.97e-04 | -0.200000 | 2.32e-03 |
Prostacyclin signalling through prostacyclin receptor | 12 | 2.32e-01 | 0.199000 | 3.91e-01 |
Translesion synthesis by REV1 | 14 | 1.98e-01 | -0.199000 | 3.47e-01 |
Translation | 238 | 1.46e-07 | -0.199000 | 9.28e-06 |
Class I peroxisomal membrane protein import | 19 | 1.34e-01 | -0.199000 | 2.65e-01 |
Cilium Assembly | 150 | 2.85e-05 | -0.198000 | 7.28e-04 |
Apoptosis | 133 | 8.20e-05 | -0.198000 | 1.52e-03 |
Mitochondrial biogenesis | 54 | 1.18e-02 | -0.198000 | 4.50e-02 |
Formation of Incision Complex in GG-NER | 36 | 4.01e-02 | -0.198000 | 1.15e-01 |
Transcriptional regulation by RUNX2 | 84 | 1.78e-03 | -0.197000 | 1.02e-02 |
HDR through Homologous Recombination (HRR) | 60 | 8.45e-03 | -0.197000 | 3.39e-02 |
G2/M Transition | 156 | 2.35e-05 | -0.197000 | 6.43e-04 |
Nuclear Receptor transcription pathway | 27 | 7.81e-02 | -0.196000 | 1.81e-01 |
Arachidonic acid metabolism | 21 | 1.20e-01 | 0.196000 | 2.44e-01 |
Viral mRNA Translation | 69 | 5.02e-03 | -0.196000 | 2.22e-02 |
Depolymerisation of the Nuclear Lamina | 13 | 2.22e-01 | 0.195000 | 3.78e-01 |
Diseases of mitotic cell cycle | 34 | 4.88e-02 | -0.195000 | 1.34e-01 |
DDX58/IFIH1-mediated induction of interferon-alpha/beta | 58 | 1.05e-02 | -0.194000 | 4.06e-02 |
Signaling by the B Cell Receptor (BCR) | 90 | 1.47e-03 | -0.194000 | 8.83e-03 |
Formation of a pool of free 40S subunits | 78 | 3.08e-03 | -0.194000 | 1.55e-02 |
Mitochondrial iron-sulfur cluster biogenesis | 12 | 2.46e-01 | -0.194000 | 4.08e-01 |
RNA Polymerase I Promoter Clearance | 44 | 2.64e-02 | -0.194000 | 8.40e-02 |
RNA Polymerase I Transcription | 44 | 2.64e-02 | -0.194000 | 8.40e-02 |
Nucleotide biosynthesis | 12 | 2.46e-01 | -0.193000 | 4.08e-01 |
tRNA processing | 93 | 1.30e-03 | -0.193000 | 8.28e-03 |
ABC-family proteins mediated transport | 74 | 4.10e-03 | -0.193000 | 1.88e-02 |
Global Genome Nucleotide Excision Repair (GG-NER) | 76 | 3.71e-03 | -0.193000 | 1.78e-02 |
Gamma carboxylation, hypusine formation and arylsulfatase activation | 23 | 1.10e-01 | -0.193000 | 2.28e-01 |
Synthesis of DNA | 106 | 6.30e-04 | -0.192000 | 5.37e-03 |
Response of EIF2AK4 (GCN2) to amino acid deficiency | 78 | 3.41e-03 | -0.192000 | 1.68e-02 |
Intrinsic Pathway for Apoptosis | 47 | 2.29e-02 | -0.192000 | 7.66e-02 |
Signaling by ERBB2 KD Mutants | 12 | 2.50e-01 | -0.192000 | 4.13e-01 |
C-type lectin receptors (CLRs) | 100 | 9.71e-04 | -0.191000 | 7.03e-03 |
SUMOylation of DNA replication proteins | 43 | 3.03e-02 | -0.191000 | 9.28e-02 |
ABC transporters in lipid homeostasis | 10 | 2.96e-01 | 0.191000 | 4.66e-01 |
Meiosis | 42 | 3.28e-02 | -0.190000 | 9.74e-02 |
COPI-dependent Golgi-to-ER retrograde traffic | 66 | 7.53e-03 | -0.190000 | 3.06e-02 |
Regulated Necrosis | 43 | 3.09e-02 | -0.190000 | 9.33e-02 |
Methylation | 10 | 2.98e-01 | -0.190000 | 4.67e-01 |
RNA Polymerase III Transcription Initiation | 35 | 5.18e-02 | -0.190000 | 1.37e-01 |
Cell Cycle, Mitotic | 425 | 2.80e-11 | -0.190000 | 4.80e-09 |
Golgi-to-ER retrograde transport | 95 | 1.50e-03 | -0.189000 | 8.96e-03 |
Constitutive Signaling by AKT1 E17K in Cancer | 23 | 1.17e-01 | -0.189000 | 2.40e-01 |
Unwinding of DNA | 11 | 2.79e-01 | -0.189000 | 4.48e-01 |
Interleukin-1 family signaling | 99 | 1.21e-03 | -0.188000 | 7.94e-03 |
Metabolism of non-coding RNA | 48 | 2.42e-02 | -0.188000 | 7.89e-02 |
snRNP Assembly | 48 | 2.42e-02 | -0.188000 | 7.89e-02 |
RHO GTPases activate PKNs | 26 | 9.75e-02 | -0.188000 | 2.10e-01 |
SARS-CoV-2 activates/modulates innate and adaptive immune responses | 88 | 2.38e-03 | -0.188000 | 1.29e-02 |
DNA Repair | 248 | 4.03e-07 | -0.188000 | 2.02e-05 |
Cellular response to chemical stress | 145 | 1.02e-04 | -0.187000 | 1.70e-03 |
GTP hydrolysis and joining of the 60S ribosomal subunit | 88 | 2.48e-03 | -0.187000 | 1.34e-02 |
Cytoprotection by HMOX1 | 44 | 3.21e-02 | -0.187000 | 9.59e-02 |
TICAM1-dependent activation of IRF3/IRF7 | 12 | 2.64e-01 | -0.186000 | 4.28e-01 |
Cell Cycle | 530 | 4.69e-13 | -0.185000 | 1.41e-10 |
Respiratory electron transport, ATP synthesis by chemiosmotic coupling, and heat production by uncoupling proteins. | 83 | 3.67e-03 | -0.185000 | 1.77e-02 |
Metabolism of water-soluble vitamins and cofactors | 82 | 3.92e-03 | -0.184000 | 1.82e-02 |
HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand | 33 | 6.69e-02 | -0.184000 | 1.64e-01 |
Presynaptic phase of homologous DNA pairing and strand exchange | 36 | 5.61e-02 | -0.184000 | 1.47e-01 |
Transport of Mature mRNA derived from an Intron-Containing Transcript | 55 | 1.87e-02 | -0.183000 | 6.55e-02 |
RHOD GTPase cycle | 36 | 5.70e-02 | 0.183000 | 1.47e-01 |
Translesion synthesis by POLK | 15 | 2.19e-01 | -0.183000 | 3.74e-01 |
COPI-independent Golgi-to-ER retrograde traffic | 29 | 8.86e-02 | -0.183000 | 1.98e-01 |
Cell-cell junction organization | 13 | 2.54e-01 | 0.183000 | 4.18e-01 |
PCP/CE pathway | 71 | 8.05e-03 | -0.182000 | 3.26e-02 |
Translesion Synthesis by POLH | 17 | 1.94e-01 | -0.182000 | 3.42e-01 |
Circadian Clock | 52 | 2.36e-02 | -0.182000 | 7.78e-02 |
TGF-beta receptor signaling in EMT (epithelial to mesenchymal transition) | 13 | 2.59e-01 | -0.181000 | 4.22e-01 |
The citric acid (TCA) cycle and respiratory electron transport | 121 | 6.11e-04 | -0.181000 | 5.25e-03 |
Semaphorin interactions | 39 | 5.11e-02 | 0.181000 | 1.36e-01 |
HATs acetylate histones | 63 | 1.34e-02 | -0.180000 | 4.97e-02 |
Intra-Golgi and retrograde Golgi-to-ER traffic | 158 | 1.12e-04 | -0.178000 | 1.75e-03 |
RUNX1 regulates genes involved in megakaryocyte differentiation and platelet function | 29 | 9.66e-02 | 0.178000 | 2.09e-01 |
Estrogen-dependent nuclear events downstream of ESR-membrane signaling | 16 | 2.18e-01 | -0.178000 | 3.73e-01 |
L13a-mediated translational silencing of Ceruloplasmin expression | 87 | 4.22e-03 | -0.178000 | 1.92e-02 |
Miscellaneous transport and binding events | 14 | 2.50e-01 | -0.178000 | 4.13e-01 |
GPCR ligand binding | 80 | 6.11e-03 | 0.178000 | 2.55e-02 |
Regulation of IFNA/IFNB signaling | 12 | 2.87e-01 | -0.177000 | 4.58e-01 |
Programmed Cell Death | 155 | 1.45e-04 | -0.177000 | 1.92e-03 |
Respiratory electron transport | 82 | 5.69e-03 | -0.177000 | 2.43e-02 |
Aberrant regulation of mitotic cell cycle due to RB1 defects | 33 | 7.92e-02 | -0.177000 | 1.82e-01 |
Translation of Structural Proteins | 27 | 1.12e-01 | -0.177000 | 2.33e-01 |
Keratan sulfate biosynthesis | 14 | 2.54e-01 | -0.176000 | 4.18e-01 |
DAG and IP3 signaling | 26 | 1.20e-01 | -0.176000 | 2.44e-01 |
Signaling by Hedgehog | 99 | 2.55e-03 | -0.176000 | 1.37e-02 |
Complex I biogenesis | 43 | 4.67e-02 | -0.175000 | 1.31e-01 |
Diseases of signal transduction by growth factor receptors and second messengers | 299 | 2.11e-07 | -0.175000 | 1.27e-05 |
Signalling to RAS | 12 | 2.94e-01 | -0.175000 | 4.66e-01 |
Extension of Telomeres | 44 | 4.49e-02 | -0.175000 | 1.27e-01 |
Post-chaperonin tubulin folding pathway | 13 | 2.77e-01 | -0.174000 | 4.45e-01 |
Aggrephagy | 19 | 1.90e-01 | -0.174000 | 3.36e-01 |
Switching of origins to a post-replicative state | 81 | 6.94e-03 | -0.174000 | 2.84e-02 |
Defective homologous recombination repair (HRR) due to BRCA2 loss of function | 37 | 6.76e-02 | -0.174000 | 1.64e-01 |
Diseases of DNA Double-Strand Break Repair | 37 | 6.76e-02 | -0.174000 | 1.64e-01 |
Signaling by FGFR | 52 | 3.06e-02 | -0.173000 | 9.32e-02 |
Sema3A PAK dependent Axon repulsion | 11 | 3.19e-01 | 0.173000 | 4.94e-01 |
ISG15 antiviral mechanism | 70 | 1.24e-02 | -0.173000 | 4.66e-02 |
ESR-mediated signaling | 115 | 1.38e-03 | -0.173000 | 8.55e-03 |
DNA Replication | 113 | 1.54e-03 | -0.173000 | 9.07e-03 |
Activation of BAD and translocation to mitochondria | 14 | 2.64e-01 | -0.173000 | 4.27e-01 |
PTK6 Regulates RHO GTPases, RAS GTPase and MAP kinases | 10 | 3.45e-01 | -0.173000 | 5.19e-01 |
Signaling by FLT3 fusion proteins | 16 | 2.33e-01 | -0.172000 | 3.91e-01 |
Translesion synthesis by Y family DNA polymerases bypasses lesions on DNA template | 35 | 7.82e-02 | -0.172000 | 1.81e-01 |
SARS-CoV-2-host interactions | 150 | 2.89e-04 | -0.172000 | 3.04e-03 |
Regulation of TNFR1 signaling | 31 | 9.84e-02 | -0.172000 | 2.12e-01 |
Peroxisomal lipid metabolism | 22 | 1.64e-01 | -0.172000 | 2.98e-01 |
Termination of translesion DNA synthesis | 28 | 1.17e-01 | -0.171000 | 2.40e-01 |
RNA Polymerase II Transcription Termination | 45 | 4.94e-02 | -0.169000 | 1.35e-01 |
Recognition of DNA damage by PCNA-containing replication complex | 26 | 1.36e-01 | -0.169000 | 2.66e-01 |
Phase II - Conjugation of compounds | 46 | 4.75e-02 | -0.169000 | 1.31e-01 |
Activation of BH3-only proteins | 27 | 1.30e-01 | -0.169000 | 2.59e-01 |
Platelet sensitization by LDL | 13 | 2.93e-01 | -0.168000 | 4.66e-01 |
Metabolism of vitamins and cofactors | 111 | 2.28e-03 | -0.168000 | 1.24e-02 |
Signaling by Nuclear Receptors | 151 | 4.00e-04 | -0.167000 | 3.76e-03 |
Cargo trafficking to the periciliary membrane | 40 | 6.74e-02 | -0.167000 | 1.64e-01 |
G-protein mediated events | 32 | 1.02e-01 | -0.167000 | 2.16e-01 |
FLT3 signaling in disease | 24 | 1.56e-01 | -0.167000 | 2.89e-01 |
Inwardly rectifying K+ channels | 13 | 2.97e-01 | 0.167000 | 4.66e-01 |
Glycosphingolipid metabolism | 27 | 1.34e-01 | -0.166000 | 2.65e-01 |
CD28 co-stimulation | 27 | 1.34e-01 | -0.166000 | 2.65e-01 |
Glycogen storage diseases | 10 | 3.62e-01 | -0.166000 | 5.36e-01 |
Negative epigenetic regulation of rRNA expression | 44 | 5.66e-02 | -0.166000 | 1.47e-01 |
Disease | 1086 | 1.37e-19 | -0.166000 | 1.65e-16 |
Metabolism of cofactors | 17 | 2.38e-01 | -0.165000 | 3.97e-01 |
Disorders of transmembrane transporters | 111 | 2.74e-03 | -0.165000 | 1.43e-02 |
SUMOylation of RNA binding proteins | 42 | 6.49e-02 | -0.165000 | 1.61e-01 |
ADP signalling through P2Y purinoceptor 1 | 16 | 2.55e-01 | 0.164000 | 4.19e-01 |
HDR through MMEJ (alt-NHEJ) | 11 | 3.45e-01 | -0.164000 | 5.19e-01 |
Assembly of the pre-replicative complex | 76 | 1.36e-02 | -0.164000 | 5.02e-02 |
Constitutive Signaling by NOTCH1 HD+PEST Domain Mutants | 41 | 6.98e-02 | -0.164000 | 1.67e-01 |
Constitutive Signaling by NOTCH1 PEST Domain Mutants | 41 | 6.98e-02 | -0.164000 | 1.67e-01 |
Signaling by NOTCH1 HD+PEST Domain Mutants in Cancer | 41 | 6.98e-02 | -0.164000 | 1.67e-01 |
Signaling by NOTCH1 PEST Domain Mutants in Cancer | 41 | 6.98e-02 | -0.164000 | 1.67e-01 |
Signaling by NOTCH1 in Cancer | 41 | 6.98e-02 | -0.164000 | 1.67e-01 |
IKK complex recruitment mediated by RIP1 | 17 | 2.43e-01 | -0.164000 | 4.04e-01 |
SARS-CoV-2 targets host intracellular signalling and regulatory pathways | 11 | 3.47e-01 | -0.164000 | 5.21e-01 |
Interleukin-12 family signaling | 42 | 6.74e-02 | -0.163000 | 1.64e-01 |
HCMV Late Events | 51 | 4.40e-02 | -0.163000 | 1.25e-01 |
RHO GTPase Effectors | 188 | 1.25e-04 | -0.163000 | 1.75e-03 |
Post-translational modification: synthesis of GPI-anchored proteins | 31 | 1.17e-01 | -0.163000 | 2.40e-01 |
MHC class II antigen presentation | 69 | 1.97e-02 | -0.163000 | 6.78e-02 |
RAC3 GTPase cycle | 59 | 3.09e-02 | 0.163000 | 9.33e-02 |
VxPx cargo-targeting to cilium | 16 | 2.61e-01 | -0.162000 | 4.23e-01 |
Chaperonin-mediated protein folding | 57 | 3.42e-02 | -0.162000 | 1.01e-01 |
DNA Replication Pre-Initiation | 90 | 8.13e-03 | -0.162000 | 3.28e-02 |
Nucleotide catabolism | 21 | 2.00e-01 | -0.161000 | 3.50e-01 |
Processing of Capped Intron-Containing Pre-mRNA | 199 | 1.00e-04 | -0.160000 | 1.70e-03 |
Infectious disease | 627 | 1.38e-11 | -0.160000 | 2.77e-09 |
Regulation of TP53 Activity | 136 | 1.32e-03 | -0.160000 | 8.38e-03 |
Metabolism of RNA | 553 | 2.04e-10 | -0.160000 | 3.06e-08 |
DNA Damage Bypass | 42 | 7.35e-02 | -0.160000 | 1.73e-01 |
Smooth Muscle Contraction | 19 | 2.29e-01 | -0.159000 | 3.87e-01 |
Metabolism of nucleotides | 73 | 1.87e-02 | -0.159000 | 6.55e-02 |
Protein folding | 63 | 2.90e-02 | -0.159000 | 9.02e-02 |
Transcriptional Regulation by TP53 | 302 | 2.36e-06 | -0.159000 | 9.15e-05 |
Factors involved in megakaryocyte development and platelet production | 87 | 1.09e-02 | -0.158000 | 4.19e-02 |
Energy dependent regulation of mTOR by LKB1-AMPK | 25 | 1.72e-01 | -0.158000 | 3.10e-01 |
Metabolism of amino acids and derivatives | 225 | 4.88e-05 | -0.158000 | 1.01e-03 |
Major pathway of rRNA processing in the nucleolus and cytosol | 152 | 8.26e-04 | -0.158000 | 6.49e-03 |
Role of LAT2/NTAL/LAB on calcium mobilization | 10 | 3.89e-01 | -0.157000 | 5.58e-01 |
Selective autophagy | 50 | 5.46e-02 | -0.157000 | 1.43e-01 |
PERK regulates gene expression | 26 | 1.66e-01 | -0.157000 | 3.01e-01 |
Reproduction | 48 | 6.09e-02 | -0.156000 | 1.53e-01 |
NOTCH2 Activation and Transmission of Signal to the Nucleus | 12 | 3.48e-01 | -0.156000 | 5.21e-01 |
Fc epsilon receptor (FCERI) signaling | 107 | 5.30e-03 | -0.156000 | 2.31e-02 |
Cyclin D associated events in G1 | 41 | 8.38e-02 | -0.156000 | 1.90e-01 |
G1 Phase | 41 | 8.38e-02 | -0.156000 | 1.90e-01 |
TNF signaling | 38 | 9.63e-02 | -0.156000 | 2.09e-01 |
p75 NTR receptor-mediated signalling | 59 | 3.84e-02 | -0.156000 | 1.11e-01 |
E3 ubiquitin ligases ubiquitinate target proteins | 41 | 8.55e-02 | -0.155000 | 1.93e-01 |
G beta:gamma signalling through BTK | 11 | 3.73e-01 | 0.155000 | 5.45e-01 |
Thromboxane signalling through TP receptor | 15 | 2.99e-01 | 0.155000 | 4.68e-01 |
Epigenetic regulation of gene expression | 76 | 1.97e-02 | -0.155000 | 6.78e-02 |
TCF dependent signaling in response to WNT | 119 | 3.60e-03 | -0.155000 | 1.74e-02 |
TNFR2 non-canonical NF-kB pathway | 68 | 2.78e-02 | -0.154000 | 8.73e-02 |
PLC beta mediated events | 29 | 1.52e-01 | -0.154000 | 2.85e-01 |
Signaling by EGFR | 35 | 1.15e-01 | -0.154000 | 2.39e-01 |
ZBP1(DAI) mediated induction of type I IFNs | 17 | 2.74e-01 | -0.153000 | 4.40e-01 |
Chaperone Mediated Autophagy | 12 | 3.58e-01 | -0.153000 | 5.31e-01 |
NOTCH1 Intracellular Domain Regulates Transcription | 37 | 1.07e-01 | -0.153000 | 2.26e-01 |
DNA Damage Recognition in GG-NER | 35 | 1.19e-01 | -0.152000 | 2.43e-01 |
Transcriptional Regulation by E2F6 | 29 | 1.56e-01 | -0.152000 | 2.89e-01 |
Signaling by CSF3 (G-CSF) | 24 | 1.98e-01 | -0.152000 | 3.47e-01 |
Interleukin-20 family signaling | 13 | 3.44e-01 | -0.152000 | 5.19e-01 |
SHC1 events in ERBB2 signaling | 11 | 3.84e-01 | 0.152000 | 5.55e-01 |
Apoptotic factor-mediated response | 16 | 2.95e-01 | -0.151000 | 4.66e-01 |
Nuclear Events (kinase and transcription factor activation) | 42 | 9.03e-02 | -0.151000 | 1.99e-01 |
SUMO E3 ligases SUMOylate target proteins | 132 | 2.88e-03 | -0.151000 | 1.48e-02 |
rRNA processing in the nucleus and cytosol | 159 | 1.09e-03 | -0.151000 | 7.59e-03 |
Golgi Associated Vesicle Biogenesis | 38 | 1.09e-01 | -0.150000 | 2.28e-01 |
Regulation of TP53 Degradation | 33 | 1.36e-01 | -0.150000 | 2.66e-01 |
MyD88-independent TLR4 cascade | 74 | 2.59e-02 | -0.150000 | 8.31e-02 |
TRIF(TICAM1)-mediated TLR4 signaling | 74 | 2.59e-02 | -0.150000 | 8.31e-02 |
rRNA processing | 164 | 9.65e-04 | -0.150000 | 7.03e-03 |
Regulation of TP53 Expression and Degradation | 34 | 1.34e-01 | -0.149000 | 2.65e-01 |
Deactivation of the beta-catenin transactivating complex | 28 | 1.73e-01 | -0.149000 | 3.11e-01 |
Activation of G protein gated Potassium channels | 12 | 3.74e-01 | 0.148000 | 5.45e-01 |
G protein gated Potassium channels | 12 | 3.74e-01 | 0.148000 | 5.45e-01 |
Inhibition of voltage gated Ca2+ channels via Gbeta/gamma subunits | 12 | 3.74e-01 | 0.148000 | 5.45e-01 |
Toll Like Receptor 4 (TLR4) Cascade | 94 | 1.32e-02 | -0.148000 | 4.91e-02 |
Interleukin-4 and Interleukin-13 signaling | 49 | 7.41e-02 | -0.148000 | 1.74e-01 |
Mitochondrial protein import | 48 | 7.74e-02 | -0.147000 | 1.80e-01 |
Drug ADME | 27 | 1.86e-01 | -0.147000 | 3.32e-01 |
Plasma lipoprotein clearance | 24 | 2.13e-01 | -0.147000 | 3.67e-01 |
FOXO-mediated transcription of cell death genes | 14 | 3.42e-01 | -0.147000 | 5.19e-01 |
Peroxisomal protein import | 48 | 7.90e-02 | -0.147000 | 1.82e-01 |
ATF4 activates genes in response to endoplasmic reticulum stress | 23 | 2.24e-01 | -0.146000 | 3.80e-01 |
Protein localization | 123 | 5.17e-03 | -0.146000 | 2.27e-02 |
SUMOylation of DNA damage response and repair proteins | 67 | 3.94e-02 | -0.146000 | 1.13e-01 |
TP53 Regulates Transcription of Genes Involved in Cytochrome C Release | 14 | 3.46e-01 | -0.145000 | 5.19e-01 |
Cellular response to starvation | 120 | 6.02e-03 | -0.145000 | 2.53e-02 |
Signaling by MET | 41 | 1.08e-01 | -0.145000 | 2.27e-01 |
Interferon alpha/beta signaling | 51 | 7.40e-02 | -0.145000 | 1.74e-01 |
AKT phosphorylates targets in the cytosol | 13 | 3.67e-01 | -0.144000 | 5.41e-01 |
Signaling by KIT in disease | 16 | 3.18e-01 | -0.144000 | 4.93e-01 |
Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutants | 16 | 3.18e-01 | -0.144000 | 4.93e-01 |
VLDLR internalisation and degradation | 11 | 4.09e-01 | -0.144000 | 5.76e-01 |
Formation of the ternary complex, and subsequently, the 43S complex | 40 | 1.16e-01 | -0.144000 | 2.39e-01 |
Interleukin-6 family signaling | 13 | 3.70e-01 | -0.144000 | 5.43e-01 |
Neddylation | 188 | 7.21e-04 | -0.143000 | 5.80e-03 |
NoRC negatively regulates rRNA expression | 42 | 1.08e-01 | -0.143000 | 2.27e-01 |
Signaling by ALK fusions and activated point mutants | 46 | 9.29e-02 | -0.143000 | 2.03e-01 |
Signaling by ALK in cancer | 46 | 9.29e-02 | -0.143000 | 2.03e-01 |
ER to Golgi Anterograde Transport | 108 | 1.04e-02 | -0.143000 | 4.03e-02 |
SARS-CoV-2 Infection | 213 | 3.42e-04 | -0.143000 | 3.37e-03 |
N-Glycan antennae elongation | 10 | 4.34e-01 | -0.143000 | 6.00e-01 |
Azathioprine ADME | 15 | 3.40e-01 | -0.142000 | 5.17e-01 |
Resolution of D-loop Structures through Holliday Junction Intermediates | 28 | 1.92e-01 | -0.142000 | 3.40e-01 |
Plasma lipoprotein assembly, remodeling, and clearance | 39 | 1.27e-01 | -0.141000 | 2.54e-01 |
Interleukin-12 signaling | 36 | 1.43e-01 | -0.141000 | 2.74e-01 |
Metabolism of porphyrins | 15 | 3.45e-01 | -0.141000 | 5.19e-01 |
Cellular responses to stimuli | 551 | 2.34e-08 | -0.141000 | 2.01e-06 |
Downstream signaling of activated FGFR1 | 12 | 3.99e-01 | -0.140000 | 5.69e-01 |
Downstream signaling of activated FGFR2 | 12 | 3.99e-01 | -0.140000 | 5.69e-01 |
Downstream signaling of activated FGFR3 | 12 | 3.99e-01 | -0.140000 | 5.69e-01 |
Downstream signaling of activated FGFR4 | 12 | 3.99e-01 | -0.140000 | 5.69e-01 |
TP53 Regulates Metabolic Genes | 71 | 4.11e-02 | -0.140000 | 1.17e-01 |
MET promotes cell motility | 13 | 3.82e-01 | -0.140000 | 5.53e-01 |
Antiviral mechanism by IFN-stimulated genes | 77 | 3.43e-02 | -0.140000 | 1.01e-01 |
RAS processing | 15 | 3.49e-01 | -0.140000 | 5.21e-01 |
Signaling by NOTCH | 135 | 5.27e-03 | -0.139000 | 2.30e-02 |
SUMOylation | 138 | 4.84e-03 | -0.139000 | 2.16e-02 |
Death Receptor Signalling | 96 | 1.86e-02 | -0.139000 | 6.54e-02 |
Cellular responses to stress | 546 | 3.64e-08 | -0.139000 | 2.80e-06 |
Condensation of Prophase Chromosomes | 12 | 4.04e-01 | -0.139000 | 5.73e-01 |
Mitochondrial translation | 89 | 2.38e-02 | -0.139000 | 7.85e-02 |
Transport to the Golgi and subsequent modification | 130 | 6.69e-03 | -0.138000 | 2.76e-02 |
mRNA Splicing - Major Pathway | 148 | 3.88e-03 | -0.138000 | 1.82e-02 |
MyD88 dependent cascade initiated on endosome | 67 | 5.13e-02 | -0.138000 | 1.36e-01 |
Toll Like Receptor 7/8 (TLR7/8) Cascade | 67 | 5.13e-02 | -0.138000 | 1.36e-01 |
Regulation of beta-cell development | 16 | 3.42e-01 | -0.137000 | 5.19e-01 |
mRNA 3’-end processing | 37 | 1.49e-01 | -0.137000 | 2.84e-01 |
DNA Double Strand Break Response | 36 | 1.56e-01 | -0.137000 | 2.89e-01 |
Nuclear Envelope (NE) Reassembly | 60 | 6.75e-02 | -0.137000 | 1.64e-01 |
N-glycan antennae elongation in the medial/trans-Golgi | 17 | 3.32e-01 | -0.136000 | 5.07e-01 |
MyD88 cascade initiated on plasma membrane | 65 | 5.83e-02 | -0.136000 | 1.49e-01 |
Toll Like Receptor 10 (TLR10) Cascade | 65 | 5.83e-02 | -0.136000 | 1.49e-01 |
Toll Like Receptor 5 (TLR5) Cascade | 65 | 5.83e-02 | -0.136000 | 1.49e-01 |
Platelet degranulation | 49 | 1.01e-01 | -0.135000 | 2.16e-01 |
Regulation of HSF1-mediated heat shock response | 67 | 5.63e-02 | -0.135000 | 1.47e-01 |
Gene expression (Transcription) | 1040 | 5.89e-13 | -0.135000 | 1.42e-10 |
Insertion of tail-anchored proteins into the endoplasmic reticulum membrane | 14 | 3.86e-01 | -0.134000 | 5.58e-01 |
Resolution of D-Loop Structures | 29 | 2.14e-01 | -0.133000 | 3.68e-01 |
Molecules associated with elastic fibres | 12 | 4.24e-01 | 0.133000 | 5.91e-01 |
Assembly of collagen fibrils and other multimeric structures | 14 | 3.87e-01 | 0.133000 | 5.58e-01 |
mRNA Splicing | 158 | 3.90e-03 | -0.133000 | 1.82e-02 |
PRC2 methylates histones and DNA | 12 | 4.24e-01 | -0.133000 | 5.91e-01 |
Deadenylation-dependent mRNA decay | 52 | 9.71e-02 | -0.133000 | 2.10e-01 |
Class I MHC mediated antigen processing & presentation | 289 | 1.12e-04 | -0.133000 | 1.75e-03 |
Kinesins | 32 | 1.95e-01 | -0.133000 | 3.42e-01 |
Toll Like Receptor 3 (TLR3) Cascade | 74 | 4.92e-02 | -0.132000 | 1.35e-01 |
RHOG GTPase cycle | 49 | 1.09e-01 | 0.132000 | 2.28e-01 |
Heme biosynthesis | 10 | 4.69e-01 | -0.132000 | 6.31e-01 |
Response to elevated platelet cytosolic Ca2+ | 53 | 9.74e-02 | -0.132000 | 2.10e-01 |
Metabolism of proteins | 1246 | 2.53e-14 | -0.131000 | 1.52e-11 |
Resolution of D-loop Structures through Synthesis-Dependent Strand Annealing (SDSA) | 24 | 2.66e-01 | -0.131000 | 4.30e-01 |
RMTs methylate histone arginines | 25 | 2.59e-01 | -0.131000 | 4.22e-01 |
Signaling by NOTCH3 | 30 | 2.16e-01 | -0.131000 | 3.71e-01 |
RHOF GTPase cycle | 25 | 2.60e-01 | 0.130000 | 4.23e-01 |
Metabolism | 1253 | 4.19e-14 | -0.130000 | 1.68e-11 |
Signaling by ERBB2 TMD/JMD mutants | 10 | 4.78e-01 | -0.129000 | 6.37e-01 |
Diseases of metabolism | 126 | 1.24e-02 | -0.129000 | 4.66e-02 |
Glutamate binding, activation of AMPA receptors and synaptic plasticity | 12 | 4.39e-01 | 0.129000 | 6.02e-01 |
Trafficking of AMPA receptors | 12 | 4.39e-01 | 0.129000 | 6.02e-01 |
STING mediated induction of host immune responses | 10 | 4.80e-01 | 0.129000 | 6.39e-01 |
Nephrin family interactions | 14 | 4.05e-01 | -0.129000 | 5.73e-01 |
SARS-CoV Infections | 270 | 3.18e-04 | -0.128000 | 3.27e-03 |
Negative regulation of NMDA receptor-mediated neuronal transmission | 12 | 4.43e-01 | 0.128000 | 6.04e-01 |
ER Quality Control Compartment (ERQC) | 18 | 3.48e-01 | 0.128000 | 5.21e-01 |
Ca-dependent events | 21 | 3.13e-01 | -0.127000 | 4.87e-01 |
NGF-stimulated transcription | 25 | 2.71e-01 | -0.127000 | 4.38e-01 |
TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation | 66 | 7.57e-02 | -0.127000 | 1.77e-01 |
Generic Transcription Pathway | 826 | 1.35e-09 | -0.126000 | 1.47e-07 |
Asparagine N-linked glycosylation | 225 | 1.17e-03 | -0.126000 | 7.75e-03 |
Mitochondrial translation termination | 83 | 4.75e-02 | -0.126000 | 1.31e-01 |
BBSome-mediated cargo-targeting to cilium | 19 | 3.42e-01 | -0.126000 | 5.19e-01 |
Glucagon-type ligand receptors | 14 | 4.16e-01 | 0.126000 | 5.82e-01 |
Mitochondrial translation initiation | 84 | 4.71e-02 | -0.125000 | 1.31e-01 |
Interferon Signaling | 142 | 1.02e-02 | -0.125000 | 3.96e-02 |
Cholesterol biosynthesis | 22 | 3.10e-01 | -0.125000 | 4.84e-01 |
Cell death signalling via NRAGE, NRIF and NADE | 45 | 1.50e-01 | -0.124000 | 2.84e-01 |
Diseases of carbohydrate metabolism | 23 | 3.03e-01 | -0.124000 | 4.73e-01 |
Nicotinamide salvaging | 11 | 4.76e-01 | 0.124000 | 6.36e-01 |
tRNA modification in the nucleus and cytosol | 34 | 2.11e-01 | -0.124000 | 3.64e-01 |
Branched-chain amino acid catabolism | 20 | 3.37e-01 | -0.124000 | 5.14e-01 |
SUMOylation of transcription factors | 13 | 4.39e-01 | -0.124000 | 6.02e-01 |
PTEN Regulation | 115 | 2.20e-02 | -0.124000 | 7.40e-02 |
Metabolism of steroids | 86 | 4.76e-02 | -0.124000 | 1.31e-01 |
Metal ion SLC transporters | 16 | 3.92e-01 | -0.124000 | 5.60e-01 |
Meiotic synapsis | 25 | 2.84e-01 | -0.124000 | 4.54e-01 |
Ribosomal scanning and start codon recognition | 47 | 1.43e-01 | -0.123000 | 2.74e-01 |
Antigen processing: Ubiquitination & Proteasome degradation | 241 | 1.01e-03 | -0.123000 | 7.23e-03 |
DAP12 interactions | 21 | 3.28e-01 | -0.123000 | 5.04e-01 |
Signaling by WNT | 177 | 4.96e-03 | -0.123000 | 2.20e-02 |
Aquaporin-mediated transport | 25 | 2.89e-01 | 0.123000 | 4.59e-01 |
RNA Polymerase II Transcription | 927 | 5.42e-10 | -0.122000 | 7.24e-08 |
Translation initiation complex formation | 47 | 1.47e-01 | -0.122000 | 2.81e-01 |
Recruitment and ATM-mediated phosphorylation of repair and signaling proteins at DNA double strand breaks | 35 | 2.11e-01 | -0.122000 | 3.64e-01 |
Negative regulation of MAPK pathway | 36 | 2.06e-01 | -0.122000 | 3.58e-01 |
Signaling by WNT in cancer | 23 | 3.12e-01 | -0.122000 | 4.86e-01 |
Beta-catenin independent WNT signaling | 106 | 3.21e-02 | -0.121000 | 9.59e-02 |
SARS-CoV-2 modulates host translation machinery | 39 | 1.93e-01 | -0.121000 | 3.40e-01 |
Post-translational protein modification | 917 | 1.26e-09 | -0.120000 | 1.47e-07 |
Defective HDR through Homologous Recombination (HRR) due to BRCA1 loss-of-function | 22 | 3.29e-01 | -0.120000 | 5.04e-01 |
Defective HDR through Homologous Recombination (HRR) due to PALB2 loss of function | 22 | 3.29e-01 | -0.120000 | 5.04e-01 |
Defective HDR through Homologous Recombination Repair (HRR) due to PALB2 loss of BRCA1 binding function | 22 | 3.29e-01 | -0.120000 | 5.04e-01 |
Defective HDR through Homologous Recombination Repair (HRR) due to PALB2 loss of BRCA2/RAD51/RAD51C binding function | 22 | 3.29e-01 | -0.120000 | 5.04e-01 |
Impaired BRCA2 binding to PALB2 | 22 | 3.29e-01 | -0.120000 | 5.04e-01 |
RIP-mediated NFkB activation via ZBP1 | 14 | 4.36e-01 | -0.120000 | 6.01e-01 |
Biosynthesis of the N-glycan precursor (dolichol lipid-linked oligosaccharide, LLO) and transfer to a nascent protein | 61 | 1.05e-01 | -0.120000 | 2.22e-01 |
Synthesis of PA | 18 | 3.78e-01 | 0.120000 | 5.50e-01 |
CaM pathway | 20 | 3.53e-01 | -0.120000 | 5.25e-01 |
Calmodulin induced events | 20 | 3.53e-01 | -0.120000 | 5.25e-01 |
SMAD2/SMAD3:SMAD4 heterotrimer regulates transcription | 27 | 2.82e-01 | -0.120000 | 4.52e-01 |
Pexophagy | 11 | 4.92e-01 | -0.120000 | 6.45e-01 |
Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs) | 35 | 2.21e-01 | 0.120000 | 3.77e-01 |
MTOR signalling | 36 | 2.15e-01 | -0.119000 | 3.69e-01 |
Signaling by NOTCH1 | 51 | 1.41e-01 | -0.119000 | 2.70e-01 |
Cellular response to heat stress | 80 | 6.53e-02 | -0.119000 | 1.62e-01 |
Non-integrin membrane-ECM interactions | 14 | 4.42e-01 | 0.119000 | 6.04e-01 |
Cell junction organization | 26 | 2.96e-01 | 0.118000 | 4.66e-01 |
The phototransduction cascade | 18 | 3.86e-01 | 0.118000 | 5.57e-01 |
Diseases of glycosylation | 69 | 9.01e-02 | -0.118000 | 1.99e-01 |
Activation of ATR in response to replication stress | 36 | 2.21e-01 | -0.118000 | 3.76e-01 |
Signaling by NTRK1 (TRKA) | 79 | 7.01e-02 | -0.118000 | 1.67e-01 |
Transcriptional activation of mitochondrial biogenesis | 40 | 1.99e-01 | -0.117000 | 3.48e-01 |
Regulation of TP53 Activity through Acetylation | 27 | 2.93e-01 | -0.117000 | 4.66e-01 |
Adrenaline,noradrenaline inhibits insulin secretion | 15 | 4.33e-01 | 0.117000 | 6.00e-01 |
PKMTs methylate histone lysines | 31 | 2.61e-01 | 0.117000 | 4.23e-01 |
KSRP (KHSRP) binds and destabilizes mRNA | 15 | 4.34e-01 | -0.117000 | 6.00e-01 |
FCGR3A-mediated IL10 synthesis | 22 | 3.44e-01 | -0.117000 | 5.19e-01 |
Inactivation of CSF3 (G-CSF) signaling | 19 | 3.80e-01 | -0.116000 | 5.50e-01 |
TCR signaling | 87 | 6.09e-02 | -0.116000 | 1.53e-01 |
Ion transport by P-type ATPases | 27 | 2.96e-01 | -0.116000 | 4.66e-01 |
Signaling by ERBB4 | 31 | 2.64e-01 | -0.116000 | 4.28e-01 |
Extra-nuclear estrogen signaling | 49 | 1.62e-01 | -0.116000 | 2.96e-01 |
VEGFA-VEGFR2 Pathway | 71 | 9.29e-02 | -0.115000 | 2.03e-01 |
MAPK family signaling cascades | 191 | 6.11e-03 | -0.115000 | 2.55e-02 |
RND1 GTPase cycle | 29 | 2.82e-01 | -0.115000 | 4.52e-01 |
Vesicle-mediated transport | 454 | 2.94e-05 | -0.115000 | 7.37e-04 |
trans-Golgi Network Vesicle Budding | 51 | 1.55e-01 | -0.115000 | 2.88e-01 |
Activation of the mRNA upon binding of the cap-binding complex and eIFs, and subsequent binding to 43S | 48 | 1.68e-01 | -0.115000 | 3.03e-01 |
MAPK1/MAPK3 signaling | 164 | 1.17e-02 | -0.114000 | 4.47e-02 |
Collagen biosynthesis and modifying enzymes | 19 | 3.89e-01 | 0.114000 | 5.58e-01 |
NF-kB activation through FADD/RIP-1 pathway mediated by caspase-8 and -10 | 11 | 5.15e-01 | -0.113000 | 6.57e-01 |
Golgi Cisternae Pericentriolar Stack Reorganization | 14 | 4.64e-01 | -0.113000 | 6.25e-01 |
RHOV GTPase cycle | 28 | 3.01e-01 | -0.113000 | 4.70e-01 |
Metabolism of nitric oxide: NOS3 activation and regulation | 12 | 4.98e-01 | -0.113000 | 6.48e-01 |
Toll Like Receptor 9 (TLR9) Cascade | 70 | 1.03e-01 | -0.113000 | 2.18e-01 |
Gene and protein expression by JAK-STAT signaling after Interleukin-12 stimulation | 29 | 2.95e-01 | -0.112000 | 4.66e-01 |
Interferon gamma signaling | 55 | 1.50e-01 | -0.112000 | 2.84e-01 |
Signaling by PDGF | 25 | 3.33e-01 | -0.112000 | 5.08e-01 |
G alpha (q) signalling events | 78 | 8.83e-02 | 0.112000 | 1.98e-01 |
Membrane binding and targetting of GAG proteins | 12 | 5.03e-01 | -0.112000 | 6.51e-01 |
Synthesis And Processing Of GAG, GAGPOL Polyproteins | 12 | 5.03e-01 | -0.112000 | 6.51e-01 |
Membrane Trafficking | 446 | 6.95e-05 | -0.111000 | 1.35e-03 |
Glucagon-like Peptide-1 (GLP1) regulates insulin secretion | 22 | 3.69e-01 | -0.111000 | 5.43e-01 |
Fcgamma receptor (FCGR) dependent phagocytosis | 62 | 1.34e-01 | -0.110000 | 2.65e-01 |
Signaling by cytosolic FGFR1 fusion mutants | 16 | 4.46e-01 | -0.110000 | 6.06e-01 |
ECM proteoglycans | 13 | 4.93e-01 | 0.110000 | 6.46e-01 |
G alpha (z) signalling events | 25 | 3.43e-01 | 0.110000 | 5.19e-01 |
Signaling by Hippo | 12 | 5.12e-01 | -0.109000 | 6.55e-01 |
TRAF6-mediated induction of TAK1 complex within TLR4 complex | 10 | 5.50e-01 | -0.109000 | 6.84e-01 |
Toll-like Receptor Cascades | 108 | 5.07e-02 | -0.109000 | 1.36e-01 |
VEGFR2 mediated vascular permeability | 21 | 3.88e-01 | -0.109000 | 5.58e-01 |
Interleukin receptor SHC signaling | 15 | 4.69e-01 | -0.108000 | 6.31e-01 |
Intracellular signaling by second messengers | 210 | 7.26e-03 | -0.108000 | 2.96e-02 |
ERCC6 (CSB) and EHMT2 (G9a) positively regulate rRNA expression | 15 | 4.70e-01 | -0.108000 | 6.31e-01 |
Signaling by Activin | 12 | 5.20e-01 | 0.107000 | 6.61e-01 |
Hyaluronan uptake and degradation | 10 | 5.57e-01 | -0.107000 | 6.89e-01 |
Ras activation upon Ca2+ influx through NMDA receptor | 10 | 5.57e-01 | 0.107000 | 6.89e-01 |
SUMOylation of DNA methylation proteins | 14 | 4.88e-01 | 0.107000 | 6.42e-01 |
EPHB-mediated forward signaling | 25 | 3.55e-01 | -0.107000 | 5.28e-01 |
Fatty acid metabolism | 104 | 6.03e-02 | -0.107000 | 1.53e-01 |
Mitochondrial translation elongation | 84 | 9.17e-02 | -0.107000 | 2.02e-01 |
EGFR downregulation | 20 | 4.09e-01 | -0.107000 | 5.76e-01 |
RND2 GTPase cycle | 34 | 2.84e-01 | -0.106000 | 4.53e-01 |
Caspase activation via extrinsic apoptotic signalling pathway | 15 | 4.76e-01 | -0.106000 | 6.36e-01 |
RHO GTPases activate PAKs | 13 | 5.07e-01 | -0.106000 | 6.53e-01 |
Listeria monocytogenes entry into host cells | 14 | 4.95e-01 | -0.105000 | 6.47e-01 |
Antigen activates B Cell Receptor (BCR) leading to generation of second messengers | 21 | 4.04e-01 | -0.105000 | 5.73e-01 |
Signaling by NTRKs | 87 | 9.01e-02 | -0.105000 | 1.99e-01 |
Signaling by Interleukins | 265 | 3.35e-03 | -0.105000 | 1.67e-02 |
NOTCH4 Intracellular Domain Regulates Transcription | 14 | 4.96e-01 | -0.105000 | 6.47e-01 |
JNK (c-Jun kinases) phosphorylation and activation mediated by activated human TAK1 | 12 | 5.29e-01 | 0.105000 | 6.67e-01 |
Signaling by VEGF | 73 | 1.23e-01 | -0.105000 | 2.48e-01 |
SUMOylation of chromatin organization proteins | 49 | 2.07e-01 | -0.104000 | 3.59e-01 |
G alpha (i) signalling events | 93 | 8.39e-02 | 0.104000 | 1.90e-01 |
O-linked glycosylation | 42 | 2.44e-01 | 0.104000 | 4.07e-01 |
HDACs deacetylate histones | 28 | 3.43e-01 | -0.104000 | 5.19e-01 |
Synthesis of very long-chain fatty acyl-CoAs | 16 | 4.73e-01 | 0.104000 | 6.34e-01 |
Unfolded Protein Response (UPR) | 76 | 1.20e-01 | -0.103000 | 2.43e-01 |
SLC transporter disorders | 52 | 1.99e-01 | -0.103000 | 3.48e-01 |
Nuclear Envelope Breakdown | 49 | 2.12e-01 | -0.103000 | 3.66e-01 |
Protein ubiquitination | 59 | 1.72e-01 | -0.103000 | 3.10e-01 |
Metabolism of fat-soluble vitamins | 13 | 5.21e-01 | -0.103000 | 6.61e-01 |
Josephin domain DUBs | 11 | 5.56e-01 | -0.103000 | 6.89e-01 |
Mitophagy | 25 | 3.79e-01 | -0.102000 | 5.50e-01 |
HSF1 activation | 21 | 4.23e-01 | -0.101000 | 5.91e-01 |
Signaling by ERBB2 in Cancer | 13 | 5.29e-01 | -0.101000 | 6.67e-01 |
Assembly and cell surface presentation of NMDA receptors | 13 | 5.29e-01 | 0.101000 | 6.67e-01 |
RAF/MAP kinase cascade | 159 | 2.98e-02 | -0.100000 | 9.15e-02 |
Fatty acyl-CoA biosynthesis | 26 | 3.77e-01 | -0.100000 | 5.49e-01 |
RNA Polymerase III Transcription Initiation From Type 3 Promoter | 27 | 3.70e-01 | -0.099800 | 5.43e-01 |
Potential therapeutics for SARS | 66 | 1.62e-01 | -0.099600 | 2.96e-01 |
Cytochrome P450 - arranged by substrate type | 14 | 5.19e-01 | 0.099500 | 6.61e-01 |
Gastrin-CREB signalling pathway via PKC and MAPK | 11 | 5.68e-01 | -0.099300 | 6.98e-01 |
MyD88:MAL(TIRAP) cascade initiated on plasma membrane | 71 | 1.51e-01 | -0.098800 | 2.84e-01 |
Toll Like Receptor 2 (TLR2) Cascade | 71 | 1.51e-01 | -0.098800 | 2.84e-01 |
Toll Like Receptor TLR1:TLR2 Cascade | 71 | 1.51e-01 | -0.098800 | 2.84e-01 |
Toll Like Receptor TLR6:TLR2 Cascade | 71 | 1.51e-01 | -0.098800 | 2.84e-01 |
PKA-mediated phosphorylation of CREB | 11 | 5.71e-01 | -0.098600 | 6.99e-01 |
Other interleukin signaling | 15 | 5.09e-01 | -0.098600 | 6.53e-01 |
Signaling by Receptor Tyrosine Kinases | 293 | 3.89e-03 | -0.098500 | 1.82e-02 |
Activation of kainate receptors upon glutamate binding | 17 | 4.82e-01 | 0.098400 | 6.40e-01 |
Adaptive Immune System | 481 | 2.55e-04 | -0.098200 | 2.76e-03 |
PIP3 activates AKT signaling | 185 | 2.22e-02 | -0.097800 | 7.46e-02 |
SARS-CoV-1 Infection | 46 | 2.54e-01 | -0.097300 | 4.18e-01 |
TAK1-dependent IKK and NF-kappa-B activation | 18 | 4.76e-01 | -0.097000 | 6.36e-01 |
Transcriptional regulation of white adipocyte differentiation | 56 | 2.11e-01 | -0.096700 | 3.64e-01 |
Intra-Golgi traffic | 39 | 2.96e-01 | -0.096700 | 4.66e-01 |
Diseases associated with the TLR signaling cascade | 17 | 4.91e-01 | -0.096600 | 6.44e-01 |
Diseases of Immune System | 17 | 4.91e-01 | -0.096600 | 6.44e-01 |
Synthesis of PC | 22 | 4.34e-01 | -0.096400 | 6.00e-01 |
G beta:gamma signalling through PLC beta | 13 | 5.47e-01 | 0.096400 | 6.82e-01 |
Presynaptic function of Kainate receptors | 13 | 5.47e-01 | 0.096400 | 6.82e-01 |
FOXO-mediated transcription | 46 | 2.58e-01 | -0.096400 | 4.22e-01 |
Macroautophagy | 97 | 1.02e-01 | -0.096200 | 2.17e-01 |
Formation of the beta-catenin:TCF transactivating complex | 25 | 4.05e-01 | -0.096200 | 5.73e-01 |
PKA activation | 10 | 6.01e-01 | -0.095500 | 7.27e-01 |
MAP3K8 (TPL2)-dependent MAPK1/3 activation | 14 | 5.36e-01 | -0.095500 | 6.71e-01 |
EPH-ephrin mediated repulsion of cells | 25 | 4.09e-01 | -0.095400 | 5.76e-01 |
RET signaling | 23 | 4.29e-01 | -0.095400 | 5.96e-01 |
Pyroptosis | 18 | 4.88e-01 | -0.094400 | 6.42e-01 |
Cytokine Signaling in Immune system | 427 | 9.13e-04 | -0.094300 | 6.81e-03 |
Post-translational protein phosphorylation | 34 | 3.45e-01 | 0.093700 | 5.19e-01 |
Mitotic Prophase | 75 | 1.61e-01 | -0.093600 | 2.96e-01 |
ADP signalling through P2Y purinoceptor 12 | 13 | 5.66e-01 | 0.092000 | 6.97e-01 |
Signaling by ERBB2 | 33 | 3.61e-01 | -0.092000 | 5.34e-01 |
Axon guidance | 300 | 6.73e-03 | -0.091400 | 2.77e-02 |
Cytosolic sensors of pathogen-associated DNA | 53 | 2.51e-01 | -0.091200 | 4.15e-01 |
Oncogene Induced Senescence | 30 | 3.89e-01 | -0.090800 | 5.58e-01 |
PI3K/AKT Signaling in Cancer | 52 | 2.59e-01 | -0.090600 | 4.22e-01 |
Autophagy | 106 | 1.09e-01 | -0.090400 | 2.27e-01 |
Activation of GABAB receptors | 18 | 5.08e-01 | 0.090200 | 6.53e-01 |
GABA B receptor activation | 18 | 5.08e-01 | 0.090200 | 6.53e-01 |
TNF receptor superfamily (TNFSF) members mediating non-canonical NF-kB pathway | 10 | 6.23e-01 | -0.089900 | 7.47e-01 |
GPCR downstream signalling | 197 | 3.04e-02 | 0.089800 | 9.28e-02 |
Mucopolysaccharidoses | 10 | 6.24e-01 | -0.089600 | 7.47e-01 |
G alpha (12/13) signalling events | 40 | 3.28e-01 | 0.089500 | 5.04e-01 |
HDMs demethylate histones | 15 | 5.49e-01 | -0.089300 | 6.84e-01 |
Signaling by Erythropoietin | 19 | 5.02e-01 | -0.089100 | 6.50e-01 |
Signaling by BMP | 15 | 5.51e-01 | 0.089000 | 6.85e-01 |
TICAM1, RIP1-mediated IKK complex recruitment | 17 | 5.27e-01 | -0.088700 | 6.67e-01 |
Glutamate Neurotransmitter Release Cycle | 12 | 5.96e-01 | 0.088400 | 7.24e-01 |
CDC42 GTPase cycle | 97 | 1.34e-01 | 0.088100 | 2.65e-01 |
DARPP-32 events | 21 | 4.86e-01 | -0.087900 | 6.42e-01 |
PINK1-PRKN Mediated Mitophagy | 20 | 4.99e-01 | -0.087300 | 6.48e-01 |
Signalling to ERKs | 25 | 4.52e-01 | -0.087000 | 6.13e-01 |
Chromatin modifying enzymes | 158 | 6.11e-02 | -0.086600 | 1.53e-01 |
Chromatin organization | 158 | 6.11e-02 | -0.086600 | 1.53e-01 |
Nervous system development | 313 | 8.89e-03 | -0.086500 | 3.53e-02 |
Cargo recognition for clathrin-mediated endocytosis | 63 | 2.37e-01 | -0.086100 | 3.97e-01 |
Synthesis of substrates in N-glycan biosythesis | 48 | 3.06e-01 | -0.085400 | 4.78e-01 |
Signaling by NODAL | 12 | 6.09e-01 | 0.085200 | 7.35e-01 |
The role of Nef in HIV-1 replication and disease pathogenesis | 19 | 5.21e-01 | 0.085000 | 6.61e-01 |
RAC2 GTPase cycle | 56 | 2.72e-01 | 0.084800 | 4.39e-01 |
RHOH GTPase cycle | 29 | 4.30e-01 | 0.084600 | 5.97e-01 |
Interleukin-15 signaling | 11 | 6.28e-01 | -0.084300 | 7.49e-01 |
NR1H3 & NR1H2 regulate gene expression linked to cholesterol transport and efflux | 23 | 4.84e-01 | 0.084200 | 6.42e-01 |
Cellular Senescence | 106 | 1.42e-01 | -0.082700 | 2.72e-01 |
Insulin processing | 17 | 5.56e-01 | -0.082500 | 6.89e-01 |
GPVI-mediated activation cascade | 23 | 4.96e-01 | -0.082100 | 6.47e-01 |
RHO GTPases Activate WASPs and WAVEs | 29 | 4.45e-01 | -0.082000 | 6.05e-01 |
Downregulation of SMAD2/3:SMAD4 transcriptional activity | 24 | 4.88e-01 | 0.081700 | 6.42e-01 |
Pre-NOTCH Processing in Golgi | 16 | 5.72e-01 | -0.081500 | 6.99e-01 |
Activation of NMDA receptors and postsynaptic events | 44 | 3.50e-01 | -0.081500 | 5.22e-01 |
N-glycan trimming in the ER and Calnexin/Calreticulin cycle | 32 | 4.27e-01 | -0.081200 | 5.94e-01 |
Iron uptake and transport | 38 | 3.89e-01 | -0.080800 | 5.58e-01 |
HSF1-dependent transactivation | 25 | 4.85e-01 | -0.080700 | 6.42e-01 |
Extracellular matrix organization | 93 | 1.80e-01 | 0.080600 | 3.21e-01 |
Collagen formation | 28 | 4.60e-01 | 0.080600 | 6.21e-01 |
MAP2K and MAPK activation | 25 | 4.86e-01 | 0.080500 | 6.42e-01 |
Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell | 31 | 4.40e-01 | 0.080200 | 6.02e-01 |
Integrin signaling | 16 | 5.82e-01 | -0.079400 | 7.09e-01 |
Platelet Aggregation (Plug Formation) | 16 | 5.82e-01 | -0.079400 | 7.09e-01 |
Senescence-Associated Secretory Phenotype (SASP) | 42 | 3.74e-01 | -0.079400 | 5.45e-01 |
Innate Immune System | 620 | 8.63e-04 | -0.079300 | 6.56e-03 |
Deadenylation of mRNA | 23 | 5.11e-01 | -0.079200 | 6.55e-01 |
Signaling by GPCR | 216 | 4.68e-02 | 0.078800 | 1.31e-01 |
Inositol phosphate metabolism | 30 | 4.57e-01 | -0.078600 | 6.17e-01 |
APC-Cdc20 mediated degradation of Nek2A | 24 | 5.06e-01 | -0.078400 | 6.53e-01 |
Metabolism of steroid hormones | 13 | 6.26e-01 | -0.078100 | 7.48e-01 |
EPH-Ephrin signaling | 55 | 3.17e-01 | -0.078000 | 4.92e-01 |
Regulation of signaling by CBL | 14 | 6.13e-01 | -0.078000 | 7.38e-01 |
Intraflagellar transport | 33 | 4.40e-01 | -0.077800 | 6.02e-01 |
Mitochondrial calcium ion transport | 19 | 5.58e-01 | -0.077600 | 6.89e-01 |
Signaling by TGF-beta Receptor Complex | 72 | 2.55e-01 | -0.077600 | 4.19e-01 |
Apoptotic execution phase | 33 | 4.41e-01 | -0.077500 | 6.03e-01 |
RAC1 GTPase cycle | 110 | 1.62e-01 | 0.077400 | 2.96e-01 |
NCAM signaling for neurite out-growth | 24 | 5.14e-01 | 0.077000 | 6.57e-01 |
RHOBTB GTPase Cycle | 29 | 4.79e-01 | -0.076000 | 6.37e-01 |
Cell surface interactions at the vascular wall | 56 | 3.27e-01 | 0.075900 | 5.04e-01 |
Biological oxidations | 79 | 2.46e-01 | -0.075600 | 4.08e-01 |
Cytochrome c-mediated apoptotic response | 11 | 6.66e-01 | -0.075200 | 7.80e-01 |
Disassembly of the destruction complex and recruitment of AXIN to the membrane | 26 | 5.07e-01 | -0.075200 | 6.53e-01 |
Recycling pathway of L1 | 15 | 6.15e-01 | -0.074900 | 7.39e-01 |
FCERI mediated Ca+2 mobilization | 23 | 5.36e-01 | -0.074600 | 6.71e-01 |
Developmental Biology | 468 | 6.13e-03 | -0.074600 | 2.55e-02 |
Class B/2 (Secretin family receptors) | 29 | 4.88e-01 | 0.074500 | 6.42e-01 |
Interleukin-10 signaling | 13 | 6.43e-01 | -0.074300 | 7.61e-01 |
Inactivation, recovery and regulation of the phototransduction cascade | 17 | 5.98e-01 | 0.073800 | 7.25e-01 |
Clathrin-mediated endocytosis | 89 | 2.33e-01 | -0.073200 | 3.91e-01 |
Insulin receptor signalling cascade | 26 | 5.19e-01 | 0.073000 | 6.61e-01 |
Sphingolipid metabolism | 49 | 3.79e-01 | -0.072700 | 5.50e-01 |
Interleukin-3, Interleukin-5 and GM-CSF signaling | 29 | 5.00e-01 | -0.072400 | 6.48e-01 |
Stimuli-sensing channels | 39 | 4.34e-01 | 0.072400 | 6.00e-01 |
mRNA decay by 3’ to 5’ exoribonuclease | 14 | 6.39e-01 | -0.072300 | 7.59e-01 |
Signaling by Non-Receptor Tyrosine Kinases | 36 | 4.53e-01 | -0.072300 | 6.13e-01 |
Signaling by PTK6 | 36 | 4.53e-01 | -0.072300 | 6.13e-01 |
MAPK targets/ Nuclear events mediated by MAP kinases | 23 | 5.54e-01 | -0.071300 | 6.88e-01 |
Signal Transduction | 1356 | 1.91e-05 | -0.071100 | 5.45e-04 |
Response of EIF2AK1 (HRI) to heme deficiency | 14 | 6.46e-01 | -0.070900 | 7.63e-01 |
Regulation of FZD by ubiquitination | 12 | 6.71e-01 | 0.070700 | 7.83e-01 |
Sialic acid metabolism | 23 | 5.59e-01 | -0.070400 | 6.89e-01 |
Fanconi Anemia Pathway | 31 | 4.98e-01 | -0.070400 | 6.48e-01 |
SUMOylation of transcription cofactors | 35 | 4.72e-01 | -0.070200 | 6.34e-01 |
G alpha (s) signalling events | 48 | 4.01e-01 | 0.070200 | 5.70e-01 |
Oncogenic MAPK signaling | 56 | 3.68e-01 | -0.069500 | 5.43e-01 |
Transcriptional activity of SMAD2/SMAD3:SMAD4 heterotrimer | 39 | 4.53e-01 | -0.069400 | 6.13e-01 |
Hyaluronan metabolism | 11 | 6.91e-01 | -0.069300 | 8.00e-01 |
Immune System | 1156 | 1.14e-04 | -0.068900 | 1.75e-03 |
APC/C:Cdc20 mediated degradation of Cyclin B | 22 | 5.77e-01 | -0.068700 | 7.04e-01 |
Peptide hormone metabolism | 31 | 5.09e-01 | 0.068500 | 6.53e-01 |
Activated NOTCH1 Transmits Signal to the Nucleus | 19 | 6.10e-01 | -0.067700 | 7.35e-01 |
Regulation of innate immune responses to cytosolic DNA | 12 | 6.87e-01 | 0.067100 | 7.97e-01 |
Paradoxical activation of RAF signaling by kinase inactive BRAF | 29 | 5.33e-01 | -0.066900 | 6.70e-01 |
Signaling by RAS mutants | 29 | 5.33e-01 | -0.066900 | 6.70e-01 |
Signaling by moderate kinase activity BRAF mutants | 29 | 5.33e-01 | -0.066900 | 6.70e-01 |
Signaling downstream of RAS mutants | 29 | 5.33e-01 | -0.066900 | 6.70e-01 |
Costimulation by the CD28 family | 44 | 4.43e-01 | -0.066800 | 6.04e-01 |
Signaling by FGFR1 in disease | 24 | 5.73e-01 | -0.066600 | 6.99e-01 |
Vasopressin regulates renal water homeostasis via Aquaporins | 23 | 5.83e-01 | 0.066100 | 7.10e-01 |
Post NMDA receptor activation events | 38 | 4.82e-01 | -0.065900 | 6.40e-01 |
GPER1 signaling | 25 | 5.69e-01 | 0.065900 | 6.98e-01 |
RHOQ GTPase cycle | 39 | 4.79e-01 | 0.065600 | 6.37e-01 |
Interleukin-37 signaling | 17 | 6.42e-01 | 0.065100 | 7.61e-01 |
Signaling by Leptin | 10 | 7.24e-01 | 0.064500 | 8.25e-01 |
Attenuation phase | 19 | 6.29e-01 | -0.063900 | 7.49e-01 |
Signaling by Rho GTPases, Miro GTPases and RHOBTB3 | 449 | 2.30e-02 | -0.063100 | 7.66e-02 |
Nicotinate metabolism | 19 | 6.36e-01 | 0.062800 | 7.55e-01 |
Signal amplification | 20 | 6.30e-01 | 0.062300 | 7.49e-01 |
RAF activation | 28 | 5.70e-01 | -0.062100 | 6.99e-01 |
Neutrophil degranulation | 307 | 6.32e-02 | -0.062000 | 1.58e-01 |
Integration of energy metabolism | 60 | 4.12e-01 | -0.061300 | 5.77e-01 |
Signaling by Rho GTPases | 437 | 2.95e-02 | -0.061200 | 9.10e-02 |
DCC mediated attractive signaling | 11 | 7.26e-01 | 0.061100 | 8.25e-01 |
CREB1 phosphorylation through NMDA receptor-mediated activation of RAS signaling | 16 | 6.73e-01 | 0.061000 | 7.83e-01 |
Transport of small molecules | 359 | 4.86e-02 | -0.061000 | 1.34e-01 |
L1CAM interactions | 41 | 5.00e-01 | -0.061000 | 6.48e-01 |
Cytosolic sulfonation of small molecules | 10 | 7.39e-01 | -0.060900 | 8.35e-01 |
Metabolism of lipids | 439 | 3.06e-02 | -0.060700 | 9.32e-02 |
Nef-mediates down modulation of cell surface receptors by recruiting them to clathrin adapters | 14 | 6.96e-01 | 0.060300 | 8.04e-01 |
XBP1(S) activates chaperone genes | 42 | 5.00e-01 | -0.060200 | 6.48e-01 |
FGFR1 mutant receptor activation | 20 | 6.45e-01 | -0.059500 | 7.63e-01 |
Cargo concentration in the ER | 20 | 6.48e-01 | -0.058900 | 7.65e-01 |
Bile acid and bile salt metabolism | 15 | 6.95e-01 | 0.058400 | 8.04e-01 |
GABA receptor activation | 19 | 6.61e-01 | 0.058100 | 7.77e-01 |
A tetrasaccharide linker sequence is required for GAG synthesis | 10 | 7.51e-01 | 0.057900 | 8.47e-01 |
Inactivation of APC/C via direct inhibition of the APC/C complex | 19 | 6.63e-01 | -0.057800 | 7.77e-01 |
Inhibition of the proteolytic activity of APC/C required for the onset of anaphase by mitotic spindle checkpoint components | 19 | 6.63e-01 | -0.057800 | 7.77e-01 |
CTLA4 inhibitory signaling | 16 | 6.91e-01 | 0.057500 | 8.00e-01 |
Amino acids regulate mTORC1 | 42 | 5.20e-01 | -0.057400 | 6.61e-01 |
Opioid Signalling | 58 | 4.50e-01 | -0.057400 | 6.12e-01 |
Transport of vitamins, nucleosides, and related molecules | 21 | 6.49e-01 | -0.057300 | 7.65e-01 |
Glycosaminoglycan metabolism | 64 | 4.30e-01 | -0.057100 | 5.97e-01 |
NOTCH3 Intracellular Domain Regulates Transcription | 15 | 7.03e-01 | -0.056900 | 8.08e-01 |
Nonhomologous End-Joining (NHEJ) | 29 | 5.96e-01 | -0.056900 | 7.24e-01 |
Signaling by TGFB family members | 85 | 3.66e-01 | -0.056800 | 5.40e-01 |
Regulation of KIT signaling | 10 | 7.57e-01 | 0.056600 | 8.51e-01 |
Assembly Of The HIV Virion | 14 | 7.15e-01 | -0.056300 | 8.20e-01 |
Regulation of actin dynamics for phagocytic cup formation | 44 | 5.21e-01 | -0.056000 | 6.61e-01 |
Netrin-1 signaling | 25 | 6.29e-01 | 0.055900 | 7.49e-01 |
IRE1alpha activates chaperones | 43 | 5.29e-01 | -0.055600 | 6.67e-01 |
Phase I - Functionalization of compounds | 30 | 6.00e-01 | 0.055400 | 7.26e-01 |
NOD1/2 Signaling Pathway | 23 | 6.46e-01 | 0.055300 | 7.63e-01 |
RHOA GTPase cycle | 93 | 3.59e-01 | 0.055100 | 5.32e-01 |
Heparan sulfate/heparin (HS-GAG) metabolism | 22 | 6.59e-01 | -0.054400 | 7.75e-01 |
Endosomal Sorting Complex Required For Transport (ESCRT) | 27 | 6.25e-01 | -0.054300 | 7.48e-01 |
RHOJ GTPase cycle | 37 | 5.72e-01 | 0.053700 | 6.99e-01 |
Ca2+ pathway | 40 | 5.59e-01 | -0.053500 | 6.89e-01 |
Gap junction trafficking | 10 | 7.71e-01 | 0.053200 | 8.61e-01 |
PPARA activates gene expression | 82 | 4.10e-01 | -0.052700 | 5.77e-01 |
Gap junction trafficking and regulation | 11 | 7.64e-01 | 0.052400 | 8.56e-01 |
Signaling by SCF-KIT | 32 | 6.10e-01 | -0.052100 | 7.35e-01 |
Nuclear signaling by ERBB4 | 16 | 7.19e-01 | -0.052000 | 8.20e-01 |
Activation of the pre-replicative complex | 30 | 6.28e-01 | -0.051100 | 7.49e-01 |
Signaling by BRAF and RAF1 fusions | 42 | 5.68e-01 | -0.051000 | 6.98e-01 |
Insulin receptor recycling | 17 | 7.17e-01 | -0.050800 | 8.20e-01 |
Frs2-mediated activation | 11 | 7.72e-01 | 0.050500 | 8.61e-01 |
Transferrin endocytosis and recycling | 19 | 7.04e-01 | -0.050300 | 8.09e-01 |
Conversion from APC/C:Cdc20 to APC/C:Cdh1 in late anaphase | 18 | 7.14e-01 | -0.049900 | 8.20e-01 |
COPII-mediated vesicle transport | 51 | 5.38e-01 | -0.049800 | 6.73e-01 |
Regulation of lipid metabolism by PPARalpha | 84 | 4.36e-01 | -0.049200 | 6.01e-01 |
Rab regulation of trafficking | 94 | 4.11e-01 | -0.049100 | 5.77e-01 |
Butyrate Response Factor 1 (BRF1) binds and destabilizes mRNA | 16 | 7.34e-01 | -0.049000 | 8.32e-01 |
Downregulation of TGF-beta receptor signaling | 26 | 6.68e-01 | -0.048600 | 7.80e-01 |
G-protein beta:gamma signalling | 21 | 7.02e-01 | -0.048300 | 8.08e-01 |
Effects of PIP2 hydrolysis | 19 | 7.16e-01 | 0.048200 | 8.20e-01 |
IGF1R signaling cascade | 23 | 6.98e-01 | -0.046800 | 8.04e-01 |
Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R) | 23 | 6.98e-01 | -0.046800 | 8.04e-01 |
Basigin interactions | 14 | 7.62e-01 | 0.046800 | 8.55e-01 |
RHOBTB2 GTPase cycle | 20 | 7.18e-01 | -0.046700 | 8.20e-01 |
Telomere Extension By Telomerase | 20 | 7.22e-01 | -0.046000 | 8.23e-01 |
Transcriptional regulation of granulopoiesis | 25 | 6.92e-01 | 0.045800 | 8.00e-01 |
Cardiac conduction | 43 | 6.04e-01 | 0.045800 | 7.29e-01 |
RHOBTB1 GTPase cycle | 18 | 7.37e-01 | -0.045700 | 8.34e-01 |
Transcriptional Regulation by VENTX | 30 | 6.68e-01 | 0.045300 | 7.80e-01 |
RAB GEFs exchange GTP for GDP on RABs | 64 | 5.35e-01 | 0.044900 | 6.70e-01 |
Hemostasis | 304 | 1.85e-01 | -0.044400 | 3.30e-01 |
RHO GTPases Activate NADPH Oxidases | 14 | 7.74e-01 | -0.044200 | 8.61e-01 |
RHOU GTPase cycle | 32 | 6.67e-01 | -0.044000 | 7.80e-01 |
Erythropoietin activates RAS | 10 | 8.11e-01 | -0.043700 | 8.89e-01 |
Platelet homeostasis | 49 | 5.99e-01 | -0.043500 | 7.25e-01 |
G beta:gamma signalling through CDC42 | 13 | 7.87e-01 | 0.043300 | 8.70e-01 |
Sphingolipid de novo biosynthesis | 22 | 7.29e-01 | 0.042600 | 8.27e-01 |
Cell recruitment (pro-inflammatory response) | 15 | 7.78e-01 | 0.042100 | 8.63e-01 |
Purinergic signaling in leishmaniasis infection | 15 | 7.78e-01 | 0.042100 | 8.63e-01 |
Platelet activation, signaling and aggregation | 132 | 4.05e-01 | -0.042000 | 5.73e-01 |
Metalloprotease DUBs | 17 | 7.65e-01 | -0.041900 | 8.56e-01 |
Glycerophospholipid biosynthesis | 74 | 5.35e-01 | -0.041800 | 6.70e-01 |
activated TAK1 mediates p38 MAPK activation | 13 | 7.95e-01 | 0.041500 | 8.75e-01 |
Neuronal System | 139 | 4.04e-01 | 0.041100 | 5.73e-01 |
Transcriptional regulation by RUNX1 | 137 | 4.11e-01 | -0.040800 | 5.77e-01 |
Retinoid metabolism and transport | 11 | 8.15e-01 | -0.040700 | 8.91e-01 |
Initiation of Nuclear Envelope (NE) Reformation | 17 | 7.73e-01 | -0.040500 | 8.61e-01 |
Signal transduction by L1 | 11 | 8.17e-01 | -0.040300 | 8.91e-01 |
Neurotransmitter release cycle | 20 | 7.61e-01 | -0.039300 | 8.55e-01 |
Sensory processing of sound by outer hair cells of the cochlea | 18 | 7.74e-01 | -0.039100 | 8.61e-01 |
Transport of inorganic cations/anions and amino acids/oligopeptides | 45 | 6.51e-01 | -0.039000 | 7.67e-01 |
Negative regulation of FLT3 | 13 | 8.10e-01 | 0.038600 | 8.89e-01 |
Cooperation of PDCL (PhLP1) and TRiC/CCT in G-protein beta folding | 23 | 7.49e-01 | 0.038500 | 8.46e-01 |
IRS-related events triggered by IGF1R | 22 | 7.59e-01 | -0.037800 | 8.53e-01 |
Glucagon signaling in metabolic regulation | 18 | 7.83e-01 | 0.037500 | 8.68e-01 |
Suppression of phagosomal maturation | 12 | 8.27e-01 | 0.036500 | 9.00e-01 |
FCERI mediated MAPK activation | 23 | 7.66e-01 | 0.035900 | 8.56e-01 |
DAP12 signaling | 19 | 7.88e-01 | -0.035600 | 8.71e-01 |
Muscle contraction | 67 | 6.15e-01 | -0.035600 | 7.39e-01 |
Synthesis of active ubiquitin: roles of E1 and E2 enzymes | 27 | 7.50e-01 | 0.035500 | 8.46e-01 |
Caspase-mediated cleavage of cytoskeletal proteins | 10 | 8.46e-01 | 0.035500 | 9.18e-01 |
Visual phototransduction | 34 | 7.25e-01 | 0.034900 | 8.25e-01 |
G beta:gamma signalling through PI3Kgamma | 17 | 8.06e-01 | 0.034400 | 8.85e-01 |
MAP kinase activation | 49 | 6.81e-01 | -0.034000 | 7.90e-01 |
Anti-inflammatory response favouring Leishmania parasite infection | 54 | 6.80e-01 | -0.032500 | 7.90e-01 |
Leishmania parasite growth and survival | 54 | 6.80e-01 | -0.032500 | 7.90e-01 |
Negative regulation of FGFR1 signaling | 18 | 8.17e-01 | 0.031500 | 8.91e-01 |
Negative regulation of FGFR2 signaling | 18 | 8.17e-01 | 0.031500 | 8.91e-01 |
Negative regulation of FGFR3 signaling | 18 | 8.17e-01 | 0.031500 | 8.91e-01 |
Negative regulation of FGFR4 signaling | 18 | 8.17e-01 | 0.031500 | 8.91e-01 |
Regulation of MECP2 expression and activity | 23 | 7.95e-01 | 0.031300 | 8.75e-01 |
Plasma lipoprotein remodeling | 11 | 8.60e-01 | -0.030700 | 9.28e-01 |
Termination of O-glycan biosynthesis | 10 | 8.69e-01 | 0.030100 | 9.33e-01 |
rRNA modification in the nucleus and cytosol | 49 | 7.17e-01 | -0.030000 | 8.20e-01 |
Ephrin signaling | 12 | 8.59e-01 | -0.029700 | 9.27e-01 |
Chondroitin sulfate/dermatan sulfate metabolism | 27 | 7.90e-01 | 0.029700 | 8.71e-01 |
Pre-NOTCH Expression and Processing | 46 | 7.29e-01 | -0.029600 | 8.27e-01 |
Regulation of IFNG signaling | 13 | 8.54e-01 | 0.029600 | 9.23e-01 |
Regulation of PTEN gene transcription | 48 | 7.26e-01 | -0.029200 | 8.25e-01 |
RAB geranylgeranylation | 40 | 7.52e-01 | 0.028900 | 8.47e-01 |
RUNX1 interacts with co-factors whose precise effect on RUNX1 targets is not known | 33 | 7.74e-01 | 0.028900 | 8.61e-01 |
Transcriptional regulation by the AP-2 (TFAP2) family of transcription factors | 20 | 8.27e-01 | -0.028300 | 9.00e-01 |
Pre-NOTCH Transcription and Translation | 31 | 7.86e-01 | -0.028200 | 8.70e-01 |
Downregulation of ERBB2:ERBB3 signaling | 10 | 8.78e-01 | 0.028000 | 9.37e-01 |
Regulation of BACH1 activity | 11 | 8.74e-01 | -0.027700 | 9.34e-01 |
Protein methylation | 14 | 8.66e-01 | 0.026000 | 9.31e-01 |
Synthesis of bile acids and bile salts | 13 | 8.74e-01 | 0.025500 | 9.34e-01 |
Spry regulation of FGF signaling | 15 | 8.65e-01 | -0.025400 | 9.31e-01 |
Transmission across Chemical Synapses | 101 | 6.69e-01 | 0.024700 | 7.81e-01 |
Phospholipid metabolism | 133 | 6.25e-01 | -0.024600 | 7.48e-01 |
Zinc transporters | 12 | 8.84e-01 | -0.024400 | 9.39e-01 |
RHOB GTPase cycle | 44 | 7.93e-01 | -0.022900 | 8.73e-01 |
EGR2 and SOX10-mediated initiation of Schwann cell myelination | 14 | 8.83e-01 | 0.022800 | 9.39e-01 |
Late endosomal microautophagy | 23 | 8.51e-01 | -0.022700 | 9.21e-01 |
Signaling by FGFR4 | 25 | 8.46e-01 | -0.022400 | 9.18e-01 |
Integrin cell surface interactions | 25 | 8.51e-01 | 0.021800 | 9.21e-01 |
Constitutive Signaling by Aberrant PI3K in Cancer | 28 | 8.43e-01 | 0.021700 | 9.17e-01 |
Regulation of TP53 Activity through Methylation | 17 | 8.78e-01 | -0.021500 | 9.37e-01 |
ROS and RNS production in phagocytes | 23 | 8.63e-01 | -0.020800 | 9.30e-01 |
Negative regulation of the PI3K/AKT network | 56 | 7.90e-01 | -0.020600 | 8.71e-01 |
Inflammasomes | 16 | 8.87e-01 | -0.020400 | 9.41e-01 |
Apoptotic cleavage of cellular proteins | 25 | 8.63e-01 | -0.019900 | 9.30e-01 |
Prolonged ERK activation events | 13 | 9.02e-01 | 0.019800 | 9.51e-01 |
Detoxification of Reactive Oxygen Species | 23 | 8.70e-01 | 0.019600 | 9.33e-01 |
RHO GTPases Activate ROCKs | 13 | 9.07e-01 | -0.018700 | 9.52e-01 |
Metabolic disorders of biological oxidation enzymes | 14 | 9.06e-01 | -0.018300 | 9.52e-01 |
Calnexin/calreticulin cycle | 23 | 8.80e-01 | -0.018100 | 9.37e-01 |
Sealing of the nuclear envelope (NE) by ESCRT-III | 19 | 8.91e-01 | -0.018100 | 9.44e-01 |
Phosphorylation of the APC/C | 18 | 8.94e-01 | -0.018100 | 9.45e-01 |
Carboxyterminal post-translational modifications of tubulin | 24 | 8.79e-01 | -0.018000 | 9.37e-01 |
Processing of SMDT1 | 13 | 9.11e-01 | -0.017800 | 9.54e-01 |
NR1H2 and NR1H3-mediated signaling | 27 | 8.73e-01 | 0.017800 | 9.34e-01 |
Negative regulation of MET activity | 16 | 9.02e-01 | 0.017800 | 9.51e-01 |
Infection with Mycobacterium tuberculosis | 22 | 8.86e-01 | 0.017600 | 9.41e-01 |
CD209 (DC-SIGN) signaling | 15 | 9.07e-01 | -0.017400 | 9.52e-01 |
Tristetraprolin (TTP, ZFP36) binds and destabilizes mRNA | 16 | 9.07e-01 | -0.016800 | 9.52e-01 |
Synthesis of PIPs at the Golgi membrane | 12 | 9.21e-01 | -0.016500 | 9.58e-01 |
Leishmania infection | 112 | 7.64e-01 | -0.016400 | 8.56e-01 |
Regulation of RUNX1 Expression and Activity | 17 | 9.07e-01 | 0.016300 | 9.52e-01 |
Cell-Cell communication | 48 | 8.46e-01 | 0.016200 | 9.18e-01 |
FOXO-mediated transcription of cell cycle genes | 13 | 9.20e-01 | -0.016000 | 9.58e-01 |
Synthesis of PIPs at the early endosome membrane | 12 | 9.25e-01 | 0.015800 | 9.59e-01 |
SLC-mediated transmembrane transport | 105 | 7.87e-01 | -0.015300 | 8.70e-01 |
Neurexins and neuroligins | 21 | 9.04e-01 | -0.015200 | 9.52e-01 |
Regulation of insulin secretion | 40 | 8.68e-01 | 0.015200 | 9.33e-01 |
Myogenesis | 13 | 9.25e-01 | -0.015100 | 9.59e-01 |
Nuclear events stimulated by ALK signaling in cancer | 14 | 9.28e-01 | 0.014000 | 9.61e-01 |
FLT3 Signaling | 32 | 8.93e-01 | -0.013700 | 9.44e-01 |
Synthesis of PIPs at the plasma membrane | 36 | 8.88e-01 | -0.013500 | 9.41e-01 |
The NLRP3 inflammasome | 12 | 9.39e-01 | 0.012700 | 9.66e-01 |
Syndecan interactions | 10 | 9.45e-01 | -0.012500 | 9.69e-01 |
RUNX2 regulates osteoblast differentiation | 13 | 9.38e-01 | -0.012400 | 9.66e-01 |
PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling | 50 | 8.79e-01 | -0.012400 | 9.37e-01 |
Interconversion of nucleotide di- and triphosphates | 25 | 9.15e-01 | -0.012300 | 9.55e-01 |
Ion channel transport | 80 | 8.53e-01 | -0.012000 | 9.23e-01 |
RND3 GTPase cycle | 29 | 9.11e-01 | -0.012000 | 9.54e-01 |
PI3K Cascade | 19 | 9.30e-01 | 0.011600 | 9.62e-01 |
Sensory processing of sound | 27 | 9.17e-01 | -0.011500 | 9.55e-01 |
Sensory processing of sound by inner hair cells of the cochlea | 27 | 9.17e-01 | -0.011500 | 9.55e-01 |
Growth hormone receptor signaling | 17 | 9.36e-01 | 0.011300 | 9.66e-01 |
NRAGE signals death through JNK | 30 | 9.16e-01 | 0.011200 | 9.55e-01 |
Downregulation of ERBB2 signaling | 17 | 9.37e-01 | -0.011100 | 9.66e-01 |
Transport of bile salts and organic acids, metal ions and amine compounds | 34 | 9.15e-01 | 0.010600 | 9.55e-01 |
Lysosome Vesicle Biogenesis | 24 | 9.31e-01 | -0.010200 | 9.62e-01 |
PI Metabolism | 60 | 8.92e-01 | -0.010100 | 9.44e-01 |
O-linked glycosylation of mucins | 26 | 9.29e-01 | 0.010000 | 9.62e-01 |
Signaling by RAF1 mutants | 25 | 9.36e-01 | -0.009240 | 9.66e-01 |
Response of Mtb to phagocytosis | 20 | 9.44e-01 | -0.009050 | 9.68e-01 |
Signaling by high-kinase activity BRAF mutants | 22 | 9.42e-01 | -0.008940 | 9.67e-01 |
Uptake and actions of bacterial toxins | 18 | 9.49e-01 | 0.008630 | 9.71e-01 |
Signaling by Insulin receptor | 42 | 9.24e-01 | 0.008540 | 9.59e-01 |
Interleukin-2 family signaling | 28 | 9.38e-01 | 0.008460 | 9.66e-01 |
Dopamine Neurotransmitter Release Cycle | 12 | 9.60e-01 | 0.008440 | 9.78e-01 |
RUNX2 regulates bone development | 18 | 9.52e-01 | 0.008260 | 9.73e-01 |
Signaling by FGFR1 | 28 | 9.41e-01 | -0.008140 | 9.66e-01 |
Amino acid transport across the plasma membrane | 16 | 9.59e-01 | 0.007420 | 9.78e-01 |
Protein-protein interactions at synapses | 33 | 9.49e-01 | 0.006460 | 9.71e-01 |
mTORC1-mediated signalling | 21 | 9.61e-01 | 0.006240 | 9.78e-01 |
Degradation of the extracellular matrix | 35 | 9.55e-01 | 0.005530 | 9.75e-01 |
Aberrant regulation of mitotic exit in cancer due to RB1 defects | 18 | 9.69e-01 | -0.005220 | 9.83e-01 |
Signaling by FGFR3 | 26 | 9.64e-01 | -0.005160 | 9.81e-01 |
Amyloid fiber formation | 27 | 9.67e-01 | -0.004630 | 9.83e-01 |
FOXO-mediated transcription of oxidative stress, metabolic and neuronal genes | 15 | 9.80e-01 | -0.003710 | 9.90e-01 |
RHO GTPase cycle | 294 | 9.15e-01 | 0.003630 | 9.55e-01 |
IRS-mediated signalling | 21 | 9.78e-01 | 0.003410 | 9.89e-01 |
FCGR3A-mediated phagocytosis | 42 | 9.71e-01 | 0.003240 | 9.83e-01 |
Leishmania phagocytosis | 42 | 9.71e-01 | 0.003240 | 9.83e-01 |
Parasite infection | 42 | 9.71e-01 | 0.003240 | 9.83e-01 |
Maturation of nucleoprotein | 11 | 9.85e-01 | -0.003210 | 9.91e-01 |
Oxidative Stress Induced Senescence | 55 | 9.71e-01 | 0.002880 | 9.83e-01 |
ADORA2B mediated anti-inflammatory cytokines production | 33 | 9.82e-01 | -0.002300 | 9.91e-01 |
Sensory Perception | 68 | 9.76e-01 | 0.002150 | 9.87e-01 |
Nucleotide-binding domain, leucine rich repeat containing receptor (NLR) signaling pathways | 38 | 9.83e-01 | 0.001940 | 9.91e-01 |
TGF-beta receptor signaling activates SMADs | 39 | 9.85e-01 | 0.001710 | 9.91e-01 |
E2F mediated regulation of DNA replication | 19 | 9.91e-01 | -0.001550 | 9.94e-01 |
RHOC GTPase cycle | 49 | 9.87e-01 | 0.001360 | 9.91e-01 |
Interleukin-17 signaling | 52 | 9.87e-01 | -0.001340 | 9.91e-01 |
Neurotransmitter receptors and postsynaptic signal transmission | 77 | 9.84e-01 | 0.001330 | 9.91e-01 |
Budding and maturation of HIV virion | 24 | 9.92e-01 | -0.001140 | 9.95e-01 |
Translation of Replicase and Assembly of the Replication Transcription Complex | 11 | 9.96e-01 | 0.000803 | 9.97e-01 |
TP53 Regulates Transcription of Cell Death Genes | 31 | 9.95e-01 | 0.000608 | 9.97e-01 |
Transcriptional Regulation by MECP2 | 31 | 9.97e-01 | 0.000358 | 9.97e-01 |
Signaling by FGFR2 IIIa TM
971 | |
---|---|
set | Signaling by FGFR2 IIIa TM |
setSize | 15 |
pANOVA | 9.84e-05 |
s.dist | -0.581 |
p.adjustANOVA | 0.00169 |
Top enriched genes
GeneID | Gene Rank |
---|---|
NCBP1 | -11114.5 |
POLR2D | -10830.0 |
POLR2A | -10548.0 |
POLR2B | -10534.0 |
GTF2F2 | -10486.0 |
POLR2F | -10467.5 |
POLR2L | -10380.5 |
GTF2F1 | -8706.0 |
POLR2E | -8601.0 |
POLR2I | -8371.5 |
NCBP2 | -8252.0 |
POLR2C | -7787.0 |
POLR2H | -7744.0 |
POLR2G | -3915.0 |
POLR2K | -2872.0 |
GeneID | Gene Rank |
---|---|
NCBP1 | -11114.5 |
POLR2D | -10830.0 |
POLR2A | -10548.0 |
POLR2B | -10534.0 |
GTF2F2 | -10486.0 |
POLR2F | -10467.5 |
POLR2L | -10380.5 |
GTF2F1 | -8706.0 |
POLR2E | -8601.0 |
POLR2I | -8371.5 |
NCBP2 | -8252.0 |
POLR2C | -7787.0 |
POLR2H | -7744.0 |
POLR2G | -3915.0 |
POLR2K | -2872.0 |
TNFs bind their physiological receptors
1066 | |
---|---|
set | TNFs bind their physiological receptors |
setSize | 10 |
pANOVA | 0.00935 |
s.dist | 0.475 |
p.adjustANOVA | 0.0366 |
Top enriched genes
GeneID | Gene Rank |
---|---|
TNFRSF25 | 566.0 |
EDARADD | 0.5 |
TNFSF14 | 0.5 |
CD27 | -1338.0 |
TNFRSF1B | -1498.0 |
LTA | -1742.0 |
TNFSF13 | -1822.5 |
TNFSF9 | -3475.0 |
TNFRSF1A | -6875.0 |
TNFSF13B | -7586.0 |
GeneID | Gene Rank |
---|---|
TNFRSF25 | 566.0 |
EDARADD | 0.5 |
TNFSF14 | 0.5 |
CD27 | -1338.0 |
TNFRSF1B | -1498.0 |
LTA | -1742.0 |
TNFSF13 | -1822.5 |
TNFSF9 | -3475.0 |
TNFRSF1A | -6875.0 |
TNFSF13B | -7586.0 |
Inhibition of DNA recombination at telomere
448 | |
---|---|
set | Inhibition of DNA recombination at telomere |
setSize | 18 |
pANOVA | 0.000678 |
s.dist | -0.463 |
p.adjustANOVA | 0.00559 |
Top enriched genes
GeneID | Gene Rank |
---|---|
POLR2D | -10830.0 |
POLR2A | -10548.0 |
POLR2B | -10534.0 |
TERF2IP | -10500.5 |
POLR2F | -10467.5 |
POLR2L | -10380.5 |
DAXX | -10076.0 |
TINF2 | -9186.0 |
POLR2E | -8601.0 |
POLR2I | -8371.5 |
POLR2C | -7787.0 |
POLR2H | -7744.0 |
ACD | -6775.5 |
TERF2 | -6009.0 |
H2AFX | -4953.0 |
TERF1 | -4423.0 |
POLR2G | -3915.0 |
POLR2K | -2872.0 |
GeneID | Gene Rank |
---|---|
POLR2D | -10830.0 |
POLR2A | -10548.0 |
POLR2B | -10534.0 |
TERF2IP | -10500.5 |
POLR2F | -10467.5 |
POLR2L | -10380.5 |
DAXX | -10076.0 |
TINF2 | -9186.0 |
POLR2E | -8601.0 |
POLR2I | -8371.5 |
POLR2C | -7787.0 |
POLR2H | -7744.0 |
ACD | -6775.5 |
TERF2 | -6009.0 |
H2AFX | -4953.0 |
TERF1 | -4423.0 |
POLR2G | -3915.0 |
POLR2K | -2872.0 |
FGFR2 mutant receptor activation
309 | |
---|---|
set | FGFR2 mutant receptor activation |
setSize | 17 |
pANOVA | 0.00117 |
s.dist | -0.455 |
p.adjustANOVA | 0.00775 |
Top enriched genes
GeneID | Gene Rank |
---|---|
NCBP1 | -11114.5 |
POLR2D | -10830.0 |
POLR2A | -10548.0 |
POLR2B | -10534.0 |
GTF2F2 | -10486.0 |
POLR2F | -10467.5 |
POLR2L | -10380.5 |
GTF2F1 | -8706.0 |
POLR2E | -8601.0 |
POLR2I | -8371.5 |
NCBP2 | -8252.0 |
POLR2C | -7787.0 |
POLR2H | -7744.0 |
FGF9 | -4554.0 |
POLR2G | -3915.0 |
POLR2K | -2872.0 |
FGF8 | 0.5 |
GeneID | Gene Rank |
---|---|
NCBP1 | -11114.5 |
POLR2D | -10830.0 |
POLR2A | -10548.0 |
POLR2B | -10534.0 |
GTF2F2 | -10486.0 |
POLR2F | -10467.5 |
POLR2L | -10380.5 |
GTF2F1 | -8706.0 |
POLR2E | -8601.0 |
POLR2I | -8371.5 |
NCBP2 | -8252.0 |
POLR2C | -7787.0 |
POLR2H | -7744.0 |
FGF9 | -4554.0 |
POLR2G | -3915.0 |
POLR2K | -2872.0 |
FGF8 | 0.5 |
TP53 Regulates Transcription of Genes Involved in G1 Cell Cycle Arrest
1072 | |
---|---|
set | TP53 Regulates Transcription of Genes Involved in G1 Cell Cycle Arrest |
setSize | 12 |
pANOVA | 0.0089 |
s.dist | -0.436 |
p.adjustANOVA | 0.0353 |
Top enriched genes
GeneID | Gene Rank |
---|---|
CDKN1B | -10926.0 |
E2F7 | -10184.0 |
CCNE1 | -10174.0 |
CCNA2 | -9888.0 |
TP53 | -9885.5 |
E2F8 | -9811.0 |
PCBP4 | -9678.0 |
E2F1 | -7525.0 |
CCNE2 | -5648.0 |
CDK2 | -5295.0 |
ARID3A | -5076.0 |
CDKN1A | 0.5 |
GeneID | Gene Rank |
---|---|
CDKN1B | -10926.0 |
E2F7 | -10184.0 |
CCNE1 | -10174.0 |
CCNA2 | -9888.0 |
TP53 | -9885.5 |
E2F8 | -9811.0 |
PCBP4 | -9678.0 |
E2F1 | -7525.0 |
CCNE2 | -5648.0 |
CDK2 | -5295.0 |
ARID3A | -5076.0 |
CDKN1A | 0.5 |
TNFR1-induced proapoptotic signaling
1064 | |
---|---|
set | TNFR1-induced proapoptotic signaling |
setSize | 12 |
pANOVA | 0.00903 |
s.dist | -0.435 |
p.adjustANOVA | 0.0356 |
Top enriched genes
GeneID | Gene Rank |
---|---|
TNFAIP3 | -10705.0 |
USP4 | -10459.0 |
CYLD | -9698.0 |
FADD | -9600.0 |
TRADD | -9428.5 |
USP2 | -7516.0 |
USP21 | -7350.0 |
TRAF2 | -7293.0 |
TNFRSF1A | -6875.0 |
OTUD7B | -6731.0 |
CASP8 | -4236.0 |
TNF | -4137.0 |
GeneID | Gene Rank |
---|---|
TNFAIP3 | -10705.0 |
USP4 | -10459.0 |
CYLD | -9698.0 |
FADD | -9600.0 |
TRADD | -9428.5 |
USP2 | -7516.0 |
USP21 | -7350.0 |
TRAF2 | -7293.0 |
TNFRSF1A | -6875.0 |
OTUD7B | -6731.0 |
CASP8 | -4236.0 |
TNF | -4137.0 |
mRNA Capping
1181 | |
---|---|
set | mRNA Capping |
setSize | 26 |
pANOVA | 0.000206 |
s.dist | -0.421 |
p.adjustANOVA | 0.00239 |
Top enriched genes
GeneID | Gene Rank |
---|---|
NCBP1 | -11114.5 |
GTF2H3 | -10911.5 |
POLR2D | -10830.0 |
POLR2A | -10548.0 |
POLR2B | -10534.0 |
GTF2H4 | -10510.0 |
GTF2F2 | -10486.0 |
POLR2F | -10467.5 |
RNMT | -10466.0 |
POLR2L | -10380.5 |
SUPT5H | -10348.0 |
GTF2F1 | -8706.0 |
POLR2E | -8601.0 |
POLR2I | -8371.5 |
NCBP2 | -8252.0 |
ERCC2 | -7919.0 |
POLR2C | -7787.0 |
POLR2H | -7744.0 |
CCNH | -7205.0 |
GTF2H5 | -6121.5 |
GeneID | Gene Rank |
---|---|
NCBP1 | -11114.5 |
GTF2H3 | -10911.5 |
POLR2D | -10830.0 |
POLR2A | -10548.0 |
POLR2B | -10534.0 |
GTF2H4 | -10510.0 |
GTF2F2 | -10486.0 |
POLR2F | -10467.5 |
RNMT | -10466.0 |
POLR2L | -10380.5 |
SUPT5H | -10348.0 |
GTF2F1 | -8706.0 |
POLR2E | -8601.0 |
POLR2I | -8371.5 |
NCBP2 | -8252.0 |
ERCC2 | -7919.0 |
POLR2C | -7787.0 |
POLR2H | -7744.0 |
CCNH | -7205.0 |
GTF2H5 | -6121.5 |
POLR2G | -3915.0 |
CDK7 | -3477.0 |
POLR2K | -2872.0 |
MNAT1 | -1528.0 |
ERCC3 | -1496.0 |
RNGTT | -771.0 |
Signaling by FGFR2 in disease
972 | |
---|---|
set | Signaling by FGFR2 in disease |
setSize | 24 |
pANOVA | 0.000366 |
s.dist | -0.42 |
p.adjustANOVA | 0.00352 |
Top enriched genes
GeneID | Gene Rank |
---|---|
NCBP1 | -11114.5 |
GRB2 | -10839.0 |
POLR2D | -10830.0 |
POLR2A | -10548.0 |
POLR2B | -10534.0 |
GTF2F2 | -10486.0 |
POLR2F | -10467.5 |
POLR2L | -10380.5 |
PIK3R1 | -9732.0 |
GTF2F1 | -8706.0 |
POLR2E | -8601.0 |
POLR2I | -8371.5 |
NCBP2 | -8252.0 |
POLR2C | -7787.0 |
POLR2H | -7744.0 |
PIK3CA | -6756.0 |
PLCG1 | -6564.0 |
KRAS | -5891.0 |
HRAS | -5455.0 |
FRS2 | -5433.0 |
GeneID | Gene Rank |
---|---|
NCBP1 | -11114.5 |
GRB2 | -10839.0 |
POLR2D | -10830.0 |
POLR2A | -10548.0 |
POLR2B | -10534.0 |
GTF2F2 | -10486.0 |
POLR2F | -10467.5 |
POLR2L | -10380.5 |
PIK3R1 | -9732.0 |
GTF2F1 | -8706.0 |
POLR2E | -8601.0 |
POLR2I | -8371.5 |
NCBP2 | -8252.0 |
POLR2C | -7787.0 |
POLR2H | -7744.0 |
PIK3CA | -6756.0 |
PLCG1 | -6564.0 |
KRAS | -5891.0 |
HRAS | -5455.0 |
FRS2 | -5433.0 |
FGF9 | -4554.0 |
POLR2G | -3915.0 |
POLR2K | -2872.0 |
FGF8 | 0.5 |
Competing endogenous RNAs (ceRNAs) regulate PTEN translation
162 | |
---|---|
set | Competing endogenous RNAs (ceRNAs) regulate PTEN translation |
setSize | 10 |
pANOVA | 0.0214 |
s.dist | 0.42 |
p.adjustANOVA | 0.0726 |
Top enriched genes
GeneID | Gene Rank |
---|---|
AGO3 | 0.5 |
AGO1 | 0.5 |
MIR19A | 0.5 |
MIR17 | -1762.0 |
TNRC6B | -2401.0 |
MOV10 | -2500.0 |
AGO2 | -2845.0 |
CNOT6L | -4728.0 |
TNRC6A | -5956.0 |
VAPA | -6852.0 |
GeneID | Gene Rank |
---|---|
AGO3 | 0.5 |
AGO1 | 0.5 |
MIR19A | 0.5 |
MIR17 | -1762.0 |
TNRC6B | -2401.0 |
MOV10 | -2500.0 |
AGO2 | -2845.0 |
CNOT6L | -4728.0 |
TNRC6A | -5956.0 |
VAPA | -6852.0 |
Purine salvage
745 | |
---|---|
set | Purine salvage |
setSize | 11 |
pANOVA | 0.0176 |
s.dist | -0.413 |
p.adjustANOVA | 0.0627 |
Top enriched genes
GeneID | Gene Rank |
---|---|
GMPR2 | -10971.5 |
ADK | -10538.0 |
AMPD2 | -10260.0 |
APRT | -9472.0 |
ADAL | -9312.5 |
DCK | -7773.0 |
AMPD3 | -6759.0 |
PNP | -6639.0 |
DGUOK | -5513.0 |
GMPR | -5145.0 |
ADA | -2358.0 |
GeneID | Gene Rank |
---|---|
GMPR2 | -10971.5 |
ADK | -10538.0 |
AMPD2 | -10260.0 |
APRT | -9472.0 |
ADAL | -9312.5 |
DCK | -7773.0 |
AMPD3 | -6759.0 |
PNP | -6639.0 |
DGUOK | -5513.0 |
GMPR | -5145.0 |
ADA | -2358.0 |
Abortive elongation of HIV-1 transcript in the absence of Tat
24 | |
---|---|
set | Abortive elongation of HIV-1 transcript in the absence of Tat |
setSize | 22 |
pANOVA | 0.000932 |
s.dist | -0.408 |
p.adjustANOVA | 0.00691 |
Top enriched genes
GeneID | Gene Rank |
---|---|
NCBP1 | -11114.5 |
POLR2D | -10830.0 |
SUPT4H1 | -10827.0 |
POLR2A | -10548.0 |
POLR2B | -10534.0 |
GTF2F2 | -10486.0 |
POLR2F | -10467.5 |
POLR2L | -10380.5 |
SUPT5H | -10348.0 |
CTDP1 | -9760.0 |
GTF2F1 | -8706.0 |
POLR2E | -8601.0 |
POLR2I | -8371.5 |
NCBP2 | -8252.0 |
POLR2C | -7787.0 |
POLR2H | -7744.0 |
POLR2G | -3915.0 |
NELFA | -3818.0 |
NELFB | -3347.0 |
POLR2K | -2872.0 |
GeneID | Gene Rank |
---|---|
NCBP1 | -11114.5 |
POLR2D | -10830.0 |
SUPT4H1 | -10827.0 |
POLR2A | -10548.0 |
POLR2B | -10534.0 |
GTF2F2 | -10486.0 |
POLR2F | -10467.5 |
POLR2L | -10380.5 |
SUPT5H | -10348.0 |
CTDP1 | -9760.0 |
GTF2F1 | -8706.0 |
POLR2E | -8601.0 |
POLR2I | -8371.5 |
NCBP2 | -8252.0 |
POLR2C | -7787.0 |
POLR2H | -7744.0 |
POLR2G | -3915.0 |
NELFA | -3818.0 |
NELFB | -3347.0 |
POLR2K | -2872.0 |
NELFCD | 0.5 |
NELFE | 0.5 |
SLBP Dependent Processing of Replication-Dependent Histone Pre-mRNAs
908 | |
---|---|
set | SLBP Dependent Processing of Replication-Dependent Histone Pre-mRNAs |
setSize | 10 |
pANOVA | 0.0274 |
s.dist | -0.403 |
p.adjustANOVA | 0.0863 |
Top enriched genes
GeneID | Gene Rank |
---|---|
NCBP1 | -11114.5 |
SNRPG | -10153.0 |
LSM10 | -9096.0 |
LSM11 | -8890.0 |
NCBP2 | -8252.0 |
ZNF473 | -8201.5 |
SNRPD3 | -8084.0 |
SLBP | -7252.0 |
SNRPE | -4548.0 |
SNRPB | -829.0 |
GeneID | Gene Rank |
---|---|
NCBP1 | -11114.5 |
SNRPG | -10153.0 |
LSM10 | -9096.0 |
LSM11 | -8890.0 |
NCBP2 | -8252.0 |
ZNF473 | -8201.5 |
SNRPD3 | -8084.0 |
SLBP | -7252.0 |
SNRPE | -4548.0 |
SNRPB | -829.0 |
Aberrant regulation of mitotic G1/S transition in cancer due to RB1 defects
21 | |
---|---|
set | Aberrant regulation of mitotic G1/S transition in cancer due to RB1 defects |
setSize | 16 |
pANOVA | 0.00549 |
s.dist | -0.401 |
p.adjustANOVA | 0.0236 |
Top enriched genes
GeneID | Gene Rank |
---|---|
CDKN1B | -10926.0 |
CCND1 | -10727.0 |
CCND2 | -10382.0 |
CCND3 | -10179.0 |
CCNE1 | -10174.0 |
RB1 | -9349.0 |
CDK6 | -9142.0 |
E2F3 | -8327.0 |
E2F1 | -7525.0 |
CDK4 | -7376.0 |
E2F2 | -6440.0 |
TFDP1 | -6131.0 |
CCNE2 | -5648.0 |
CDK2 | -5295.0 |
TFDP2 | -4443.0 |
CDKN1A | 0.5 |
GeneID | Gene Rank |
---|---|
CDKN1B | -10926.0 |
CCND1 | -10727.0 |
CCND2 | -10382.0 |
CCND3 | -10179.0 |
CCNE1 | -10174.0 |
RB1 | -9349.0 |
CDK6 | -9142.0 |
E2F3 | -8327.0 |
E2F1 | -7525.0 |
CDK4 | -7376.0 |
E2F2 | -6440.0 |
TFDP1 | -6131.0 |
CCNE2 | -5648.0 |
CDK2 | -5295.0 |
TFDP2 | -4443.0 |
CDKN1A | 0.5 |
Defective binding of RB1 mutants to E2F1,(E2F2, E2F3)
214 | |
---|---|
set | Defective binding of RB1 mutants to E2F1,(E2F2, E2F3) |
setSize | 16 |
pANOVA | 0.00549 |
s.dist | -0.401 |
p.adjustANOVA | 0.0236 |
Top enriched genes
GeneID | Gene Rank |
---|---|
CDKN1B | -10926.0 |
CCND1 | -10727.0 |
CCND2 | -10382.0 |
CCND3 | -10179.0 |
CCNE1 | -10174.0 |
RB1 | -9349.0 |
CDK6 | -9142.0 |
E2F3 | -8327.0 |
E2F1 | -7525.0 |
CDK4 | -7376.0 |
E2F2 | -6440.0 |
TFDP1 | -6131.0 |
CCNE2 | -5648.0 |
CDK2 | -5295.0 |
TFDP2 | -4443.0 |
CDKN1A | 0.5 |
GeneID | Gene Rank |
---|---|
CDKN1B | -10926.0 |
CCND1 | -10727.0 |
CCND2 | -10382.0 |
CCND3 | -10179.0 |
CCNE1 | -10174.0 |
RB1 | -9349.0 |
CDK6 | -9142.0 |
E2F3 | -8327.0 |
E2F1 | -7525.0 |
CDK4 | -7376.0 |
E2F2 | -6440.0 |
TFDP1 | -6131.0 |
CCNE2 | -5648.0 |
CDK2 | -5295.0 |
TFDP2 | -4443.0 |
CDKN1A | 0.5 |
Synthesis of Leukotrienes (LT) and Eoxins (EX)
1042 | |
---|---|
set | Synthesis of Leukotrienes (LT) and Eoxins (EX) |
setSize | 10 |
pANOVA | 0.0288 |
s.dist | 0.399 |
p.adjustANOVA | 0.0896 |
Top enriched genes
GeneID | Gene Rank |
---|---|
GGT1 | 591 |
DPEP2 | -1249 |
LTA4H | -1314 |
ALOX5AP | -1446 |
LTC4S | -2396 |
CYP4F22 | -2423 |
PTGR1 | -2444 |
MAPKAPK2 | -3310 |
ALOX5 | -5585 |
ABCC1 | -8712 |
GeneID | Gene Rank |
---|---|
GGT1 | 591 |
DPEP2 | -1249 |
LTA4H | -1314 |
ALOX5AP | -1446 |
LTC4S | -2396 |
CYP4F22 | -2423 |
PTGR1 | -2444 |
MAPKAPK2 | -3310 |
ALOX5 | -5585 |
ABCC1 | -8712 |
Assembly of the ORC complex at the origin of replication
66 | |
---|---|
set | Assembly of the ORC complex at the origin of replication |
setSize | 10 |
pANOVA | 0.0293 |
s.dist | 0.398 |
p.adjustANOVA | 0.0908 |
Top enriched genes
GeneID | Gene Rank |
---|---|
ORC1 | 727.0 |
ORC3 | 0.5 |
KPNA6 | -854.0 |
ORC5 | -1355.0 |
ORC6 | -1833.0 |
ORC4 | -2085.5 |
ORC2 | -3423.0 |
H2AFX | -4953.0 |
KPNB1 | -7061.0 |
KPNA1 | -7530.0 |
GeneID | Gene Rank |
---|---|
ORC1 | 727.0 |
ORC3 | 0.5 |
KPNA6 | -854.0 |
ORC5 | -1355.0 |
ORC6 | -1833.0 |
ORC4 | -2085.5 |
ORC2 | -3423.0 |
H2AFX | -4953.0 |
KPNB1 | -7061.0 |
KPNA1 | -7530.0 |
Endosomal/Vacuolar pathway
287 | |
---|---|
set | Endosomal/Vacuolar pathway |
setSize | 10 |
pANOVA | 0.0297 |
s.dist | -0.397 |
p.adjustANOVA | 0.0914 |
Top enriched genes
GeneID | Gene Rank |
---|---|
HLA-E | -11221 |
HLA-C | -11127 |
HLA-B | -10804 |
HLA-H | -10398 |
HLA-F | -9491 |
LNPEP | -8485 |
HLA-A | -6825 |
CTSL | -4314 |
CTSV | -2858 |
B2M | -551 |
GeneID | Gene Rank |
---|---|
HLA-E | -11221 |
HLA-C | -11127 |
HLA-B | -10804 |
HLA-H | -10398 |
HLA-F | -9491 |
LNPEP | -8485 |
HLA-A | -6825 |
CTSL | -4314 |
CTSV | -2858 |
B2M | -551 |
RNA Pol II CTD phosphorylation and interaction with CE
786 | |
---|---|
set | RNA Pol II CTD phosphorylation and interaction with CE |
setSize | 24 |
pANOVA | 0.000847 |
s.dist | -0.394 |
p.adjustANOVA | 0.00656 |
Top enriched genes
GeneID | Gene Rank |
---|---|
GTF2H3 | -10911.5 |
POLR2D | -10830.0 |
POLR2A | -10548.0 |
POLR2B | -10534.0 |
GTF2H4 | -10510.0 |
GTF2F2 | -10486.0 |
POLR2F | -10467.5 |
RNMT | -10466.0 |
POLR2L | -10380.5 |
SUPT5H | -10348.0 |
GTF2F1 | -8706.0 |
POLR2E | -8601.0 |
POLR2I | -8371.5 |
ERCC2 | -7919.0 |
POLR2C | -7787.0 |
POLR2H | -7744.0 |
CCNH | -7205.0 |
GTF2H5 | -6121.5 |
POLR2G | -3915.0 |
CDK7 | -3477.0 |
GeneID | Gene Rank |
---|---|
GTF2H3 | -10911.5 |
POLR2D | -10830.0 |
POLR2A | -10548.0 |
POLR2B | -10534.0 |
GTF2H4 | -10510.0 |
GTF2F2 | -10486.0 |
POLR2F | -10467.5 |
RNMT | -10466.0 |
POLR2L | -10380.5 |
SUPT5H | -10348.0 |
GTF2F1 | -8706.0 |
POLR2E | -8601.0 |
POLR2I | -8371.5 |
ERCC2 | -7919.0 |
POLR2C | -7787.0 |
POLR2H | -7744.0 |
CCNH | -7205.0 |
GTF2H5 | -6121.5 |
POLR2G | -3915.0 |
CDK7 | -3477.0 |
POLR2K | -2872.0 |
MNAT1 | -1528.0 |
ERCC3 | -1496.0 |
RNGTT | -771.0 |
RNA Pol II CTD phosphorylation and interaction with CE during HIV infection
787 | |
---|---|
set | RNA Pol II CTD phosphorylation and interaction with CE during HIV infection |
setSize | 24 |
pANOVA | 0.000847 |
s.dist | -0.394 |
p.adjustANOVA | 0.00656 |
Top enriched genes
GeneID | Gene Rank |
---|---|
GTF2H3 | -10911.5 |
POLR2D | -10830.0 |
POLR2A | -10548.0 |
POLR2B | -10534.0 |
GTF2H4 | -10510.0 |
GTF2F2 | -10486.0 |
POLR2F | -10467.5 |
RNMT | -10466.0 |
POLR2L | -10380.5 |
SUPT5H | -10348.0 |
GTF2F1 | -8706.0 |
POLR2E | -8601.0 |
POLR2I | -8371.5 |
ERCC2 | -7919.0 |
POLR2C | -7787.0 |
POLR2H | -7744.0 |
CCNH | -7205.0 |
GTF2H5 | -6121.5 |
POLR2G | -3915.0 |
CDK7 | -3477.0 |
GeneID | Gene Rank |
---|---|
GTF2H3 | -10911.5 |
POLR2D | -10830.0 |
POLR2A | -10548.0 |
POLR2B | -10534.0 |
GTF2H4 | -10510.0 |
GTF2F2 | -10486.0 |
POLR2F | -10467.5 |
RNMT | -10466.0 |
POLR2L | -10380.5 |
SUPT5H | -10348.0 |
GTF2F1 | -8706.0 |
POLR2E | -8601.0 |
POLR2I | -8371.5 |
ERCC2 | -7919.0 |
POLR2C | -7787.0 |
POLR2H | -7744.0 |
CCNH | -7205.0 |
GTF2H5 | -6121.5 |
POLR2G | -3915.0 |
CDK7 | -3477.0 |
POLR2K | -2872.0 |
MNAT1 | -1528.0 |
ERCC3 | -1496.0 |
RNGTT | -771.0 |
FGFR2 alternative splicing
308 | |
---|---|
set | FGFR2 alternative splicing |
setSize | 22 |
pANOVA | 0.00157 |
s.dist | -0.389 |
p.adjustANOVA | 0.00921 |
Top enriched genes
GeneID | Gene Rank |
---|---|
NCBP1 | -11114.5 |
HNRNPF | -11102.0 |
POLR2D | -10830.0 |
POLR2A | -10548.0 |
POLR2B | -10534.0 |
GTF2F2 | -10486.0 |
POLR2F | -10467.5 |
POLR2L | -10380.5 |
GTF2F1 | -8706.0 |
POLR2E | -8601.0 |
POLR2I | -8371.5 |
NCBP2 | -8252.0 |
POLR2C | -7787.0 |
POLR2H | -7744.0 |
TIA1 | -7651.0 |
TIAL1 | -6974.0 |
POLR2G | -3915.0 |
ESRP2 | -3327.0 |
POLR2K | -2872.0 |
HNRNPH1 | -2782.0 |
GeneID | Gene Rank |
---|---|
NCBP1 | -11114.5 |
HNRNPF | -11102.0 |
POLR2D | -10830.0 |
POLR2A | -10548.0 |
POLR2B | -10534.0 |
GTF2F2 | -10486.0 |
POLR2F | -10467.5 |
POLR2L | -10380.5 |
GTF2F1 | -8706.0 |
POLR2E | -8601.0 |
POLR2I | -8371.5 |
NCBP2 | -8252.0 |
POLR2C | -7787.0 |
POLR2H | -7744.0 |
TIA1 | -7651.0 |
TIAL1 | -6974.0 |
POLR2G | -3915.0 |
ESRP2 | -3327.0 |
POLR2K | -2872.0 |
HNRNPH1 | -2782.0 |
PTBP1 | -2566.0 |
HNRNPM | -1277.0 |
alpha-linolenic (omega3) and linoleic (omega6) acid metabolism
1178 | |
---|---|
set | alpha-linolenic (omega3) and linoleic (omega6) acid metabolism |
setSize | 10 |
pANOVA | 0.0393 |
s.dist | -0.376 |
p.adjustANOVA | 0.113 |
Top enriched genes
GeneID | Gene Rank |
---|---|
ELOVL1 | -10920.0 |
FADS2 | -10853.0 |
FADS1 | -10280.0 |
ACOX1 | -8873.0 |
ACAA1 | -8609.0 |
SCP2 | -7055.0 |
ELOVL5 | -6979.0 |
ACOT8 | -5223.5 |
ACSL1 | -3458.0 |
HSD17B4 | -2577.0 |
GeneID | Gene Rank |
---|---|
ELOVL1 | -10920.0 |
FADS2 | -10853.0 |
FADS1 | -10280.0 |
ACOX1 | -8873.0 |
ACAA1 | -8609.0 |
SCP2 | -7055.0 |
ELOVL5 | -6979.0 |
ACOT8 | -5223.5 |
ACSL1 | -3458.0 |
HSD17B4 | -2577.0 |
alpha-linolenic acid (ALA) metabolism
1179 | |
---|---|
set | alpha-linolenic acid (ALA) metabolism |
setSize | 10 |
pANOVA | 0.0393 |
s.dist | -0.376 |
p.adjustANOVA | 0.113 |
Top enriched genes
GeneID | Gene Rank |
---|---|
ELOVL1 | -10920.0 |
FADS2 | -10853.0 |
FADS1 | -10280.0 |
ACOX1 | -8873.0 |
ACAA1 | -8609.0 |
SCP2 | -7055.0 |
ELOVL5 | -6979.0 |
ACOT8 | -5223.5 |
ACSL1 | -3458.0 |
HSD17B4 | -2577.0 |
GeneID | Gene Rank |
---|---|
ELOVL1 | -10920.0 |
FADS2 | -10853.0 |
FADS1 | -10280.0 |
ACOX1 | -8873.0 |
ACAA1 | -8609.0 |
SCP2 | -7055.0 |
ELOVL5 | -6979.0 |
ACOT8 | -5223.5 |
ACSL1 | -3458.0 |
HSD17B4 | -2577.0 |
Processing of Intronless Pre-mRNAs
731 | |
---|---|
set | Processing of Intronless Pre-mRNAs |
setSize | 15 |
pANOVA | 0.0125 |
s.dist | -0.373 |
p.adjustANOVA | 0.0468 |
Top enriched genes
GeneID | Gene Rank |
---|---|
NCBP1 | -11114.5 |
CPSF4 | -10263.5 |
CLP1 | -10254.0 |
SYMPK | -10049.0 |
CPSF2 | -10040.5 |
PAPOLA | -9422.0 |
CPSF1 | -8812.0 |
FIP1L1 | -8322.0 |
NCBP2 | -8252.0 |
CPSF3 | -6846.5 |
CSTF1 | -5237.5 |
WDR33 | -5196.0 |
NUDT21 | -4334.5 |
CPSF6 | -2510.0 |
PABPN1 | -1239.0 |
GeneID | Gene Rank |
---|---|
NCBP1 | -11114.5 |
CPSF4 | -10263.5 |
CLP1 | -10254.0 |
SYMPK | -10049.0 |
CPSF2 | -10040.5 |
PAPOLA | -9422.0 |
CPSF1 | -8812.0 |
FIP1L1 | -8322.0 |
NCBP2 | -8252.0 |
CPSF3 | -6846.5 |
CSTF1 | -5237.5 |
WDR33 | -5196.0 |
NUDT21 | -4334.5 |
CPSF6 | -2510.0 |
PABPN1 | -1239.0 |
SUMOylation of immune response proteins
922 | |
---|---|
set | SUMOylation of immune response proteins |
setSize | 10 |
pANOVA | 0.0443 |
s.dist | -0.367 |
p.adjustANOVA | 0.126 |
Top enriched genes
GeneID | Gene Rank |
---|---|
NFKB2 | -10948 |
UBE2I | -9641 |
NFKBIA | -9113 |
PIAS4 | -7982 |
RELA | -7688 |
PIAS3 | -7677 |
IKBKE | -6700 |
SUMO1 | -6129 |
TOPORS | -5898 |
SUMO3 | -2508 |
GeneID | Gene Rank |
---|---|
NFKB2 | -10948 |
UBE2I | -9641 |
NFKBIA | -9113 |
PIAS4 | -7982 |
RELA | -7688 |
PIAS3 | -7677 |
IKBKE | -6700 |
SUMO1 | -6129 |
TOPORS | -5898 |
SUMO3 | -2508 |
Other semaphorin interactions
664 | |
---|---|
set | Other semaphorin interactions |
setSize | 10 |
pANOVA | 0.0454 |
s.dist | 0.365 |
p.adjustANOVA | 0.128 |
Top enriched genes
GeneID | Gene Rank |
---|---|
SEMA4D | 620.0 |
TYROBP | 0.5 |
SEMA4A | 0.5 |
PTPRC | 0.5 |
PLXNA2 | -711.0 |
CD72 | -878.0 |
PLXNC1 | -4978.0 |
PLXND1 | -6751.0 |
ITGA1 | -7915.5 |
SEMA7A | -9712.0 |
GeneID | Gene Rank |
---|---|
SEMA4D | 620.0 |
TYROBP | 0.5 |
SEMA4A | 0.5 |
PTPRC | 0.5 |
PLXNA2 | -711.0 |
CD72 | -878.0 |
PLXNC1 | -4978.0 |
PLXND1 | -6751.0 |
ITGA1 | -7915.5 |
SEMA7A | -9712.0 |
Signaling by ERBB2 ECD mutants
960 | |
---|---|
set | Signaling by ERBB2 ECD mutants |
setSize | 10 |
pANOVA | 0.0465 |
s.dist | -0.364 |
p.adjustANOVA | 0.131 |
Top enriched genes
GeneID | Gene Rank |
---|---|
GRB2 | -10839.0 |
HSP90AA1 | -10443.0 |
PIK3R1 | -9732.0 |
CDC37 | -9273.5 |
PIK3CA | -6756.0 |
SHC1 | -6692.5 |
PLCG1 | -6564.0 |
KRAS | -5891.0 |
HRAS | -5455.0 |
ERBB2 | -2414.0 |
GeneID | Gene Rank |
---|---|
GRB2 | -10839.0 |
HSP90AA1 | -10443.0 |
PIK3R1 | -9732.0 |
CDC37 | -9273.5 |
PIK3CA | -6756.0 |
SHC1 | -6692.5 |
PLCG1 | -6564.0 |
KRAS | -5891.0 |
HRAS | -5455.0 |
ERBB2 | -2414.0 |
Antigen Presentation: Folding, assembly and peptide loading of class I MHC
51 | |
---|---|
set | Antigen Presentation: Folding, assembly and peptide loading of class I MHC |
setSize | 26 |
pANOVA | 0.00158 |
s.dist | -0.358 |
p.adjustANOVA | 0.00921 |
Top enriched genes
GeneID | Gene Rank |
---|---|
HLA-E | -11221.0 |
TAPBP | -11220.0 |
TAP1 | -11215.0 |
HLA-C | -11127.0 |
SEC24A | -10906.0 |
SEC23A | -10888.0 |
HLA-B | -10804.0 |
HLA-H | -10398.0 |
PDIA3 | -9865.5 |
SEC24B | -9588.0 |
ERAP1 | -9538.0 |
HLA-F | -9491.0 |
CALR | -9246.0 |
SEC13 | -8862.0 |
SEC31A | -8445.0 |
BECN1 | -7977.0 |
SAR1B | -7849.0 |
TAP2 | -6868.0 |
HLA-A | -6825.0 |
CANX | -3277.0 |
GeneID | Gene Rank |
---|---|
HLA-E | -11221.0 |
TAPBP | -11220.0 |
TAP1 | -11215.0 |
HLA-C | -11127.0 |
SEC24A | -10906.0 |
SEC23A | -10888.0 |
HLA-B | -10804.0 |
HLA-H | -10398.0 |
PDIA3 | -9865.5 |
SEC24B | -9588.0 |
ERAP1 | -9538.0 |
HLA-F | -9491.0 |
CALR | -9246.0 |
SEC13 | -8862.0 |
SEC31A | -8445.0 |
BECN1 | -7977.0 |
SAR1B | -7849.0 |
TAP2 | -6868.0 |
HLA-A | -6825.0 |
CANX | -3277.0 |
SEC24D | -2308.0 |
PIK3R4 | -1874.0 |
SEC24C | -1281.0 |
B2M | -551.0 |
ATG14 | 0.5 |
ERAP2 | 0.5 |
Disorders of Developmental Biology
248 | |
---|---|
set | Disorders of Developmental Biology |
setSize | 10 |
pANOVA | 0.05 |
s.dist | -0.358 |
p.adjustANOVA | 0.135 |
Top enriched genes
GeneID | Gene Rank |
---|---|
PRKACA | -10561 |
HDAC3 | -10075 |
SIN3A | -9334 |
NCOR1 | -9314 |
CALM1 | -8409 |
HDAC1 | -7321 |
CAMK4 | -6998 |
TBL1XR1 | -6891 |
GPS2 | -3196 |
NCOR2 | -1627 |
GeneID | Gene Rank |
---|---|
PRKACA | -10561 |
HDAC3 | -10075 |
SIN3A | -9334 |
NCOR1 | -9314 |
CALM1 | -8409 |
HDAC1 | -7321 |
CAMK4 | -6998 |
TBL1XR1 | -6891 |
GPS2 | -3196 |
NCOR2 | -1627 |
Disorders of Nervous System Development
249 | |
---|---|
set | Disorders of Nervous System Development |
setSize | 10 |
pANOVA | 0.05 |
s.dist | -0.358 |
p.adjustANOVA | 0.135 |
Top enriched genes
GeneID | Gene Rank |
---|---|
PRKACA | -10561 |
HDAC3 | -10075 |
SIN3A | -9334 |
NCOR1 | -9314 |
CALM1 | -8409 |
HDAC1 | -7321 |
CAMK4 | -6998 |
TBL1XR1 | -6891 |
GPS2 | -3196 |
NCOR2 | -1627 |
GeneID | Gene Rank |
---|---|
PRKACA | -10561 |
HDAC3 | -10075 |
SIN3A | -9334 |
NCOR1 | -9314 |
CALM1 | -8409 |
HDAC1 | -7321 |
CAMK4 | -6998 |
TBL1XR1 | -6891 |
GPS2 | -3196 |
NCOR2 | -1627 |
Loss of function of MECP2 in Rett syndrome
515 | |
---|---|
set | Loss of function of MECP2 in Rett syndrome |
setSize | 10 |
pANOVA | 0.05 |
s.dist | -0.358 |
p.adjustANOVA | 0.135 |
Top enriched genes
GeneID | Gene Rank |
---|---|
PRKACA | -10561 |
HDAC3 | -10075 |
SIN3A | -9334 |
NCOR1 | -9314 |
CALM1 | -8409 |
HDAC1 | -7321 |
CAMK4 | -6998 |
TBL1XR1 | -6891 |
GPS2 | -3196 |
NCOR2 | -1627 |
GeneID | Gene Rank |
---|---|
PRKACA | -10561 |
HDAC3 | -10075 |
SIN3A | -9334 |
NCOR1 | -9314 |
CALM1 | -8409 |
HDAC1 | -7321 |
CAMK4 | -6998 |
TBL1XR1 | -6891 |
GPS2 | -3196 |
NCOR2 | -1627 |
Pervasive developmental disorders
695 | |
---|---|
set | Pervasive developmental disorders |
setSize | 10 |
pANOVA | 0.05 |
s.dist | -0.358 |
p.adjustANOVA | 0.135 |
Top enriched genes
GeneID | Gene Rank |
---|---|
PRKACA | -10561 |
HDAC3 | -10075 |
SIN3A | -9334 |
NCOR1 | -9314 |
CALM1 | -8409 |
HDAC1 | -7321 |
CAMK4 | -6998 |
TBL1XR1 | -6891 |
GPS2 | -3196 |
NCOR2 | -1627 |
GeneID | Gene Rank |
---|---|
PRKACA | -10561 |
HDAC3 | -10075 |
SIN3A | -9334 |
NCOR1 | -9314 |
CALM1 | -8409 |
HDAC1 | -7321 |
CAMK4 | -6998 |
TBL1XR1 | -6891 |
GPS2 | -3196 |
NCOR2 | -1627 |
Degradation of cysteine and homocysteine
223 | |
---|---|
set | Degradation of cysteine and homocysteine |
setSize | 10 |
pANOVA | 0.0503 |
s.dist | -0.357 |
p.adjustANOVA | 0.136 |
Top enriched genes
GeneID | Gene Rank |
---|---|
GOT2 | -10070.0 |
SQRDL | -9997.0 |
CSAD | -9926.5 |
ADO | -9825.0 |
TSTD1 | -9043.0 |
ETHE1 | -6588.0 |
CTH | -5391.0 |
TXN2 | -4750.0 |
MPST | -4050.5 |
TST | -4050.5 |
GeneID | Gene Rank |
---|---|
GOT2 | -10070.0 |
SQRDL | -9997.0 |
CSAD | -9926.5 |
ADO | -9825.0 |
TSTD1 | -9043.0 |
ETHE1 | -6588.0 |
CTH | -5391.0 |
TXN2 | -4750.0 |
MPST | -4050.5 |
TST | -4050.5 |
HIV elongation arrest and recovery
411 | |
---|---|
set | HIV elongation arrest and recovery |
setSize | 27 |
pANOVA | 0.00133 |
s.dist | -0.357 |
p.adjustANOVA | 0.00838 |
Top enriched genes
GeneID | Gene Rank |
---|---|
POLR2D | -10830.0 |
SUPT4H1 | -10827.0 |
CCNK | -10778.5 |
CDK9 | -10699.0 |
POLR2A | -10548.0 |
POLR2B | -10534.0 |
GTF2F2 | -10486.0 |
POLR2F | -10467.5 |
POLR2L | -10380.5 |
SUPT5H | -10348.0 |
CTDP1 | -9760.0 |
GTF2F1 | -8706.0 |
POLR2E | -8601.0 |
POLR2I | -8371.5 |
CCNT1 | -8065.0 |
POLR2C | -7787.0 |
POLR2H | -7744.0 |
SSRP1 | -6661.0 |
TCEA1 | -5199.0 |
SUPT16H | -4348.0 |
GeneID | Gene Rank |
---|---|
POLR2D | -10830.0 |
SUPT4H1 | -10827.0 |
CCNK | -10778.5 |
CDK9 | -10699.0 |
POLR2A | -10548.0 |
POLR2B | -10534.0 |
GTF2F2 | -10486.0 |
POLR2F | -10467.5 |
POLR2L | -10380.5 |
SUPT5H | -10348.0 |
CTDP1 | -9760.0 |
GTF2F1 | -8706.0 |
POLR2E | -8601.0 |
POLR2I | -8371.5 |
CCNT1 | -8065.0 |
POLR2C | -7787.0 |
POLR2H | -7744.0 |
SSRP1 | -6661.0 |
TCEA1 | -5199.0 |
SUPT16H | -4348.0 |
POLR2G | -3915.0 |
NELFA | -3818.0 |
ELL | -3699.0 |
NELFB | -3347.0 |
POLR2K | -2872.0 |
NELFCD | 0.5 |
NELFE | 0.5 |
Pausing and recovery of HIV elongation
688 | |
---|---|
set | Pausing and recovery of HIV elongation |
setSize | 27 |
pANOVA | 0.00133 |
s.dist | -0.357 |
p.adjustANOVA | 0.00838 |
Top enriched genes
GeneID | Gene Rank |
---|---|
POLR2D | -10830.0 |
SUPT4H1 | -10827.0 |
CCNK | -10778.5 |
CDK9 | -10699.0 |
POLR2A | -10548.0 |
POLR2B | -10534.0 |
GTF2F2 | -10486.0 |
POLR2F | -10467.5 |
POLR2L | -10380.5 |
SUPT5H | -10348.0 |
CTDP1 | -9760.0 |
GTF2F1 | -8706.0 |
POLR2E | -8601.0 |
POLR2I | -8371.5 |
CCNT1 | -8065.0 |
POLR2C | -7787.0 |
POLR2H | -7744.0 |
SSRP1 | -6661.0 |
TCEA1 | -5199.0 |
SUPT16H | -4348.0 |
GeneID | Gene Rank |
---|---|
POLR2D | -10830.0 |
SUPT4H1 | -10827.0 |
CCNK | -10778.5 |
CDK9 | -10699.0 |
POLR2A | -10548.0 |
POLR2B | -10534.0 |
GTF2F2 | -10486.0 |
POLR2F | -10467.5 |
POLR2L | -10380.5 |
SUPT5H | -10348.0 |
CTDP1 | -9760.0 |
GTF2F1 | -8706.0 |
POLR2E | -8601.0 |
POLR2I | -8371.5 |
CCNT1 | -8065.0 |
POLR2C | -7787.0 |
POLR2H | -7744.0 |
SSRP1 | -6661.0 |
TCEA1 | -5199.0 |
SUPT16H | -4348.0 |
POLR2G | -3915.0 |
NELFA | -3818.0 |
ELL | -3699.0 |
NELFB | -3347.0 |
POLR2K | -2872.0 |
NELFCD | 0.5 |
NELFE | 0.5 |
HIV Transcription Initiation
410 | |
---|---|
set | HIV Transcription Initiation |
setSize | 39 |
pANOVA | 0.000126 |
s.dist | -0.355 |
p.adjustANOVA | 0.00175 |
Top enriched genes
GeneID | Gene Rank |
---|---|
TAF9 | -11152.5 |
GTF2H3 | -10911.5 |
POLR2D | -10830.0 |
POLR2A | -10548.0 |
POLR2B | -10534.0 |
GTF2H4 | -10510.0 |
GTF2F2 | -10486.0 |
TAF6 | -10475.5 |
POLR2F | -10467.5 |
TBP | -10407.5 |
TAF11 | -10399.5 |
POLR2L | -10380.5 |
TAF10 | -9445.0 |
GTF2F1 | -8706.0 |
POLR2E | -8601.0 |
POLR2I | -8371.5 |
TAF3 | -8320.0 |
ERCC2 | -7919.0 |
POLR2C | -7787.0 |
POLR2H | -7744.0 |
GeneID | Gene Rank |
---|---|
TAF9 | -11152.5 |
GTF2H3 | -10911.5 |
POLR2D | -10830.0 |
POLR2A | -10548.0 |
POLR2B | -10534.0 |
GTF2H4 | -10510.0 |
GTF2F2 | -10486.0 |
TAF6 | -10475.5 |
POLR2F | -10467.5 |
TBP | -10407.5 |
TAF11 | -10399.5 |
POLR2L | -10380.5 |
TAF10 | -9445.0 |
GTF2F1 | -8706.0 |
POLR2E | -8601.0 |
POLR2I | -8371.5 |
TAF3 | -8320.0 |
ERCC2 | -7919.0 |
POLR2C | -7787.0 |
POLR2H | -7744.0 |
TAF12 | -7698.0 |
CCNH | -7205.0 |
TAF5 | -7185.0 |
TAF15 | -6771.0 |
GTF2E2 | -6696.0 |
GTF2A1 | -6642.0 |
TAF2 | -6349.0 |
GTF2H5 | -6121.5 |
TAF4B | -6038.0 |
GTF2A2 | -5706.0 |
TAF7 | -5597.0 |
POLR2G | -3915.0 |
TAF13 | -3572.0 |
CDK7 | -3477.0 |
TAF4 | -3206.0 |
POLR2K | -2872.0 |
MNAT1 | -1528.0 |
ERCC3 | -1496.0 |
GTF2B | -527.0 |
RNA Polymerase II HIV Promoter Escape
793 | |
---|---|
set | RNA Polymerase II HIV Promoter Escape |
setSize | 39 |
pANOVA | 0.000126 |
s.dist | -0.355 |
p.adjustANOVA | 0.00175 |
Top enriched genes
GeneID | Gene Rank |
---|---|
TAF9 | -11152.5 |
GTF2H3 | -10911.5 |
POLR2D | -10830.0 |
POLR2A | -10548.0 |
POLR2B | -10534.0 |
GTF2H4 | -10510.0 |
GTF2F2 | -10486.0 |
TAF6 | -10475.5 |
POLR2F | -10467.5 |
TBP | -10407.5 |
TAF11 | -10399.5 |
POLR2L | -10380.5 |
TAF10 | -9445.0 |
GTF2F1 | -8706.0 |
POLR2E | -8601.0 |
POLR2I | -8371.5 |
TAF3 | -8320.0 |
ERCC2 | -7919.0 |
POLR2C | -7787.0 |
POLR2H | -7744.0 |
GeneID | Gene Rank |
---|---|
TAF9 | -11152.5 |
GTF2H3 | -10911.5 |
POLR2D | -10830.0 |
POLR2A | -10548.0 |
POLR2B | -10534.0 |
GTF2H4 | -10510.0 |
GTF2F2 | -10486.0 |
TAF6 | -10475.5 |
POLR2F | -10467.5 |
TBP | -10407.5 |
TAF11 | -10399.5 |
POLR2L | -10380.5 |
TAF10 | -9445.0 |
GTF2F1 | -8706.0 |
POLR2E | -8601.0 |
POLR2I | -8371.5 |
TAF3 | -8320.0 |
ERCC2 | -7919.0 |
POLR2C | -7787.0 |
POLR2H | -7744.0 |
TAF12 | -7698.0 |
CCNH | -7205.0 |
TAF5 | -7185.0 |
TAF15 | -6771.0 |
GTF2E2 | -6696.0 |
GTF2A1 | -6642.0 |
TAF2 | -6349.0 |
GTF2H5 | -6121.5 |
TAF4B | -6038.0 |
GTF2A2 | -5706.0 |
TAF7 | -5597.0 |
POLR2G | -3915.0 |
TAF13 | -3572.0 |
CDK7 | -3477.0 |
TAF4 | -3206.0 |
POLR2K | -2872.0 |
MNAT1 | -1528.0 |
ERCC3 | -1496.0 |
GTF2B | -527.0 |
RNA Polymerase II Promoter Escape
795 | |
---|---|
set | RNA Polymerase II Promoter Escape |
setSize | 39 |
pANOVA | 0.000126 |
s.dist | -0.355 |
p.adjustANOVA | 0.00175 |
Top enriched genes
GeneID | Gene Rank |
---|---|
TAF9 | -11152.5 |
GTF2H3 | -10911.5 |
POLR2D | -10830.0 |
POLR2A | -10548.0 |
POLR2B | -10534.0 |
GTF2H4 | -10510.0 |
GTF2F2 | -10486.0 |
TAF6 | -10475.5 |
POLR2F | -10467.5 |
TBP | -10407.5 |
TAF11 | -10399.5 |
POLR2L | -10380.5 |
TAF10 | -9445.0 |
GTF2F1 | -8706.0 |
POLR2E | -8601.0 |
POLR2I | -8371.5 |
TAF3 | -8320.0 |
ERCC2 | -7919.0 |
POLR2C | -7787.0 |
POLR2H | -7744.0 |
GeneID | Gene Rank |
---|---|
TAF9 | -11152.5 |
GTF2H3 | -10911.5 |
POLR2D | -10830.0 |
POLR2A | -10548.0 |
POLR2B | -10534.0 |
GTF2H4 | -10510.0 |
GTF2F2 | -10486.0 |
TAF6 | -10475.5 |
POLR2F | -10467.5 |
TBP | -10407.5 |
TAF11 | -10399.5 |
POLR2L | -10380.5 |
TAF10 | -9445.0 |
GTF2F1 | -8706.0 |
POLR2E | -8601.0 |
POLR2I | -8371.5 |
TAF3 | -8320.0 |
ERCC2 | -7919.0 |
POLR2C | -7787.0 |
POLR2H | -7744.0 |
TAF12 | -7698.0 |
CCNH | -7205.0 |
TAF5 | -7185.0 |
TAF15 | -6771.0 |
GTF2E2 | -6696.0 |
GTF2A1 | -6642.0 |
TAF2 | -6349.0 |
GTF2H5 | -6121.5 |
TAF4B | -6038.0 |
GTF2A2 | -5706.0 |
TAF7 | -5597.0 |
POLR2G | -3915.0 |
TAF13 | -3572.0 |
CDK7 | -3477.0 |
TAF4 | -3206.0 |
POLR2K | -2872.0 |
MNAT1 | -1528.0 |
ERCC3 | -1496.0 |
GTF2B | -527.0 |
RNA Polymerase II Transcription Initiation
798 | |
---|---|
set | RNA Polymerase II Transcription Initiation |
setSize | 39 |
pANOVA | 0.000126 |
s.dist | -0.355 |
p.adjustANOVA | 0.00175 |
Top enriched genes
GeneID | Gene Rank |
---|---|
TAF9 | -11152.5 |
GTF2H3 | -10911.5 |
POLR2D | -10830.0 |
POLR2A | -10548.0 |
POLR2B | -10534.0 |
GTF2H4 | -10510.0 |
GTF2F2 | -10486.0 |
TAF6 | -10475.5 |
POLR2F | -10467.5 |
TBP | -10407.5 |
TAF11 | -10399.5 |
POLR2L | -10380.5 |
TAF10 | -9445.0 |
GTF2F1 | -8706.0 |
POLR2E | -8601.0 |
POLR2I | -8371.5 |
TAF3 | -8320.0 |
ERCC2 | -7919.0 |
POLR2C | -7787.0 |
POLR2H | -7744.0 |
GeneID | Gene Rank |
---|---|
TAF9 | -11152.5 |
GTF2H3 | -10911.5 |
POLR2D | -10830.0 |
POLR2A | -10548.0 |
POLR2B | -10534.0 |
GTF2H4 | -10510.0 |
GTF2F2 | -10486.0 |
TAF6 | -10475.5 |
POLR2F | -10467.5 |
TBP | -10407.5 |
TAF11 | -10399.5 |
POLR2L | -10380.5 |
TAF10 | -9445.0 |
GTF2F1 | -8706.0 |
POLR2E | -8601.0 |
POLR2I | -8371.5 |
TAF3 | -8320.0 |
ERCC2 | -7919.0 |
POLR2C | -7787.0 |
POLR2H | -7744.0 |
TAF12 | -7698.0 |
CCNH | -7205.0 |
TAF5 | -7185.0 |
TAF15 | -6771.0 |
GTF2E2 | -6696.0 |
GTF2A1 | -6642.0 |
TAF2 | -6349.0 |
GTF2H5 | -6121.5 |
TAF4B | -6038.0 |
GTF2A2 | -5706.0 |
TAF7 | -5597.0 |
POLR2G | -3915.0 |
TAF13 | -3572.0 |
CDK7 | -3477.0 |
TAF4 | -3206.0 |
POLR2K | -2872.0 |
MNAT1 | -1528.0 |
ERCC3 | -1496.0 |
GTF2B | -527.0 |
RNA Polymerase II Transcription Initiation And Promoter Clearance
799 | |
---|---|
set | RNA Polymerase II Transcription Initiation And Promoter Clearance |
setSize | 39 |
pANOVA | 0.000126 |
s.dist | -0.355 |
p.adjustANOVA | 0.00175 |
Top enriched genes
GeneID | Gene Rank |
---|---|
TAF9 | -11152.5 |
GTF2H3 | -10911.5 |
POLR2D | -10830.0 |
POLR2A | -10548.0 |
POLR2B | -10534.0 |
GTF2H4 | -10510.0 |
GTF2F2 | -10486.0 |
TAF6 | -10475.5 |
POLR2F | -10467.5 |
TBP | -10407.5 |
TAF11 | -10399.5 |
POLR2L | -10380.5 |
TAF10 | -9445.0 |
GTF2F1 | -8706.0 |
POLR2E | -8601.0 |
POLR2I | -8371.5 |
TAF3 | -8320.0 |
ERCC2 | -7919.0 |
POLR2C | -7787.0 |
POLR2H | -7744.0 |
GeneID | Gene Rank |
---|---|
TAF9 | -11152.5 |
GTF2H3 | -10911.5 |
POLR2D | -10830.0 |
POLR2A | -10548.0 |
POLR2B | -10534.0 |
GTF2H4 | -10510.0 |
GTF2F2 | -10486.0 |
TAF6 | -10475.5 |
POLR2F | -10467.5 |
TBP | -10407.5 |
TAF11 | -10399.5 |
POLR2L | -10380.5 |
TAF10 | -9445.0 |
GTF2F1 | -8706.0 |
POLR2E | -8601.0 |
POLR2I | -8371.5 |
TAF3 | -8320.0 |
ERCC2 | -7919.0 |
POLR2C | -7787.0 |
POLR2H | -7744.0 |
TAF12 | -7698.0 |
CCNH | -7205.0 |
TAF5 | -7185.0 |
TAF15 | -6771.0 |
GTF2E2 | -6696.0 |
GTF2A1 | -6642.0 |
TAF2 | -6349.0 |
GTF2H5 | -6121.5 |
TAF4B | -6038.0 |
GTF2A2 | -5706.0 |
TAF7 | -5597.0 |
POLR2G | -3915.0 |
TAF13 | -3572.0 |
CDK7 | -3477.0 |
TAF4 | -3206.0 |
POLR2K | -2872.0 |
MNAT1 | -1528.0 |
ERCC3 | -1496.0 |
GTF2B | -527.0 |
RNA Polymerase II Transcription Pre-Initiation And Promoter Opening
800 | |
---|---|
set | RNA Polymerase II Transcription Pre-Initiation And Promoter Opening |
setSize | 39 |
pANOVA | 0.000126 |
s.dist | -0.355 |
p.adjustANOVA | 0.00175 |
Top enriched genes
GeneID | Gene Rank |
---|---|
TAF9 | -11152.5 |
GTF2H3 | -10911.5 |
POLR2D | -10830.0 |
POLR2A | -10548.0 |
POLR2B | -10534.0 |
GTF2H4 | -10510.0 |
GTF2F2 | -10486.0 |
TAF6 | -10475.5 |
POLR2F | -10467.5 |
TBP | -10407.5 |
TAF11 | -10399.5 |
POLR2L | -10380.5 |
TAF10 | -9445.0 |
GTF2F1 | -8706.0 |
POLR2E | -8601.0 |
POLR2I | -8371.5 |
TAF3 | -8320.0 |
ERCC2 | -7919.0 |
POLR2C | -7787.0 |
POLR2H | -7744.0 |
GeneID | Gene Rank |
---|---|
TAF9 | -11152.5 |
GTF2H3 | -10911.5 |
POLR2D | -10830.0 |
POLR2A | -10548.0 |
POLR2B | -10534.0 |
GTF2H4 | -10510.0 |
GTF2F2 | -10486.0 |
TAF6 | -10475.5 |
POLR2F | -10467.5 |
TBP | -10407.5 |
TAF11 | -10399.5 |
POLR2L | -10380.5 |
TAF10 | -9445.0 |
GTF2F1 | -8706.0 |
POLR2E | -8601.0 |
POLR2I | -8371.5 |
TAF3 | -8320.0 |
ERCC2 | -7919.0 |
POLR2C | -7787.0 |
POLR2H | -7744.0 |
TAF12 | -7698.0 |
CCNH | -7205.0 |
TAF5 | -7185.0 |
TAF15 | -6771.0 |
GTF2E2 | -6696.0 |
GTF2A1 | -6642.0 |
TAF2 | -6349.0 |
GTF2H5 | -6121.5 |
TAF4B | -6038.0 |
GTF2A2 | -5706.0 |
TAF7 | -5597.0 |
POLR2G | -3915.0 |
TAF13 | -3572.0 |
CDK7 | -3477.0 |
TAF4 | -3206.0 |
POLR2K | -2872.0 |
MNAT1 | -1528.0 |
ERCC3 | -1496.0 |
GTF2B | -527.0 |
Processing of Capped Intronless Pre-mRNA
729 | |
---|---|
set | Processing of Capped Intronless Pre-mRNA |
setSize | 23 |
pANOVA | 0.00331 |
s.dist | -0.354 |
p.adjustANOVA | 0.0165 |
Top enriched genes
GeneID | Gene Rank |
---|---|
NCBP1 | -11114.5 |
CPSF4 | -10263.5 |
CLP1 | -10254.0 |
SNRPG | -10153.0 |
SYMPK | -10049.0 |
CPSF2 | -10040.5 |
PAPOLA | -9422.0 |
LSM10 | -9096.0 |
LSM11 | -8890.0 |
CPSF1 | -8812.0 |
FIP1L1 | -8322.0 |
NCBP2 | -8252.0 |
ZNF473 | -8201.5 |
SNRPD3 | -8084.0 |
SLBP | -7252.0 |
CPSF3 | -6846.5 |
CSTF1 | -5237.5 |
WDR33 | -5196.0 |
SNRPE | -4548.0 |
NUDT21 | -4334.5 |
GeneID | Gene Rank |
---|---|
NCBP1 | -11114.5 |
CPSF4 | -10263.5 |
CLP1 | -10254.0 |
SNRPG | -10153.0 |
SYMPK | -10049.0 |
CPSF2 | -10040.5 |
PAPOLA | -9422.0 |
LSM10 | -9096.0 |
LSM11 | -8890.0 |
CPSF1 | -8812.0 |
FIP1L1 | -8322.0 |
NCBP2 | -8252.0 |
ZNF473 | -8201.5 |
SNRPD3 | -8084.0 |
SLBP | -7252.0 |
CPSF3 | -6846.5 |
CSTF1 | -5237.5 |
WDR33 | -5196.0 |
SNRPE | -4548.0 |
NUDT21 | -4334.5 |
CPSF6 | -2510.0 |
PABPN1 | -1239.0 |
SNRPB | -829.0 |
Purine ribonucleoside monophosphate biosynthesis
744 | |
---|---|
set | Purine ribonucleoside monophosphate biosynthesis |
setSize | 10 |
pANOVA | 0.0539 |
s.dist | -0.352 |
p.adjustANOVA | 0.142 |
Top enriched genes
GeneID | Gene Rank |
---|---|
ATIC | -10117.0 |
GMPS | -8921.0 |
IMPDH1 | -8633.0 |
ADSL | -8486.0 |
ADSS | -8008.0 |
IMPDH2 | -6946.0 |
PFAS | -6504.0 |
PAICS | -5498.5 |
PPAT | -5498.5 |
ADSSL1 | -4759.0 |
GeneID | Gene Rank |
---|---|
ATIC | -10117.0 |
GMPS | -8921.0 |
IMPDH1 | -8633.0 |
ADSL | -8486.0 |
ADSS | -8008.0 |
IMPDH2 | -6946.0 |
PFAS | -6504.0 |
PAICS | -5498.5 |
PPAT | -5498.5 |
ADSSL1 | -4759.0 |
PIWI-interacting RNA (piRNA) biogenesis
677 | |
---|---|
set | PIWI-interacting RNA (piRNA) biogenesis |
setSize | 16 |
pANOVA | 0.015 |
s.dist | -0.351 |
p.adjustANOVA | 0.0544 |
Top enriched genes
GeneID | Gene Rank |
---|---|
POLR2D | -10830.0 |
POLR2A | -10548.0 |
POLR2B | -10534.0 |
POLR2F | -10467.5 |
HSP90AA1 | -10443.0 |
POLR2L | -10380.5 |
POLR2E | -8601.0 |
POLR2I | -8371.5 |
POLR2C | -7787.0 |
POLR2H | -7744.0 |
HENMT1 | -7103.0 |
TDRKH | -4349.0 |
POLR2G | -3915.0 |
POLR2K | -2872.0 |
MYBL1 | -2799.0 |
PLD6 | -554.0 |
GeneID | Gene Rank |
---|---|
POLR2D | -10830.0 |
POLR2A | -10548.0 |
POLR2B | -10534.0 |
POLR2F | -10467.5 |
HSP90AA1 | -10443.0 |
POLR2L | -10380.5 |
POLR2E | -8601.0 |
POLR2I | -8371.5 |
POLR2C | -7787.0 |
POLR2H | -7744.0 |
HENMT1 | -7103.0 |
TDRKH | -4349.0 |
POLR2G | -3915.0 |
POLR2K | -2872.0 |
MYBL1 | -2799.0 |
PLD6 | -554.0 |
Cross-presentation of soluble exogenous antigens (endosomes)
176 | |
---|---|
set | Cross-presentation of soluble exogenous antigens (endosomes) |
setSize | 38 |
pANOVA | 0.00018 |
s.dist | -0.351 |
p.adjustANOVA | 0.00223 |
Top enriched genes
GeneID | Gene Rank |
---|---|
PSMB8 | -11223.0 |
PSMB9 | -11203.0 |
PSMB3 | -11086.0 |
PSME1 | -10729.0 |
PSMC5 | -10693.5 |
PSMA2 | -10497.5 |
PSMB1 | -10407.5 |
PSMD11 | -10335.0 |
PSMB6 | -10197.0 |
PSME2 | -10020.5 |
PSMD4 | -9966.0 |
PSMA7 | -9928.0 |
PSMD3 | -9715.0 |
PSMD8 | -9686.0 |
PSMC3 | -9590.0 |
PSMA5 | -9370.0 |
PSMB5 | -9224.0 |
PSME3 | -8631.0 |
PSMD1 | -8165.0 |
PSMC1 | -8119.0 |
GeneID | Gene Rank |
---|---|
PSMB8 | -11223.0 |
PSMB9 | -11203.0 |
PSMB3 | -11086.0 |
PSME1 | -10729.0 |
PSMC5 | -10693.5 |
PSMA2 | -10497.5 |
PSMB1 | -10407.5 |
PSMD11 | -10335.0 |
PSMB6 | -10197.0 |
PSME2 | -10020.5 |
PSMD4 | -9966.0 |
PSMA7 | -9928.0 |
PSMD3 | -9715.0 |
PSMD8 | -9686.0 |
PSMC3 | -9590.0 |
PSMA5 | -9370.0 |
PSMB5 | -9224.0 |
PSME3 | -8631.0 |
PSMD1 | -8165.0 |
PSMC1 | -8119.0 |
PSMD14 | -7970.0 |
PSMA1 | -7634.0 |
PSMD9 | -7543.0 |
MRC2 | -7471.0 |
PSMD13 | -7448.5 |
PSMB10 | -6395.0 |
PSMA6 | -6270.0 |
PSMA3 | -5259.0 |
PSMD6 | -4860.0 |
PSMD12 | -4833.0 |
PSMD2 | -4667.0 |
PSMD7 | -4232.0 |
PSME4 | -3622.0 |
PSMC4 | -1218.0 |
PSMC6 | -827.0 |
PSMF1 | 0.5 |
PSMB2 | 0.5 |
PSMB7 | 599.0 |
Ubiquitin Mediated Degradation of Phosphorylated Cdc25A
1154 | |
---|---|
set | Ubiquitin Mediated Degradation of Phosphorylated Cdc25A |
setSize | 44 |
pANOVA | 5.62e-05 |
s.dist | -0.351 |
p.adjustANOVA | 0.00111 |
Top enriched genes
GeneID | Gene Rank |
---|---|
PSMB8 | -11223.0 |
PSMB9 | -11203.0 |
PSMB3 | -11086.0 |
PSME1 | -10729.0 |
PSMC5 | -10693.5 |
PSMA2 | -10497.5 |
PSMB1 | -10407.5 |
PSMD11 | -10335.0 |
PSMB6 | -10197.0 |
PSME2 | -10020.5 |
PSMD4 | -9966.0 |
PSMA7 | -9928.0 |
CHEK2 | -9804.5 |
PSMD3 | -9715.0 |
PSMD8 | -9686.0 |
CHEK1 | -9651.0 |
PSMC3 | -9590.0 |
PSMA5 | -9370.0 |
PSMB5 | -9224.0 |
CDC25A | -9120.0 |
GeneID | Gene Rank |
---|---|
PSMB8 | -11223.0 |
PSMB9 | -11203.0 |
PSMB3 | -11086.0 |
PSME1 | -10729.0 |
PSMC5 | -10693.5 |
PSMA2 | -10497.5 |
PSMB1 | -10407.5 |
PSMD11 | -10335.0 |
PSMB6 | -10197.0 |
PSME2 | -10020.5 |
PSMD4 | -9966.0 |
PSMA7 | -9928.0 |
CHEK2 | -9804.5 |
PSMD3 | -9715.0 |
PSMD8 | -9686.0 |
CHEK1 | -9651.0 |
PSMC3 | -9590.0 |
PSMA5 | -9370.0 |
PSMB5 | -9224.0 |
CDC25A | -9120.0 |
PSME3 | -8631.0 |
PSMD1 | -8165.0 |
PSMC1 | -8119.0 |
UBA52 | -8098.0 |
PSMD14 | -7970.0 |
PSMA1 | -7634.0 |
PSMD9 | -7543.0 |
PSMD13 | -7448.5 |
PSMB10 | -6395.0 |
PSMA6 | -6270.0 |
UBB | -5720.0 |
PSMA3 | -5259.0 |
RPS27A | -4937.0 |
PSMD6 | -4860.0 |
PSMD12 | -4833.0 |
PSMD2 | -4667.0 |
PSMD7 | -4232.0 |
UBC | -4015.0 |
PSME4 | -3622.0 |
PSMC4 | -1218.0 |
PSMC6 | -827.0 |
PSMF1 | 0.5 |
PSMB2 | 0.5 |
PSMB7 | 599.0 |
p53-Independent DNA Damage Response
1190 | |
---|---|
set | p53-Independent DNA Damage Response |
setSize | 44 |
pANOVA | 5.62e-05 |
s.dist | -0.351 |
p.adjustANOVA | 0.00111 |
Top enriched genes
GeneID | Gene Rank |
---|---|
PSMB8 | -11223.0 |
PSMB9 | -11203.0 |
PSMB3 | -11086.0 |
PSME1 | -10729.0 |
PSMC5 | -10693.5 |
PSMA2 | -10497.5 |
PSMB1 | -10407.5 |
PSMD11 | -10335.0 |
PSMB6 | -10197.0 |
PSME2 | -10020.5 |
PSMD4 | -9966.0 |
PSMA7 | -9928.0 |
CHEK2 | -9804.5 |
PSMD3 | -9715.0 |
PSMD8 | -9686.0 |
CHEK1 | -9651.0 |
PSMC3 | -9590.0 |
PSMA5 | -9370.0 |
PSMB5 | -9224.0 |
CDC25A | -9120.0 |
GeneID | Gene Rank |
---|---|
PSMB8 | -11223.0 |
PSMB9 | -11203.0 |
PSMB3 | -11086.0 |
PSME1 | -10729.0 |
PSMC5 | -10693.5 |
PSMA2 | -10497.5 |
PSMB1 | -10407.5 |
PSMD11 | -10335.0 |
PSMB6 | -10197.0 |
PSME2 | -10020.5 |
PSMD4 | -9966.0 |
PSMA7 | -9928.0 |
CHEK2 | -9804.5 |
PSMD3 | -9715.0 |
PSMD8 | -9686.0 |
CHEK1 | -9651.0 |
PSMC3 | -9590.0 |
PSMA5 | -9370.0 |
PSMB5 | -9224.0 |
CDC25A | -9120.0 |
PSME3 | -8631.0 |
PSMD1 | -8165.0 |
PSMC1 | -8119.0 |
UBA52 | -8098.0 |
PSMD14 | -7970.0 |
PSMA1 | -7634.0 |
PSMD9 | -7543.0 |
PSMD13 | -7448.5 |
PSMB10 | -6395.0 |
PSMA6 | -6270.0 |
UBB | -5720.0 |
PSMA3 | -5259.0 |
RPS27A | -4937.0 |
PSMD6 | -4860.0 |
PSMD12 | -4833.0 |
PSMD2 | -4667.0 |
PSMD7 | -4232.0 |
UBC | -4015.0 |
PSME4 | -3622.0 |
PSMC4 | -1218.0 |
PSMC6 | -827.0 |
PSMF1 | 0.5 |
PSMB2 | 0.5 |
PSMB7 | 599.0 |
p53-Independent G1/S DNA damage checkpoint
1191 | |
---|---|
set | p53-Independent G1/S DNA damage checkpoint |
setSize | 44 |
pANOVA | 5.62e-05 |
s.dist | -0.351 |
p.adjustANOVA | 0.00111 |
Top enriched genes
GeneID | Gene Rank |
---|---|
PSMB8 | -11223.0 |
PSMB9 | -11203.0 |
PSMB3 | -11086.0 |
PSME1 | -10729.0 |
PSMC5 | -10693.5 |
PSMA2 | -10497.5 |
PSMB1 | -10407.5 |
PSMD11 | -10335.0 |
PSMB6 | -10197.0 |
PSME2 | -10020.5 |
PSMD4 | -9966.0 |
PSMA7 | -9928.0 |
CHEK2 | -9804.5 |
PSMD3 | -9715.0 |
PSMD8 | -9686.0 |
CHEK1 | -9651.0 |
PSMC3 | -9590.0 |
PSMA5 | -9370.0 |
PSMB5 | -9224.0 |
CDC25A | -9120.0 |
GeneID | Gene Rank |
---|---|
PSMB8 | -11223.0 |
PSMB9 | -11203.0 |
PSMB3 | -11086.0 |
PSME1 | -10729.0 |
PSMC5 | -10693.5 |
PSMA2 | -10497.5 |
PSMB1 | -10407.5 |
PSMD11 | -10335.0 |
PSMB6 | -10197.0 |
PSME2 | -10020.5 |
PSMD4 | -9966.0 |
PSMA7 | -9928.0 |
CHEK2 | -9804.5 |
PSMD3 | -9715.0 |
PSMD8 | -9686.0 |
CHEK1 | -9651.0 |
PSMC3 | -9590.0 |
PSMA5 | -9370.0 |
PSMB5 | -9224.0 |
CDC25A | -9120.0 |
PSME3 | -8631.0 |
PSMD1 | -8165.0 |
PSMC1 | -8119.0 |
UBA52 | -8098.0 |
PSMD14 | -7970.0 |
PSMA1 | -7634.0 |
PSMD9 | -7543.0 |
PSMD13 | -7448.5 |
PSMB10 | -6395.0 |
PSMA6 | -6270.0 |
UBB | -5720.0 |
PSMA3 | -5259.0 |
RPS27A | -4937.0 |
PSMD6 | -4860.0 |
PSMD12 | -4833.0 |
PSMD2 | -4667.0 |
PSMD7 | -4232.0 |
UBC | -4015.0 |
PSME4 | -3622.0 |
PSMC4 | -1218.0 |
PSMC6 | -827.0 |
PSMF1 | 0.5 |
PSMB2 | 0.5 |
PSMB7 | 599.0 |
Viral Messenger RNA Synthesis
1166 | |
---|---|
set | Viral Messenger RNA Synthesis |
setSize | 41 |
pANOVA | 0.000108 |
s.dist | -0.35 |
p.adjustANOVA | 0.00175 |
Top enriched genes
GeneID | Gene Rank |
---|---|
NUP153 | -10890.0 |
POLR2D | -10830.0 |
NUP37 | -10665.0 |
POLR2A | -10548.0 |
POLR2B | -10534.0 |
GTF2F2 | -10486.0 |
POLR2F | -10467.5 |
POLR2L | -10380.5 |
NUP93 | -10171.0 |
NUP155 | -9979.0 |
NUP62 | -9969.5 |
NUP160 | -9771.0 |
NUP188 | -9757.5 |
NUP88 | -9734.5 |
NUP50 | -9654.0 |
SEC13 | -8862.0 |
GTF2F1 | -8706.0 |
POLR2E | -8601.0 |
POLR2I | -8371.5 |
NUP85 | -8226.0 |
GeneID | Gene Rank |
---|---|
NUP153 | -10890.0 |
POLR2D | -10830.0 |
NUP37 | -10665.0 |
POLR2A | -10548.0 |
POLR2B | -10534.0 |
GTF2F2 | -10486.0 |
POLR2F | -10467.5 |
POLR2L | -10380.5 |
NUP93 | -10171.0 |
NUP155 | -9979.0 |
NUP62 | -9969.5 |
NUP160 | -9771.0 |
NUP188 | -9757.5 |
NUP88 | -9734.5 |
NUP50 | -9654.0 |
SEC13 | -8862.0 |
GTF2F1 | -8706.0 |
POLR2E | -8601.0 |
POLR2I | -8371.5 |
NUP85 | -8226.0 |
POM121C | -8104.0 |
POLR2C | -7787.0 |
POLR2H | -7744.0 |
NUP98 | -7707.0 |
RANBP2 | -6481.0 |
NUP214 | -6458.0 |
NUP210 | -6452.0 |
NUP133 | -6383.0 |
RAE1 | -5815.0 |
POM121 | -5784.0 |
TPR | -5774.0 |
NUP43 | -5450.0 |
NUP54 | -4573.0 |
POLR2G | -3915.0 |
AAAS | -3203.0 |
POLR2K | -2872.0 |
SEH1L | -2692.0 |
NUP107 | -2551.0 |
NUP205 | -2499.0 |
NUP35 | -1130.0 |
NDC1 | 0.5 |
Striated Muscle Contraction
1033 | |
---|---|
set | Striated Muscle Contraction |
setSize | 10 |
pANOVA | 0.0569 |
s.dist | -0.348 |
p.adjustANOVA | 0.147 |
Top enriched genes
GeneID | Gene Rank |
---|---|
ACTN3 | -10907.0 |
TMOD2 | -10761.0 |
TPM3 | -10131.0 |
TPM4 | -8970.0 |
TMOD3 | -8081.0 |
TNNC1 | -6399.5 |
TPM1 | -5932.0 |
TPM2 | -5694.0 |
MYBPC2 | -3652.0 |
VIM | -2579.0 |
GeneID | Gene Rank |
---|---|
ACTN3 | -10907.0 |
TMOD2 | -10761.0 |
TPM3 | -10131.0 |
TPM4 | -8970.0 |
TMOD3 | -8081.0 |
TNNC1 | -6399.5 |
TPM1 | -5932.0 |
TPM2 | -5694.0 |
MYBPC2 | -3652.0 |
VIM | -2579.0 |
Formation of the Early Elongation Complex
328 | |
---|---|
set | Formation of the Early Elongation Complex |
setSize | 30 |
pANOVA | 0.00126 |
s.dist | -0.34 |
p.adjustANOVA | 0.00815 |
Top enriched genes
GeneID | Gene Rank |
---|---|
NCBP1 | -11114.5 |
GTF2H3 | -10911.5 |
POLR2D | -10830.0 |
SUPT4H1 | -10827.0 |
POLR2A | -10548.0 |
POLR2B | -10534.0 |
GTF2H4 | -10510.0 |
GTF2F2 | -10486.0 |
POLR2F | -10467.5 |
POLR2L | -10380.5 |
SUPT5H | -10348.0 |
CTDP1 | -9760.0 |
GTF2F1 | -8706.0 |
POLR2E | -8601.0 |
POLR2I | -8371.5 |
NCBP2 | -8252.0 |
ERCC2 | -7919.0 |
POLR2C | -7787.0 |
POLR2H | -7744.0 |
CCNH | -7205.0 |
GeneID | Gene Rank |
---|---|
NCBP1 | -11114.5 |
GTF2H3 | -10911.5 |
POLR2D | -10830.0 |
SUPT4H1 | -10827.0 |
POLR2A | -10548.0 |
POLR2B | -10534.0 |
GTF2H4 | -10510.0 |
GTF2F2 | -10486.0 |
POLR2F | -10467.5 |
POLR2L | -10380.5 |
SUPT5H | -10348.0 |
CTDP1 | -9760.0 |
GTF2F1 | -8706.0 |
POLR2E | -8601.0 |
POLR2I | -8371.5 |
NCBP2 | -8252.0 |
ERCC2 | -7919.0 |
POLR2C | -7787.0 |
POLR2H | -7744.0 |
CCNH | -7205.0 |
GTF2H5 | -6121.5 |
POLR2G | -3915.0 |
NELFA | -3818.0 |
CDK7 | -3477.0 |
NELFB | -3347.0 |
POLR2K | -2872.0 |
MNAT1 | -1528.0 |
ERCC3 | -1496.0 |
NELFCD | 0.5 |
NELFE | 0.5 |
Here is the session info with all the versions of packages used.
sessionInfo()
## R version 4.2.0 (2022-04-22)
## Platform: x86_64-pc-linux-gnu (64-bit)
## Running under: Ubuntu 20.04.4 LTS
##
## Matrix products: default
## BLAS: /usr/lib/x86_64-linux-gnu/blas/libblas.so.3.9.0
## LAPACK: /usr/lib/x86_64-linux-gnu/lapack/liblapack.so.3.9.0
##
## locale:
## [1] LC_CTYPE=en_US.UTF-8 LC_NUMERIC=C
## [3] LC_TIME=en_US.UTF-8 LC_COLLATE=en_US.UTF-8
## [5] LC_MONETARY=en_US.UTF-8 LC_MESSAGES=en_US.UTF-8
## [7] LC_PAPER=en_US.UTF-8 LC_NAME=C
## [9] LC_ADDRESS=C LC_TELEPHONE=C
## [11] LC_MEASUREMENT=en_US.UTF-8 LC_IDENTIFICATION=C
##
## attached base packages:
## [1] grid stats4 parallel stats graphics grDevices utils
## [8] datasets methods base
##
## other attached packages:
## [1] pkgload_1.2.4
## [2] GGally_2.1.2
## [3] ggplot2_3.3.6
## [4] gtools_3.9.2
## [5] tibble_3.1.7
## [6] echarts4r_0.4.3
## [7] ENmix_1.32.0
## [8] doParallel_1.0.17
## [9] qqman_0.1.8
## [10] RCircos_1.2.2
## [11] beeswarm_0.4.0
## [12] forestplot_2.0.1
## [13] checkmate_2.1.0
## [14] magrittr_2.0.3
## [15] reshape2_1.4.4
## [16] gplots_3.1.3
## [17] GEOquery_2.64.2
## [18] RColorBrewer_1.1-3
## [19] IlluminaHumanMethylation450kmanifest_0.4.0
## [20] topconfects_1.12.0
## [21] DMRcatedata_2.14.0
## [22] ExperimentHub_2.4.0
## [23] AnnotationHub_3.4.0
## [24] BiocFileCache_2.4.0
## [25] dbplyr_2.1.1
## [26] DMRcate_2.10.0
## [27] limma_3.52.1
## [28] missMethyl_1.30.0
## [29] IlluminaHumanMethylationEPICanno.ilm10b4.hg19_0.6.0
## [30] IlluminaHumanMethylation450kanno.ilmn12.hg19_0.6.1
## [31] minfi_1.42.0
## [32] bumphunter_1.38.0
## [33] locfit_1.5-9.5
## [34] iterators_1.0.14
## [35] foreach_1.5.2
## [36] Biostrings_2.64.0
## [37] XVector_0.36.0
## [38] SummarizedExperiment_1.26.1
## [39] Biobase_2.56.0
## [40] MatrixGenerics_1.8.0
## [41] matrixStats_0.62.0
## [42] GenomicRanges_1.48.0
## [43] GenomeInfoDb_1.32.2
## [44] IRanges_2.30.0
## [45] S4Vectors_0.34.0
## [46] BiocGenerics_0.42.0
## [47] R.utils_2.11.0
## [48] R.oo_1.24.0
## [49] R.methodsS3_1.8.1
## [50] plyr_1.8.7
## [51] tictoc_1.0.1
## [52] mitch_1.8.0
## [53] eulerr_6.1.1
## [54] kableExtra_1.3.4
## [55] dplyr_1.0.9
##
## loaded via a namespace (and not attached):
## [1] rappdirs_0.3.3 rtracklayer_1.56.0
## [3] tidyr_1.2.0 bit64_4.0.5
## [5] knitr_1.39 DelayedArray_0.22.0
## [7] data.table_1.14.2 rpart_4.1.16
## [9] KEGGREST_1.36.0 RCurl_1.98-1.6
## [11] AnnotationFilter_1.20.0 generics_0.1.2
## [13] GenomicFeatures_1.48.1 preprocessCore_1.58.0
## [15] RSQLite_2.2.14 bit_4.0.4
## [17] tzdb_0.3.0 webshot_0.5.3
## [19] xml2_1.3.3 httpuv_1.6.5
## [21] assertthat_0.2.1 xfun_0.31
## [23] hms_1.1.1 jquerylib_0.1.4
## [25] evaluate_0.15 promises_1.2.0.1
## [27] fansi_1.0.3 restfulr_0.0.13
## [29] scrime_1.3.5 progress_1.2.2
## [31] caTools_1.18.2 readxl_1.4.0
## [33] DBI_1.1.2 geneplotter_1.74.0
## [35] htmlwidgets_1.5.4 reshape_0.8.9
## [37] purrr_0.3.4 ellipsis_0.3.2
## [39] backports_1.4.1 permute_0.9-7
## [41] calibrate_1.7.7 annotate_1.74.0
## [43] biomaRt_2.52.0 sparseMatrixStats_1.8.0
## [45] vctrs_0.4.1 ensembldb_2.20.1
## [47] withr_2.5.0 cachem_1.0.6
## [49] Gviz_1.40.1 BSgenome_1.64.0
## [51] GenomicAlignments_1.32.0 prettyunits_1.1.1
## [53] mclust_5.4.9 svglite_2.1.0
## [55] cluster_2.1.3 RPMM_1.25
## [57] lazyeval_0.2.2 crayon_1.5.1
## [59] genefilter_1.78.0 edgeR_3.38.1
## [61] pkgconfig_2.0.3 nlme_3.1-157
## [63] ProtGenerics_1.28.0 nnet_7.3-17
## [65] rlang_1.0.2 lifecycle_1.0.1
## [67] filelock_1.0.2 dichromat_2.0-0.1
## [69] rprojroot_2.0.3 cellranger_1.1.0
## [71] rngtools_1.5.2 base64_2.0
## [73] Matrix_1.4-1 Rhdf5lib_1.18.2
## [75] base64enc_0.1-3 png_0.1-7
## [77] viridisLite_0.4.0 rjson_0.2.21
## [79] bitops_1.0-7 KernSmooth_2.23-20
## [81] rhdf5filters_1.8.0 blob_1.2.3
## [83] DelayedMatrixStats_1.18.0 doRNG_1.8.2
## [85] stringr_1.4.0 nor1mix_1.3-0
## [87] readr_2.1.2 jpeg_0.1-9
## [89] scales_1.2.0 memoise_2.0.1
## [91] zlibbioc_1.42.0 compiler_4.2.0
## [93] BiocIO_1.6.0 illuminaio_0.38.0
## [95] Rsamtools_2.12.0 cli_3.3.0
## [97] DSS_2.44.0 htmlTable_2.4.0
## [99] Formula_1.2-4 MASS_7.3-57
## [101] tidyselect_1.1.2 stringi_1.7.6
## [103] highr_0.9 yaml_2.3.5
## [105] askpass_1.1 latticeExtra_0.6-29
## [107] sass_0.4.1 VariantAnnotation_1.42.1
## [109] tools_4.2.0 rstudioapi_0.13
## [111] foreign_0.8-82 bsseq_1.32.0
## [113] gridExtra_2.3 digest_0.6.29
## [115] BiocManager_1.30.17 shiny_1.7.1
## [117] quadprog_1.5-8 Rcpp_1.0.8.3
## [119] siggenes_1.70.0 BiocVersion_3.15.2
## [121] later_1.3.0 org.Hs.eg.db_3.15.0
## [123] httr_1.4.3 AnnotationDbi_1.58.0
## [125] biovizBase_1.44.0 colorspace_2.0-3
## [127] brio_1.1.3 rvest_1.0.2
## [129] XML_3.99-0.9 splines_4.2.0
## [131] statmod_1.4.36 multtest_2.52.0
## [133] systemfonts_1.0.4 xtable_1.8-4
## [135] jsonlite_1.8.0 dynamicTreeCut_1.63-1
## [137] testthat_3.1.4 R6_2.5.1
## [139] Hmisc_4.7-0 pillar_1.7.0
## [141] htmltools_0.5.2 mime_0.12
## [143] glue_1.6.2 fastmap_1.1.0
## [145] BiocParallel_1.30.2 interactiveDisplayBase_1.34.0
## [147] beanplot_1.3.1 codetools_0.2-18
## [149] utf8_1.2.2 bslib_0.3.1
## [151] lattice_0.20-45 curl_4.3.2
## [153] openssl_2.0.1 survival_3.3-1
## [155] rmarkdown_2.14 desc_1.4.1
## [157] munsell_0.5.0 rhdf5_2.40.0
## [159] GenomeInfoDbData_1.2.8 HDF5Array_1.24.0
## [161] impute_1.70.0 gtable_0.3.0
END of report